From: "Jonna Mazet" <jkmazet@ucdavis.edu>
Sent: Sat, 28 Jan 2017 12:14:42 -0800
Subject: Outbreak preparedness
To: "Nziza Julius" <[redacted]>, "Kirsten Gilardi" <kvgilardi@ucdavis.edu>, "Mike Cranfield" <mrcranfield@gorilladoctors.org>, "Woutrina Smith" <wasmith@ucdavis.edu>, "Suzan Murray" <MurrayS@si.edu>, "Zimmerman, Dawn" <ZimmermanD@si.edu>, "Rudovick Kazwala" <[redacted]>, "Zikankuba Sijali" <zikankubasijali@gmail.com>, "Abel Ekiri" <abekiri@ucdavis.edu>, "Prime Mulembakani" <[redacted]>, "Karen Saylors" <ksaylors@metabiota.com>, "<dibesh@cmdn.org>" <[redacted], "<dibesh@cmdn.org>" <dibesh@cmdn.org>, "Jon Epstein" <epstein@ecohealthalliance.org>
Cc: predict-outbreak@ucdavis.edu, "Eddy Rubin" <erubin@metabiota.com>, "Peter Daszak" <daszak@ecohealthalliance.org>

Dear Predicters,
As concerns, preparedness measures, and responses are heating up around influenza measures in countries neighboring those that you manage, I urge you to make sure that you and your teams are up to date on your outbreak preparedness and planning, including completing the outbreak module and being prepared to effectively and professionally manage both communications and technical assistance that may be requested.
Many of you have already begun discussions with partners and ministries around planning and response. If so, please immediately begin the current Predict outbreak response form, even if you haven't been requested to do anything officially yet (Julius, you can continue to update the one you have already started as things develop).
Please also be sure to make use of the predict-outbreak@ucdavis.edu email distribution list (I will receive those messages), as then we will all have the same information in real-time. I have been receiving constant inquiries from USAID/DC and Missions regarding our activities and communications, so it is necessary in confusing times to all be receiving the same information most efficiently.
Thanks you for your continued diligent efforts & fingers crossed that things will settle down quickly,
Jonna

From: Andrew Clements <aclements@usaid.gov>
Sent: Fri, 26 May 2017 06:49:24 +0200
Subject: Re: PREDICT International Travel Requests
To: Katherine Leasure <kaleasure@ucdavis.edu>
Cc: PREDICTMGT <predictmgt@usaid.gov>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>

Travel for Zhou, Shi, Rubin, Saylors, Euren, Fine, and Goldstein approved.

Travel for Lucas, Ndolo, and Fulbert approved subject to mission concurrence.

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On May 25, 2017, at 11:16 PM, Katherine Leasure <kaleasure@ucdavis.edu> wrote:

Please find below international travel requests for your review and approval. Please let me know if you have any questions. Thanks!!

1. Zhou (USA): $2,660 airfare/ $341 (New York City), $168 (Fort Collins) max daily per diem
2. Shi (USA): $2,660 airfare/$341 (New York City), $168 (Fort Collins) max daily per diem
3. Lucas (DRC): $730 airfare/$394 (Kinshasa) max daily per diem
4. Ndolo, Fulbert (DRC): $200 ferry each/$394 (Kinshasa) max daily per diem
5. Rubin, Saylors, Euren (Canada): $529 airfare each/$231 (Nanaimo) max daily per diem
6. Fine (USA): $2950 airfare/$313 (Bronx) max daily per diem
7. Goldstein (Mexico): $2,100/$167 (San Cristobal de Las Casas) max daily per diem

Travel Requests:

1. EcoHealth Alliance would like to request travel approval for Dr. Peng Zhou from Wuhan Institute of Virology, Chinese Academy of Sciences to travel from Wuhan, China to New York, NY, USA and Fort Collins, CO, USA from June 26 to July 4, 2017 to meet with PREDICT global team and other partners, and present at the 2nd International Symposium on Infectious Diseases of Bats.

Trip purpose: Dr. Peng Zhou, together with the PREDICT China Country Coordinator, Dr. Zhengli Shi, will be meeting with PREDICT global team at EHA for China project updates, and work with the modeling team to design further data analysis plans. Drs. Zhou and Shi will also meet with other partners while in New York. In Fort Collins, Dr. Zhou will attend the 2nd International Symposium on Infectious Diseases of Bats to present his research work under PREDICT (presentation title: "Dampening of STING-dependent IFN production: an implication of virus tolerance in bats").

2. EcoHealth Alliance would like to request travel approval for Dr. Zhengli Shi from Wuhan Institute of Virology, Chinese Academy of Sciences to travel from Wuhan, China to New York, NY, USA and Fort Collins, CO, USA from June 26 to July 4, 2017 to meet with PREDICT global team and other partners, and present at the 2nd International Symposium on Infectious Diseases of Bats in the U.S.

Trip purpose: PREDICT China Country Coordinator, Dr. Zhengli Shi, will be meeting with PREDICT global team at EHA for China project updates, and work with the modeling team to design further data analysis plans. Dr. Shi will also present her work to other partners while in New York. In Fort Collins, Dr. Zhou will attend the 2nd International Symposium on Infectious Diseases of Bats to present her team's work under PREDICT (presentation title: "SARS coronavirus may have originated from frequent recombination events between SARS-like coronavirus in a single horseshoe bat habitat").

3. Metabiota would like to request travel approval for Ashley Lucas, Clinical Specialist and Behavioral Liaison, to

travel from Cape Town, South Africa to Kinshasa, Democratic Republic of Congo, from June 18-24, 2017 to oversee and provide additional training to the DRC human surveillance team, visit the two hospital sites for human surveillance, and support the learning of the RoC behavioral team who will be in Kinshasa June 18-22, 2017.

Trip purpose: Ashley will provide additional training to the DRC human surveillance team on data collection tools and entry into the data collection system, visit the two hospital sites for human surveillance and provide oversight and support to human surveillance activities. Ashley will also provide training and support to the RoC behavioral team, who will travel from Brazzaville to Kinshasa for 3 days.

4. Metabiota would like to request travel approval for Hilarion Moukala Ndolo and Dionne Onkirotin Fulbert, Behavioural Interviewer Consultants, to travel from Brazzaville, Republic of Congo to Kinshasa, Democratic Republic of Congo from June 18-22, 2017. They will join Ashley Lucas, Clinical Specialist and Behavioral Liaison, to receive training support for behavioral work from the DRC human surveillance team.

Trip purpose: Hilarion and Dionne will receive training support for behavioral work from the DRC human surveillance team. They will spend time working on EIDITH data uploading, and hands-on training in Kinshasa markets. The DRC team will also provide technical assistance needed to complete behavioral tasks.

5. Metabiota would like to request travel approval for Dr. Eddy Rubin (Chief Scientific Officer), Dr. Karen Saylors (Director of Scientific Operations), and Jason Euren (Research and Implementation Coordinator), to travel from San Francisco, California, USA to Nanaimo, British Columbia, Canada from June 19-23, 2017 to meet with the PREDICT technical support and supervision team to conduct the Supervisor's Training of Trainers (ToT) training and implementation rollout in order to standardize our approach, in preparation for country-specific re-trainings.

Trip purpose: Dr. Rubin, Dr. Saylors, and Dr. Euren will meet with the PREDICT technical support and supervision team to conduct the Supervisor's Training of Trainers (ToT) training and implementation rollout in order to standardize our approach, in preparation for country-specific re-trainings. This visit will allow the team to strategize about recent PREDICT country changes and adjust rollout and transition plans for Metabiota countries.

6. Wildlife Conservation Society would like to request travel approval for Amanda Fine to travel from Hanoi, Vietnam to Seattle, Washington, USA for Home Leave from July 15 to August 6, 2017. She will then travel from Seattle, Washington, USA to New York, New York, USA from August 7-11, 2017 for WCS PREDICT Year 4 planning meetings at the WCS Bronx Zoo headquarters. She will then return to Seattle, Washington, USA for return to Hanoi, Vietnam on August 12, 2017.

Trip purpose: Amanda Fine will travel to the US for Home Leave from July 15 to August 6, 2017. She will then travel to the WCS Bronx Zoo headquarters for one working week (August 7 - 11, 2017) to make detailed plans for PREDICT Year 4 activities in Vietnam and Mongolia, review and update project budgets, and finalize other administrative tasks related to project implementation.

7. UC Davis would like to request travel approval for Dr. Tracey Goldstein to travel from Sacramento, California, USA to San Cristobal de Las Casas, Chiapas, Mexico from July 24-28, 2017 to present at the 2017 WDA Conference.

Trip purpose: Dr. Goldstein will attend the 66th Wildlife Disease Association Annual International Conference to deliver presentation, "Global patterns in coronavirus diversity."

Katherine Leasure
HR/Payroll/Financial Assistant
One Health Institute
University of California, Davis
530-752-7526
530-752-3318 FAX
kaleasure@ucdavis.edu

--

From: Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>
To: Elizabeth Leasure <ealeasure@ucdavis.edu>
CC: Brian Bird <bhbird@ucdavis.edu>;Jonna Mazet <jkmazet@ucdavis.edu>
Sent: 6/5/2017 4:34:11 PM
Subject: Re: Guinea VHF sub award and employee questions

Hi Liz,

They have their DUNS but most likely have not registered (99.9% likely)…do you have any guiding documents that I can pass onto the CC for this? I've never done it myself so have limited advice to provide. They are most likely going to need extreme hand-holding.

Thanks
corina

From: Elizabeth Leasure
Date: Monday, June 5, 2017 at 3:42 PM
To: Corina Grigorescu Monagin
Cc: Brian Bird , Jonna Mazet
Subject: RE: Guinea VHF sub award and employee questions

One thing you could do is confirm that their SAM.gov registration is complete. The last info I have is that it was in progress, but it will need to be complete and current in order for UCD to send out the subaward for VHF signature.

We'll also need to finalize the SOW and budget for the period May 15-Sept 30, 2017. Were the SOW and budget in the approved request that I sent you okay, or do you think a revision is required?

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
530-304-1403 (cell)

From: Corina Grigorescu Monagin
Sent: Wednesday, May 31, 2017 11:42 PM
To: Elizabeth Leasure
Cc: Brian Bird; Jonna Mazet
Subject: Re: Guinea VHF sub award and employee questions

Thanks Liz. One of this first things on my list is to assess the feasibility and timeframe of moving the staff to the subaward. It's a government lab so I'm not sure what the process will be to include individuals underneath that award, as well as individuals who are not based in Conakry where the lab is. I hope to have some information soon.

I'm also not sure if we are mandated to use a payroll company (as you are in China – your memory is correct :). I will also find that out as well.

With the current mechanism, current contracts with MB and Footprint cover the following:

- CC and Field Coordinator – end of August 2017
- PA – end of July 2017
- 11 field staff in Conakry – end of June 2017
- 11 field staff in N'Zérékoré – end of July 2017 (I extended these individuals for 2 months because this area is critical to our workplan and it gives us more time for transition).

In terms of setting up the subaward with the VHL lab, what are the next steps? I know I need to clarify the staffing issue and whether that should be included but is there anything else I can be doing in the meantime to assist?

Regards,
corina

From: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
Date: Wednesday, May 31, 2017 at 10:48 PM
To: Corina Grigorescu Monagin <cgmonagin@UCDAVIS.EDU>
Cc: Brian Bird <bhbird@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>
Subject: RE: Guinea VHF sub award and employee questions

Yes, ideally we would just move forward with UCD issuing a subaward to the lab in Guinea rather than having MB put a subaward in place only to have it end and be replaced by a UCD-issued subaward. Less paperwork and (hopefully) less confusing for the in-country staff.

I have no issues with Metabiota purchasing fuel cards to contribute to the cost of running the generator for sample storage while we get the subaward in place.

For the staffing, are we required to use an outside payroll company like Footprint to facilitate payroll payments in Guinea? I know Metabiota has been using a similar payroll firm in China, but I believe they are required to due to Chinese law (if my memory serves). It is much cleaner (and less expensive without the 18% fee) to just hire the in-country staff through the subaward once it is established (unless there is a very good reason to do otherwise). To avoid a break in service for in-country staff, however, I think we have no choice but to continue to pay them through the current mechanism (meaning through MB to Footprint) until the UCD subaward is in place and hiring (or individual contracting) through the subrecipient can occur.

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
530-304-1403 (cell)

From: Corina Grigorescu Monagin
Sent: Tuesday, May 30, 2017 2:27 PM
To: Elizabeth Leasure
Cc: Brian Bird; Jonna Mazet
Subject: Guinea VHF sub award and employee questions

Hi Liz,

I've started the transition of Guinea and have had a few phone calls with the Metabiota team. A couple of questions for you.

MB has not signed the sub award with the VHF lab. I'm thinking that you do not want them to proceed and that it would be initially signed with UCD? If so, I would like to authorize MB to pay for fuel cards to contribute to the cost of the generator (where our freezer and samples are stored) until we can get the sub award in place. Please advise.

In terms of the staff – all employees (contractual field staff and full time PREDICT) are paid through a payroll company "Footprint". They charge a fee of approximately 18% on all costs. I am getting a full list of staff, salary, location and contract terms and we will have to decide how to proceed. I know the ideal would be to put them all under the subcontract but I honestly don't know the possibility or length of time it will take to put in place. While I figure out our options and timeframe - Do you want to continue with Footprint or another option?

I'm sure you have tons of questions – I'm available in the afternoons (PST) when I'm back at the hotel so let me know if it's easier to talk.

Thanks
Corina

From: Eddy Rubin <erubin@metabiota.com>
To: Jonna Mazet [REDACTED]
Sent: 6/25/2017 3:15:17 PM
Subject: Karen on Mgt call to discuss transitions in CIV, ROC, Indonesia, China, Guinea, & SL

Hi Jonna,
With regards to Monday's Management call with USAID. One of the important discussion items is about Mission communications and challenges with the transitions in CIV, ROC, Indonesia, China, Guinea, & SL . Karen has been intimately involved with these. I wonder whether it would be good for her to participate on the call so she can directly communicate where things are and plans for going forward, rather than things being filtered through me?
Eddy

From: Cara Chrisman <cchrisman@usaid.gov>
Sent: Fri, 21 Jul 2017 16:39:47 -0400
Subject: Re: GVP Action Items (as of 7/21)
To: [redacted]
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, Dennis Carroll <dcarroll@usaid.gov>

Hi [redacted]
Great, thank you!

For #1 - My web design experience starts and ends with SquareSpace, so don't want to suggest anything that's too complicated. However, either a sub-tab under Resources or a link toward the bottom of the Resources page itself would work. We would certainly defer to the team as to what would be easiest in order to move those older documents so they are no longer a focus, but are available if people would still like to access them.

For #2 - In this case, we're looking for consistency with what else we're putting out there. While matching the powerpoint would be nice, we generally would be handing out the Bellagio Initiative and perhaps since the Comms team drafted that, it would work for them to also do the 2 pager in a similar format. I think this would likely include keeping the two column format with the various sections, but updating the colors (greens, black, etc.), font (so it's the same as the Initiative), and adding the logo (even if just at the bottom). If they have any creative ideas that can be done with minimal effort, we're definitely open to that.

Happy to discuss either/both and please let me/us know if any of this is particularly onerous (or unclear). Given what a great job they did with the Bellagio Initiative, we don't want to be too prescriptive with the 2 pager, but would be happy to have it coordinate with the Initiative (and no idea how to make it look like the Powerpoint - particularly since a black background is not ideal for printing!).

Thanks again,
Cara

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

Desk: (202) 712-1161
Cell: (202) 674-3231
E-mail: cchrisman@usaid.gov

On Fri, Jul 21, 2017 at 4:09 PM, [redacted] wrote:

> Hi Cara,
>
> Great, yes I can work on that with our communications team. Just some clarifications for #1 and 2.
>
> 1. Will we create a new "Archived" section on the website?
>
> 2. What exactly does the format change look like? Colors, font, logo, page layout?
>
> Best,
> [redacted]

REDACTED

One health fellow

One Health Institute

University of California, Davis

From: Cara Chrisman [mailto:cchrisman@usaid.gov]
Sent: Friday, July 21, 2017 12:58 PM
To: REDACTED
Cc: Jonna Mazet <jkmazet@ucdavis.edu>; Dennis Carroll <dcarroll@usaid.gov>
Subject: Re: GVP Action Items (as of 7/21)

Hi REDACTED

Thanks for following up and glad it was helpful. This is timely as I was just trying to figure out the format earlier today!

Dennis and I discussed and the hope was to do a few things:

1. Move the old documents into an "Archived" section on the website. So, still available, but no longer highlighted.
2. Update the 2 pager so that the format aligns with the other current GVP documents (either the Bellagio initiative or the ppt.).
3. Update the language in the 2 pager & remove older numbers

After our discussion, we have some ideas for #3 that I can work on today and early next week and then share for review and feedback. Would #1 & 2 be things that could be handled on your end?

Thanks,

Cara

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

Desk: (202) 712-1161
Cell: (202) 674-3231
E-mail: cchrisman@usaid.gov

On Fri, Jul 21, 2017 at 12:08 PM, REDACTED wrote:

Hi Cara,

Great idea to compile action items.

For the following item, did you want to wait for the team to agree on a budget, or edit the two documents now so that it does not include specific numbers for the time being?

Cara and REDACTED – Update information on website (2-pager and quad chart)

Best,

REDACTED

REDACTED

One health fellow

One Health Institute

University of California, Davis

From: Cara Chrisman [mailto:cchrisman@usaid.gov]
Sent: Friday, July 21, 2017 7:26 AM
To: Jonna Mazet <jkmazet@ucdavis.edu>; Eddy Rubin <erubin@metabiota.com>; Nathan Wolfe <nwolfe@metabiota.com>; Peter Daszak <daszak@ecohealthalliance.org>; Brooke Watson <watson@ecohealthalliance.org>; REDACTED
Cc: Dennis Carroll <dcarroll@usaid.gov>
Subject: GVP Action Items (as of 7/21)

Hi Team,

Glad we were able to touch base yesterday. In order to move things along, please see below for an updated, compiled list of action items, pulled from Eri's Emazing E-Notes. They are also attached (that document includes all the archived action items by date, as well).

If any of these can be taken off the list as they are completed or no longer relevant, please let me know.

Best,

Cara

Current GVP Action Items (7/21/17)

Travel:

- Peter out Aug 1-20, then Sweden, back in office last week of August
- Dennis – In and out in August, will call in to GVP meetings

Jonna

Jonna – Follow up with Richard Hatchett about Zoe

UCD and EHA team – Finalize budget

[redacted]

Cara and [redacted] – Update information on website (2-pager and quad chart)

UCD and EHA team – Finalize budget

Eri- look into existing in country capacities through PREDICT

Dennis

Dennis – Set up meeting with Richard Hachett for October in DC

Dennis – Make plans for China trip & check in with Keiji about HK visit (Sept. 4th week)

Dennis - Meet with Ambassador from Costa Rica

Dennis – Meet with Brian Granfield from Princeton during E. Coast trip (WT advocate) w/ Peter

Dennis – follow up with Lancet Pam Das [move forward but with caution, keep Science in view

Dennis - follow up with Illumina

Dennis - Follow up with Ilaria after Switzerland

Dennis - Set up f/u meeting with Chris Elias

Dennis - Follow up with UNESCO individual

Dennis – Keep Larry in the loop as we move forward and run the "ask" by him when completed

Cara

Cara and [redacted] Update information on website (2-pager and quad chart)

Cara - Include ELSI and A/P docs in shared folder

Peter

Peter – Work on Science paper

Peter – Check in with George about China Trip in Sept.

UCD and EHA team – Finalize budget

Peter - send Cara various meeting schedules (cell symposium, vaccine congress etc.)

Peter – share slide on why broad spectrum approach is critical

Peter - Follow up with the Norwegians regarding GVP & CEPI

Pete - Follow up on not for profit (in progress)

Peter – Work with Dennis regarding Brian Granfeld & GVP

Brooke

UCD and EHA team – Finalize budget

Eddy

Eddy – Move forward with prototype EIDITH planning

Eddy – follow up with Richard Feachem

Eddy – Continue f/u with Sanger about GVP and the 5 yr plan

Eddy/Nathan – Follow up regarding Verily and decide about inclusion as a partner on the website

Eddy – align with Peter and reach out to Sir Michael Stratton about GVP (in progress)

Nathan

Nathan - Reach out to Peggy Hamburg regarding GVP and CEPI

Nathan – Update post-call with Richard Wilcox

Nathan - Follow up with Lance Brooks at DTRA

Eddy/Nathan – Follow up regarding Verily and decide about inclusion as a partner on the website

All

All- Send [redacted] an email for feedback on PMAC launch, suggestions from Cara and Dennis below:

- Length - It would be great to have an overall 1 day meeting (2 1/2day sessions) - but does not need to consecutive on one day. The first of the two sessions would be a closed meeting with internal GVP people and the second would be the open launch. In order to maximize everyone's ability to participate in other meetings, it would actually be helpful if the two sessions were on separate days.

- Closed/Open - Preferable to have one closed (GVP only) and one open (the launch)

- Speakers - Would like to include those people who have already been involved in or working with us on the GVP, particularly who would already be at PMAC (like a Richard Feachem).

- Participants - For the closed session, it would the Beijing folks, particularly if they would already be at PMAC (as many would be), so the SC and WG people. For the launch, once we have the PMAC attendee list, can invite people and keep it open. Those people we particularly want, we can send additional f/u to. The number for the closed would around Beijing size and for the open would be a room for about 100 ppl.

- Room - Flexible and can figure out as agenda evolves, but could have a different set-up for the two different meetings.

All – look at outreach worksheet and send modifications to Cara

All – start brainstorming who to invite to PMAC meeting and send Eri list of names

All - Continue to follow up with Skoll/Mark/Larry (Jonna completed Mark conversation)

All - Identify other key individuals to engage with the core group (Keiji, Steve, Kathleen, etc.) on particular topics

All - Consider next steps with DARPA

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

Desk: (202) 712-1161
Cell: (202) 674-3231
E-mail: cchrisman@usaid.gov

From: Molly Turner <turner@ecohealthalliance.org>
Sent: Fri, 28 Jul 2017 11:05:49 -0400
To: Elizabeth Leasure <ealeasure@ucdavis.edu>
Cc: Evelyn Luciano <luciano@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, "predict@ucdavis.edu" <predict@ucdavis.edu>, Alice Latinne <latinne@ecohealthalliance.org>
Subject: [predict] Re: Taking over contract from MB for Eijkman

Hi Liz,
I believe Peter and Jonna discussed this already, but it would be good if Metabiota could continue to disburse funds at least in the case of our collaborators in Ivory Coast (and probably Indonesia and China as well). We're still ascertaining what the understanding is between Metabiota and LANDA and IPCI (I'm writing separately to Beth about this) regarding ongoing financial obligations, but we do know that IPCI has a trip planned before the end of the project year that we may want to go ahead with if we can ensure that everything's in order training- and compliance-wise. We want to make sure that all financial transactions are conducted properly of course; I am happy to review financial reports, and I believe there also remains a question as to the proper payment accounts for both entities, please advise if you have any information on that point.

Please let us know how you'd like to proceed.

Thanks,
Molly

On Tue, Jul 25, 2017 at 4:51 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

> Hi Molly. The approvals for the new EHA subs in Indonesia, China, RoC, and Cote d'Ivoire will come through approval of the ceiling increase budget that was submitted, which OAA is pushing to have done (approved/processed) before the end of the current fiscal year. Now, how soon before 9/30 I can't say, as it all depends on OAA and how quickly they can review and whether or not they have any questions or require additional information from us before they approve. Too many unknowns to say for sure at this point. My opinion (based on past experience) is that it will come down to the wire, so I wouldn't count on getting approval until the end of September.
>
> I had not planned on UCD setting up any interim subawards given our ability to get multiple subs approved at once through the ceiling increase process, but that could potentially be revisited or discussed if you feel very strongly about it. Honestly, given that we're almost to August and I'll be travelling from 8/1-8/10 and laser-focused on Y4 budgeting from 8/11-8/31, I'm not sure interim UCD subawards are a good option at this point. Continuing to have Metabiota make certain payments (for salaries of staff, etc.) is an option, but that is also something we should discuss.
>
> Elizabeth Leasure
>
> One Health Institute
>
> University of California, Davis
>
> 530-754-9034 (office)
>
> 530-304-1403 (cell)
>
> **From:** Molly Turner [mailto:turner@ecohealthalliance.org]
> **Sent:** Tuesday, July 25, 2017 7:13 AM
> **To:** Elizabeth Leasure
> **Cc:** Evelyn Luciano; Ava Sullivan
> **Subject:** Re: Taking over contract from MB for Eijkman

Hi Liz,

Just following up.

Thanks,

Molly

On Tue, Jul 18, 2017 at 1:22 PM, Molly Turner <turner@ecohealthalliance.org> wrote:

Hi Liz,

I'd been waiting until after the cooperative-agreement-ceiling-raise madness was over to bring this up with you -- and kind of assumed that the outcome of that activity might determine the answer -- but do you know what the plan is in terms of a formal handover for the cooperative agreements in Indonesia (and RoC, China, and Ivory Coast)? I know we are hoping to secure approval via this activity to do this for Year 4, but is there any chance of it happening before the end of Year 3? And will Davis manage these agreements in the interim?

Thanks,

Molly

---------- Forwarded message ----------
From: **Kevin Olival, PhD** <olival@ecohealthalliance.org>
Date: Tue, Jul 18, 2017 at 1:05 PM
Subject: Taking over contract from MB for Eijkman
To: Evelyn Luciano <luciano@ecohealthalliance.org>, Ava Sullivan <sullivan@ecohealthalliance.org>, Molly Turner <turner@ecohealthalliance.org>, Alice Latinne <latinne@ecohealthalliance.org>

Hi Evelyn and everyone,

I had a good meeting with Dodi and Tina from Eijkman Institute today. One question that is outstanding is when will EHA take over the contract, especially for the next few months before year 4 starts. Do you have an answer to this? When we were at the UC Davis meeting one option was UCD taking this over until the end of year 3, but last month MB continued to pay salaries etc to keep the project running during the transition. It's important that we provide support so that predict trained staff etc aren't lost during the transition, and that we continue to have some funds to organize the human surveillance work that will begin soon (<1 mo) once we get IRB approval.

If you have any thoughts please let me know, I have a high-level meeting with Eijkman tomorrow afternoon Jakarta time.

Cheers,
Kevin

--

Molly Turner

Federal Grants Coordinator

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4461 (direct)

1.973.752.4627 (cell)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

--

Molly Turner

Federal Grants Coordinator

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4461 (direct)

1.973.752.4627 (cell)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

--
Molly Turner
Federal Grants Coordinator

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4461 (direct)
1.973.752.4627 (cell)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

From:	Katherine Leasure <kaleasure@ucdavis.edu>
To:	'Andrew Clements' <aclements@usaid.gov>
CC:	'PREDICTMGT' <predictmgt@usaid.gov>;'Jonna Mazet' <jkmazet@ucdavis.edu>;predict@ucdavis.edu <predict@ucdavis.edu>
Sent:	8/10/2017 11:20:01 PM
Subject:	RE: PREDICT International Travel Requests

Hi Andrew. Please disregard the original estimate; we were able to identify a comparable BC itinerary priced at $9,200.

From: Andrew Clements [mailto:aclements@usaid.gov]
Sent: Wednesday, August 09, 2017 2:48 PM
To: Katherine Leasure
Cc: PREDICTMGT; Jonna Mazet; predict@ucdavis.edu
Subject: Re: PREDICT International Travel Requests

Sorry, but I have to ask: $15,000 For BC to Sweden? Is that the best BC fare available?

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Aug 9, 2017, at 12:55 PM, Katherine Leasure <kaleasure@ucdavis.edu> wrote:

Please find below international travel requests for your review and approval. Please let me know if you have any questions. Thanks!!

1. Li (China): $2,720 airfare/$407 (Guangzhou), $377 (Beijing), $241 (Kunming) max daily per diems
2. Daszak (China): $7,670 airfare **business class required due to medical need*/$377 (Beijing), $535 (Hong Kong), $407 (Guangzhou) max daily per diems
3. Watson (China): $1,253 airfare/$377 (Beijing), $535 (Hong Kong), $407 (Guangzhou) max daily per diems
4. White, Johnson, Feferholtz, Zambrana-Torrelio (Indonesia): $1,380 airfare each/$362 (Jakarta) max daily per diem
5. O'Rourke (USA): $392 airfare/$375 (New York) max daily per diem
6. McIver (USA): $325 airfare/$375 (New York) max daily per diem
7. Mazet (Sweden): $15,000 airfare **business class required due to medical need*/$365 (Uppsala) max daily per diem

Travel Requests –

1. EcoHealth Alliance would like to request travel approval for Hongying Li to travel from Newark, New Jersey, USA to Beijing, Guangzhou, and Kunming, China from August 31 to September 29, 2017 for meetings with in-country partners in China for PREDICT-2 projects operations.

Trip purpose: Hongying Li will meet with local Field Coordinator, Dr. Guangjian Zhu, for Year 4 wild animal sampling planning, and staff from Guangdong CDC for human syndromic surveillance work. Hongying will also meet with staff from Yunnan Institute of Endemic Diseases Control and Prevention for community behavioral surveillance training and operations, as well as the Chinese Academy of Sciences and China CDC for the GVP initiative in China.

2. EcoHealth Alliance would like to request travel approval for Dr. Peter Daszak to travel from Newark, New Jersey, USA to Beijing, Hong Kong, and Guangzhou, China from September 2-9, 2017 for meetings with local partners for PREDICT and GVP operations.

Trip purpose: Dr. Daszak will attend meetings with Chinese Academy of Sciences, China CDC, and US Embassy in China for GVP planning; give a presentation on GVP at Hong Kong University, and meet with

faculty; and meet with staff from Guangdong CDC for human syndromic surveillance in China.

3. EcoHealth Alliance would like to request travel approval for Brooke Watson to travel from New York, NY, USA to Beijing, Hong Kong, and Guangzhou, China from September 2-9, 2017 for meetings with local partners for PREDICT and GVP operations.

Trip purpose: Ms. Watson will attend meetings with Chinese Academy of Sciences, China CDC, and US Embassy in China for GVP planning. She will meet with Keiji Fukuda, a member of the GVP steering committee, and give a presentation on the Global Virome Project to Hong Kong University. She will also meet with staff from Guangdong CDC for human syndromic surveillance in China.

4. EcoHealth Alliance would like to request travel approval for Allison White, Erica Johnson, Yasha Feferholtz, and Carlos Zambrana-Torrelio to travel from New York, NY, USA to Jakarta, Indonesia from September 3-9, 2017 for P-2 IDEEAL INDOHUN collaboration.

Trip purpose: The purpose of the travel is to meet with INDOHUN collaborators to assist with data collection and modeling activities and to build capacity of within Indonesia's One Health Workforce. The EHA team (White, Johnson, Feferholtz, and Zambrana-Torrelio) will conduct a programming and analysis workshop, as well as provide training on economic modeling and scientific communication and community outreach for One Health topics. **Travel will occur as part of a longer trip to the region for PREDICT and other projects; the portion related to PREDICT is reflected in the ITA, while travel outside these dates will be covered on non-PREDICT funds.*

5. Metabiota would like to request travel approval for Tammie O'Rourke, Senior Information Management Developer, to travel from Nanaimo, British Columbia, Canada to New York, NY, USA from Sept 11-13, 2017 for the PREDICT Semi-Annual Corsortium Meeting.

Trip purpose: Tammie O'Rourke will join Dr. David McIver, PREDICT Asia Regional Coordinator, at the PREDICT Semi-Annual Consortium Meeting.

6. Metabiota would like to request travel approval for Dr. David McIver, PREDICT Asia Regional Coordinator, to travel from Charlottetown, Prince Edward Island, Canada to New York, NY, USA from September 11-13, 2017 for the PREDICT Semi-Annual Corsortium Meeting.

Trip purpose: Dr. David McIver will join Tammie O'Rourke, Senior Information Management Developer, at the PREDICT Semi-Annual Consortium Meeting.

7. UC Davis would like to request travel approval for Dr. Jonna Mazet to travel from San Francisco, CA, USA to Uppsala, Sweden from October 8-11, 2017 to participate in the Uppsala Health Summit 2017: Tackling Infectious Disease.

Trip purpose: Dr. Mazet will engage as an invited participant in the Uppsala Health Summit on 'Infectious Disease Threats – Prevent, Detect, Respond with a One Health Approach' at Uppsala Castle, Sweden. The participants will discuss and work to develop practice guidelines and mechanisms to empower local research capacities, and will strategically convene as international leaders working on One Health approaches to reduce risk behavior in low-income settings. While attending the Uppsala Health Summit, Dr. Mazet will also conduct meetings with PREDICT consortium members and EPT-2 partners, as well as identify useful stakeholders and collaborators to encourage continued support for the Emerging Pandemic Threats program and promote Global Virome Project engagement.

Katherine Leasure
HR/Payroll/Financial Assistant
One Health Institute
University of California, Davis
530-752-7526
530-752-3318 FAX
kaleasure@ucdavis.edu

--

From: Elizabeth Leasure <ealeasure@ucdavis.edu>
To: Beth Edison <bedison@metabiota.com>
Cc: predict Sympa List <predict@ucdavis.edu>, Karen Saylors <ksaylors@metabiota.com>
Sent: Fri, 25 Jan 2019 17:41:35 +0000
Subject: [predict] RE: Restriction for Trafficking in persons.

I found this list online:

TIER 3
China (PRC)
Congo, Democratic Republic of
Congo, Republic of
Guinea
South Sudan
Sudan

Elizabeth Leasure
Financial Operations Manager
One Health Institute
530-304-1403 (cell)
530-754-9034 (office)
Skype: ealeasure

From: Beth Edison <bedison@metabiota.com>
Sent: Wednesday, January 23, 2019 7:31 AM
To: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
Cc: predict Sympa List <predict@ucdavis.edu>; Karen Saylors <ksaylors@metabiota.com>
Subject: Fwd: Restriction for Trafficking in persons.

Hi Liz,

Charles, our CC in DRC, received the below email from the mission. What he's saying is that DRC is on the list of countries that is restricted by the TVPA act and that no new money will be allocated until these restrictions are lifted. Apparently some organizations have already received an email advising the restriction has been lifted but FAO, CBT and UC Davis are still restricted and no new money will be allocated for DRC until an email is received. We are allowed to continue operating with funds already received.

Have you heard anything about this at all? I did a brief search for a list of countries and haven't found one yet, but it's possible that other PREDICT countries might be affected as well. If I find more info, I will send it along.

Thanks,
Beth

---------- Forwarded message ---------
From: **Charles Kumakamba** <ckumakamba@metabiota.com>
Date: Wed, Jan 23, 2019 at 1:07 AM
Subject: Fwd: Restriction for Trafficking in persons.
To: Karen Saylors <ksaylors@metabiota.com>, Beth Edison <bedison@metabiota.com>

FYI!

---------- Forwarded message ---------
From: **Jean-Felly Numbi** <jnumbi@usaid.gov>
Date: mer. 23 janv. 2019 10 h 01
Subject: Restriction for Trafficking in persons.
To: Jean Pierre Kabuayi <jpkabuayi@theunion.org>, Charles Kumakamba <ckumakamba@metabiota.com>

Bonjour Jean Pierre et Charles,
Merci pour le message sur le shutdown en rapport avec la mis en oeuvre des activités sur terrain.
En effet, il ya deux situations différentes à ce sujet à savoir :
1) Le shut-down qui est le retard d'approbation du budget du gouvernement américain par le Congrès suite aux tractations entre le président Trump et les démocrates. Comme conséquence c'est le retard pour l'argent attendu de cette année en cours. Cependant si votre projet a encore un solde de l'année passée dans ce cas vous continuez avec la mise en oeuvre si le plan d'action est déjà approuvé. Tous nous attendons le New Money de cette année quand le shut-down sera levé.

2) **Trafficking in Persons (TIP)** : cette restriction sous laquelle la RDC est tombée parmi tant autres pays,
voir le message ci-dessous,CTB, FAO, Predict 2 Davis sont encore sous cette restriction par conséquent vous ne recevrez new money tant pas levée. Bien sûr elle sera levée mais on ne sait pas quand. La levée de cette mesure est progressive car autres projets de la RDC viennent d'être autorisées de commencer la mise en oeuvre en appuyant le gouvernement. C'est la restriction suspend de faire le business avec le gouvernement concerné. Que faire? Encore une fois si vous avez de l'argent du solde de l'année passée, je vous conseillerais de continuer les activités prioritaires de cette année car on ne sait pas quand la mesure sera levée.

Merci. Je suis disponible pour toute autre information.
Jean-Felly.
---------- Forwarded message ---------
From: **Andre-Guy Soh** <asoh@usaid.gov>
Date: Wed, Dec 12, 2018 at 2:24 PM
Subject: Update Concerning Impact of Trafficking-in-Persons Legislation on USAID awards
To: Andre-Guy Soh <asoh@usaid.gov>

Dear partners,

On November 28, I informed you that the U.S. Government was in the process of clarifying the effects of restrictions imposed by the Trafficking and Victims Protection Act of 2000 (the "TVPA") on U.S. Government activities in all Tier 3 designated countries.

We have received clearance for a limited number of awards, and have informed the organizations and contractors concerned.

If you have not received an email from USAID/DRC indicating that the U.S. Government has determined that your award is NOT COVERED by TVPA restrictions, then we are still unable to provide any assurance that additional funds will be obligated into your respective awards due to the potential application of TIP restrictions.

We understand this situation may create difficulties for program operations. While we wait for further guidance from Washington, feel free to reach out to your AOR/CORs for any questions you may have.

Regards,
AG

Andre-Guy Soh
Contracting/Agreement Officer
Office of Acquisition and Assistance (OAA) | USAID/Democratic Republic of Congo
U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT
Kinshasa, Democratic Republic of Congo (DRC)
T. REDACTED | M. REDACTED U.S. Emb. Ext: REDACTED
USAID.gov | asoh@usaid.gov | @USAID

ReplyReply allForward

--
Jean-Felly Numbi
USAID-DRC TB& Infectious Disease Advisor
Office Phone #:
Cellular Phone # REDACTED

--
Beth Edison
Program Manager | Metabiota
(250)739-8987

From:	Jonna Mazet <jkmazet@ucdavis.edu>
To:	Peter Daszak <daszak@ecohealthalliance.org>
CC:	Dennis Carroll <dcarroll@usaid.gov>; [redacted];Cara Chrisman <cchrisman@usaid.gov>;Eddy Rubin <erubin@metabiota.com>;Nathan Wolfe <nwolfe@metabiota.com>;Samtha Maher <maher@ecohealthalliance.org>;Alison Andre <andre@ecohealthalliance.org>
Sent:	3/28/2019 4:46:44 PM
Subject:	Re: Draft letter to the GVP Board of Directors

Hi,
I think the letter looks great. Excellent tone. Also very exciting to see your official transition announcement -- congratulation!
My only suggestion for discussion on today's call is that we consider removing the specific references to timelines (2 year incubation period, 10 year steady state, etc.). I think our timelines will remain aspirational until we have a significant chunk of funding or several countries moving forward. I also don't think it is necessary or adds much to the letter to spell them out here but could set us up to seem like we failed or didn't meet our goals, and there is no real reason to do that. These things evolve. Instead for that sentence in the first paragraph, we may just want to say that we are excited to be in the very productive incubation period with China and Thailand initiating their national virome projects.
Talk soon,
Jonna

On Wed, Mar 27, 2019 at 6:28 PM Peter Daszak <daszak@ecohealthalliance.org> wrote:

Here are a couple of v. minor tweaks and a sentence re. the docs people will receive.

Cheers,

Peter

Peter Daszak

President

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

Tel. +1 212-380-4474

Website: www.ecohealthalliance.org

Twitter: @PeterDaszak

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

From: Dennis Carroll [mailto:dcarroll@usaid.gov]
Sent: Wednesday, March 27, 2019 5:08 PM
To: Jonna Mazet; Peter Daszak; REDACTED Cara Chrisman; Eddy Rubin; Nathan Wolfe; Samtha Maher; Alison Andre
Subject: Draft letter to the GVP Board of Directors

All, for discussion and feedback during tomorrow's phone call - attached you will find a draft of the letter to be sent to the members of the GVP Board of Directors.

d

Dr. Dennis Carroll

Director, Emerging Threats Program

Bureau for Global Health

U.S. Agency for International Development

Office: 571-551-7109

Mobile: REDACTED

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Elizabeth Leasure <ealeasure@ucdavis.edu>
CC: Brooke Genovese <bgenovese@ucdavis.edu>;David John Wolking <djwolking@ucdavis.edu>
Sent: 5/3/2019 6:44:04 PM
Subject: Re: PREDICT expenses update & questions

Great with me,
J

On Fri, May 3, 2019 at 9:13 AM Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Hi Jonna. Any objections to Hannah listening in on the call? She's been focused on subawards and hasn't really been involved in the big picture budgeting at this point, but she is eager to get up to speed. If not, no worries.

Thanks,

Liz

Elizabeth Leasure

Financial Operations Manager

One Health Institute

530-304-1403 (cell)

530-754-9034 (office)

Skype: ealeasure

From: Elizabeth Leasure
Sent: Friday, May 3, 2019 9:10 AM
To: Brooke Genovese <bgenovese@ucdavis.edu>; Jonna Mazet <jkmazet@ucdavis.edu>
Cc: Hannah R Chale <hrchale@ucdavis.edu>; David John Wolking <djwolking@ucdavis.edu>
Subject: RE: PREDICT expenses update & questions

Yes, please. Thank you!

Elizabeth Leasure

Financial Operations Manager

One Health Institute

530-304-1403 (cell)

530-754-9034 (office)

Skype: ealeasure

From: Brooke Genovese <bgenovese@ucdavis.edu>
Sent: Friday, May 3, 2019 9:09 AM
To: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>; Jonna Mazet <jkmazet@ucdavis.edu>
Cc: Hannah R Chale <hrchale@UCDAVIS.EDU>; David John Wolking <djwolking@ucdavis.edu>
Subject: Re: PREDICT expenses update & questions

Great! I'll have Jonna call your cell?

From: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
Date: Friday, May 3, 2019 at 9:01 AM
To: Brooke Genovese <bgenovese@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>
Cc: Hannah R Chale <hrchale@UCDAVIS.EDU>, David John Wolking <djwolking@ucdavis.edu>
Subject: RE: PREDICT expenses update & questions

Yup, that works for me. Thanks!

Elizabeth Leasure

Financial Operations Manager

One Health Institute

530-304-1403 (cell)

530-754-9034 (office)

Skype: ealeasure

From: Brooke Genovese <bgenovese@ucdavis.edu>
Sent: Friday, May 3, 2019 9:00 AM
To: Jonna Mazet <jkmazet@ucdavis.edu>; Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
Cc: Hannah R Chale <hrchale@UCDAVIS.EDU>; David John Wolking <djwolking@ucdavis.edu>
Subject: Re: PREDICT expenses update & questions

Hi Liz,

Jonna has a layover on May 8th from 3 – 4:30ish. Would that work for a call?

-Brooke

From: Jonna Mazet <jkmazet@ucdavis.edu>
Date: Thursday, May 2, 2019 at 10:41 PM
To: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
Cc: Hannah R Chale <hrchale@UCDAVIS.EDU>, David John Wolking <djwolking@ucdavis.edu>, Brooke Genovese <bgenovese@ucdavis.edu>
Subject: Re: PREDICT expenses update & questions

Great analysis, Liz. It would be good to have a call. I have a lot of travel coming, but I can certainly do a call from an airport, if you and Brooke want to work on that.

Appreciate it,

J

On Thu, May 2, 2019 at 4:22 PM Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Hi Jonna. I've done yet another update of the PREDICT expense tracker (attached), including an additional scenario that accounts for FY18 funds being acceptable for Global and Admin management costs incurred *on behalf of* the TVPA countries to help with decision making. I've noted some key points and questions needing your input below. I'm happy to work with Brooke to arrange a call so we can discuss in more detail since things are getting pretty complicated at this point and are probably difficult to digest by email. J I'm also happy to meet you somewhere in Davis or come to SF if you think that would be easiest. Just let me know what works for you. Thanks!!!

PREDICT/GVP Financials Updates:

1. I spoke to Shareif at Columbia, and he has indicated that the $100K obligation we began processing this week is not enough to ensure that they are able to invoice because the amount will not cover the current overdraft plus May expenses. As a result, by the time the $100K obligation would be executed and processed on their end, May expenses will have posted putting the account back into overdraft, thus prohibiting invoicing yet again. He estimates that another $48K will be needed to ensure that Columbia can invoice for Y5 expenses in June. If we can't make that work, then the invoicing will have to wait until after the Y5 funds are received from USAID and we're able to obligate the rest of Columbia's budget. He seemed fine with not being able to invoice until the full budget is obligated to Columbia, but I'm not sure how critical it is that those costs get invoiced now versus later given our current funding situation. Please advise.

   · *The attached expense trackers account for our obligating $100K from FY17 money and $48K from the borrowed Ebola funds to Columbia to ensure they can invoice. As you can see, this reduces the amount of FY17 funds available for TVPA countries.*

2. With estimated costs through May and current contractual obligations for consultants, UCD's GVP budget is $118K overdrawn. There is $116K in the *unobligated subawards* portion of the GVP budget (previously earmarked for Columbia) that is currently offsetting our UCD overdraft, but to date, the $341K for the GVP BCA study has not been obligated to the Metabiota subaward (due to the late receipt of our Y5 funds). I plan on obligating those funds to Metabiota as soon as the balance of our Y5 obligation is received from USAID, but please let me know if this is unacceptable, and I'll see what can possibly be done (creative accounting required). Metabiota has not reached out indicating that they are in desperate need of these funds (and they just received a PREDICT obligation plus a small amount of GVP), but I imagine they would appreciate receiving the BCA funds as soon as possible. I also don't see any funds available for a UCB subaward until our Y5 funds are received, but this likely will not be an issue considering the amount of time it will take to get approval from Andrew for a new subaward.

- *The attached expense trackers reflect the full amount obligated for Y5 to date as being attributed to the PREDICT Core-funded budget. However, recognizing that the distinction between PREDICT and GVP budgets is somewhat arbitrary, we could change that if necessary. It would just mean that there is less available for to obligate for PREDICT activities until the rest of the Y5 funds are received.*

3. Assuming that Global/Admin Mgt cost incurred on behalf of TVPA countries is okay on FY18 funds, we have enough FY17 funds on-hand to fully-fund the China and RoC country budgets (if that is something we want to do). SI and MB have confirmed that Myanmar and Laos are okay with the country budgets obligated to date as long as they get their full Global/Admin budgets, so no additional FY17 fund obligations are needed for those two countries to wrap up PREDICT. The $235K that is left remaining at UCD (if we fully-fund the remainder of EHA's in-country China and RoC budgets) would be all that we have left for Dx and other costs at UCD ($150K direct costs) until we get the obligation from USAID, so I'm not sure that is something we want to do. Please advise.

- *My preference would be to obligate the rest of the FY17 funds that we intend to give partners for TVPA countries **before** we receive the obligation from USAID so that it is very clear that no FY18 funds were used.*

4. Below are the GHSA country balances based on the most recent LOP expenditure by country expenditure report.

Country	Ebola Funding	Revised Caps August 2018	Cap Balances
AFRICA			
Cameroon	4,576,081	5,175,000	598,919
Cote d'Ivoire	3,602,828	4,000,000	397,172
DRC	5,474,825	5,950,000	475,175
Ethiopia	2,298,516	2,930,000	631,484
Gabon	-	-	-
Ghana	2,782,385	3,385,000	602,615
Guinea	5,030,488	5,376,000	345,512
Kenya	1,840,072	2,166,000	325,928
Liberia	4,624,092	5,451,000	826,908
RoC	-	-	-
Rwanda	-	-	-
Senegal	3,545,842	4,092,000	546,158
Sierra Leone	7,342,680	8,322,000	979,320
South Sudan	-	-	-

Sudan	-	-	-
Tanzania	4,429,426	5,363,000	933,574
Uganda	3,700,548	4,090,000	389,452
TOTAL AFRICA	**49,247,784**	**56,300,000**	**7,052,216**

Elizabeth Leasure

Financial Operations Manager

One Health Institute

530-304-1403 (cell)

530-754-9034 (office)

Skype: ealeasure

From: Christian Brechot <cbrechot@gvn.org>
To: Peter Daszak <daszak@ecohealthalliance.org>;jkmazet@ucdavis.edu" <jkmazet@ucdavis.edu>;erubin@metabiota.com <erubin@metabiota.com>;peter@gisaid.org <peter@gisaid.org>; [redacted];Jennifer Gardy <Jennifer.Gardy@gatesfoundation.org> [redacted];MurrayS@si.edu" <MurrayS@si.edu>
CC: Samtha Maher <maher@ecohealthalliance.org>; [redacted];Cara Chrisman <cchrisman@usaid.gov>
Sent: 6/18/2019 4:28:47 AM
Subject: Re: Timeline for the GVP 501c3 filing

Dear Peter
Thank you for these informations
Best regards
christian

From: Peter Daszak
Sent: Monday, June 17, 2019 8:14 PM
To: Peter Daszak; jkmazet@ucdavis.edu; erubin@metabiota.com; peter@gisaid.org; Christian Brechot; [redacted]; [redacted]); MurrayS@si.edu
Cc: Samtha Maher; [redacted]; Cara Chrisman
Subject: Timeline for the GVP 501c3 filing

Dear All,

I just wanted to check back in with you all and let you know where we are in the process of launching the GVP 501c3. Right now, the filing documents have been drafted, reviewed and revised by myself, Jonna and Eddy, and are back with our *pro bono* lawyers for final versions to be prepared.

We're planning to file on or around September 1st 2019 and at that point, or just before, we'll send documents out for your signatures. We'll then look for dates to set up our first Board meeting towards the end of the year, or early 2020.

In the meantime, we're still working hard to build the background case for the GVP with economic analyses of the return-on-investment case for the GVP, modeling to target surveillance, and extensive discussions with Thailand and China colleagues to work on the details of the Thai Virome Project (TVP) and the China Virome Project (CVP).

For more information, please keep up to date via our newsletter that Eri Togami updates, our twitter account @GlobalVirome, and the website www.globalviromeproject.org In the meantime… have a great summer, and I look forward to getting back to you all at the end of August.

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

Tel. +1 212-380-4474

Website: www.ecohealthalliance.org
Twitter: @PeterDaszak

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

From:	Nathan Wolfe <nwolfe@metabiota.com>
To:	Jonna Mazet <jkmazet@ucdavis.edu>
CC:	Cara Chrisman <cchrisman@usaid.gov>;Dennis Carroll <dcarroll@usaid.gov>;Eddy Rubin <erubin@metabiota.com>[REDACTED];Peter Daszak <daszak@ecohealthalliance.org>;Samtha Maher <maher@ecohealthalliance.org>
Sent:	7/23/2019 6:43:18 PM
Subject:	Re: GVP call + Meeting in August?

Either works for me

I Can check on Metabiota and get back shortly.

Best
Nathan

On Tue, Jul 23, 2019 at 11:14 AM Jonna Mazet <jkmazet@ucdavis.edu> wrote:
If not, I can reserve a conference room at UCSF.
Let me know,
Jonna

On Tue, Jul 23, 2019 at 10:54 AM Cara Chrisman <cchrisman@usaid.gov> wrote:
Thanks, Peter (and, my apologies, I had forgotten that you communicated that previously).

Nathan - If there is any space at Metabiota that we could use on the 20th, please let us know.

If others have suggestions for an alternative locale, please let me know!

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
U.S. Agency for International Development (USAID) Contractor
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
2100 Crystal Drive, CP3-8091A, Arlington, VA 22202

Desk: (571) 551-7413
Cell: (202) 674-3231
E-mail: cchrisman@usaid.gov

GHSI-III - Social Solutions International, Inc. prime contractor

On Tue, Jul 23, 2019 at 11:39 AM Peter Daszak <daszak@ecohealthalliance.org> wrote:

Sorry folks – I can't come to the meeting in CA – it's move-in week for my daughter's college and I'm definitely not available on the 20th, 21st and 22nd. Samantha and Yasha will be there, Carlos is hoping to but might have to be at another meeting.

Samantha can take part on the GVP stuff and I'll make sure she's briefed on all the latest from China..

Hope that works and if possible I'll try to call in at some point

Cheers,

Peter

Peter Daszak

President

EcoHealth Alliance

460 West 34th Street – 17th Floor

New York, NY 10001

Tel. +1 212-380-4474

Website: www.ecohealthalliance.org

Twitter: @PeterDaszak

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that prevent pandemics and promote conservation.

From: Cara Chrisman [mailto:cchrisman@usaid.gov]
Sent: Tuesday, July 23, 2019 11:14 AM
To: Jonna Mazet
Cc: Nathan Wolfe; Eddy Rubin; Peter Daszak; REDACTED; Dennis Carroll; Samtha Maher
Subject: Re: GVP call + Meeting in August?

Hi All,

Thanks so much for your responses!

Peter/Sam - It sounds like the 20th would be ideal, would that also work on your end?

Nathan - Any chance we could use your conference room again this time around?

Best,

Cara

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
U.S. Agency for International Development (USAID) Contractor
Bureau for Global Health, Office of Infectious Disease, Emerging Threats Division
2100 Crystal Drive, CP3-8091A, Arlington, VA 22202

Desk: (571) 551-7413
Cell: (202) 674-3231
E-mail: cchrisman@usaid.gov

GHSI-III - Social Solutions International, Inc. prime contractor

On Tue, Jul 23, 2019 at 12:18 AM Jonna Mazet <jkmazet@ucdavis.edu> wrote:

I'm available on the 20th but not the 22nd.

J

On Mon, Jul 22, 2019 at 3:47 PM Nathan Wolfe <nwolfe@metabiota.com> wrote:

Hi All

I'm around as well and flexible.

Best

Nathan

On Mon, Jul 22, 2019 at 2:26 PM Eddy Rubin <erubin@metabiota.com> wrote:

HI Cara,

I am around and available to meet whenever it is convenient for the others.

Eddy

On Wed, Jul 17, 2019 at 11:25 PM Cara Chrisman <cchrisman@usaid.gov> wrote:

Hi Team,

Dennis and I conferred regarding tomorrow's GVP call and do not have any agenda items that are pressing. We would like to propose to cancel but wanted to check in with others before doing so. Any thoughts?

Additionally, we wanted to check in with folks and see if there might be interest and availability to add on some time during the upcoming Berkeley meeting to discuss the future of the GVP overall. Would you all be free before/after the meeting, perhaps for a half day discussion?

Best,
Cara

Sent from my iPhone

From:	Zoe Grange <zlgrange@ucdavis.edu>
To:	Tracey Goldstein <tgoldstein@ucdavis.edu>
CC:	Tammie O'Rourke <torourke@metabiota.com>;Anthony, Simon J." <sja2127@cumc.columbia.edu>;Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>;Jonna Mazet <jkmazet@ucdavis.edu>
Sent:	4/27/2020 12:03:49 PM
Subject:	Re: PREDICT virus data and spillover risk ranking

Thank you Tammie and Tracey, your explanation helps, I won't include this data.

Cheers,

Zoe

From: Tracey Goldstein
Date: Friday, April 24, 2020 at 4:50 PM
To: Zoe Grange
Cc: Tammie O'Rourke , "Anthony, Simon J." , Christine Kreuder Johnson , Jonna Mazet
Subject: Re: PREDICT virus data and spillover risk ranking

Hi Zoe,

Yes, they were not able to complete testing, so please do not include in analysis.

Tammie, we were going to change those to say Testing not completed, rather than confirmation positive. I know we are still working through cleaning these up.

T

On Fri, Apr 24, 2020 at 5:01 AM Zoe Grange <zlgrange@ucdavis.edu> wrote:
Hi Tammie,

I pulled the P2 interpreted tests data for the countries (excluding the countries listed below). I found some results, predominantly for Bangladesh, that are 'ConfirmationResult' positive but do not have anything listed for the 'Virus' type and 'Interpretation' columns. I've listed them in the attached the spreadsheet. Is there a reason for these results?

Cheers,

Zoe

From: Tammie O'Rourke <torourke@metabiota.com>
Date: Friday, April 17, 2020 at 5:47 PM
To: Zoe Grange <zlgrange@ucdavis.edu>
Cc: Tracey Goldstein <tgoldstein@ucdavis.edu>, "Anthony, Simon J." <sja2127@cumc.columbia.edu>, Christine Kreuder Johnson <ckjohnson@UCDAVIS.EDU>, Jonna Mazet <jkmazet@ucdavis.edu>
Subject: Re: PREDICT virus data and spillover risk ranking

Hi Zoe,
I can address #3. All countries are fully approved, with the exception of Guinea, Liberia, Malaysia & DRC.
As for being able to use the data for your app, I will defer to Chris for confirmation.
Tammie

On Fri, Apr 17, 2020 at 7:34 AM Zoe Grange <zlgrange@ucdavis.edu> wrote:
Hi everyone,

I was discussing the PREDICT data with Jonna the other day in terms of the spillover risk ranking. I have a few questions below that I was wondering if you could help with:

1. Where is the predict data for viruses that are collaboratively collected in Thailand and China? Are they in Eidith? If, so are they the ones listed as not Predict protocol?
2. For the SpilOver manuscript, I have only included data from P1 that was collected using PREDICT protocols. Do you think it's worth adding the non-predict protocol data? (possibly post-publication)
3. What is the status of the PREDICT 2 virus data? Do we have outstanding records for government approval? Do we have some countries that are completed that I could use for the spillover risk ranking?

Many thanks for your help. Hope you are all well ☺

Zoe

--
Tammie O'Rourke
Metabiota
Senior Information Management Developer
Emerging Pandemic Threats - PREDICT Program
tel +1-250-618-2460

--
Tracey Goldstein, PhD
Associate Director, One Health Institute
Professor, Department of Pathology, Microbiology and Immunology
Director, One Health Institute Laboratory
One Health Institute
School of Veterinary Medicine
University of California
Davis, CA 95616
Phone: (530) 752-0412
Fax: (530) 752-3318
E-mail: _____

From: Cara Chrisman <cchrisman@usaid.gov>
Sent: Fri, 6 Jan 2017 09:30:02 -0500
Subject: Re: Planning GVP does San Francisco
To: Eddy Rubin <erubin@metabiota.com>
Cc: Elizabeth S Chase <eschase@ucdavis.edu>, Jonna Mazet [REDACTED], Dennis Carroll <dcarroll@usaid.gov>, Nathan Wolfe <nwolfe@metabiota.com>, Taylor Elnicki <telnicki@metabiota.com>

Hi Eddy,
This may have already been discussed, but was there interest in you meeting with any of the VC-type individuals as well? I'm not sure if there is utility in further engaging with them at this point, but wanted to check. I believe last time we met with Zach Bogue, Eric Delwart, and Michael McCullough.

Best,
Cara

Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)

Desk: (202) 712-1161
Cell: (202) 674-3231
E-mail: cchrisman@usaid.gov

On Thu, Jan 5, 2017 at 6:49 PM, Eddy Rubin <erubin@metabiota.com> wrote:

Hi

I have spoken with the people at the BioHub and what might work is that after the 24th 1:00-2:00 meeting at the Science Philanthropy Alliance in Palo Alto we would travel down the road to Stanford where there is BioHub South and where Peter Kim and Steve Quake senior members of the BioHub are based for a 3:00 meeting.

Possible Schedule so far:

24th

Dennis Arrives in SF ~10 gets picked up at airport drive to Palo Alto

1:00-2:00 meeting at the Science Philanthropy Alliance in Palo

3:00-5:00 meeting at Stanford with BioHub South

25th

2:00-4:00 meeting at Illumina Mission Bay

26th

All day meeting at Metabiota planning China

Other meetings/ people we want to inquire about their availability for the morning of the 25th ???

From: Elizabeth S Chase <eschase@ucdavis.edu>
Date: Thursday, January 5, 2017 at 11:02 AM
To: Hannah Miller <hmiller@sciphil.org>
Cc: Eddy Rubin <erubin@metabiota.com>, Taylor Elnicki <telnicki@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>
Subject: RE: Global Virome Project

Hi Hannah,

Thank you very much for looking at the possibility. I know the GVP Group is looking forward to a great meeting and will be there at 1pm on January 24.

Warmest Regards,

Liz

From: Hannah Miller [mailto:hmiller@sciphil.org]
Sent: Thursday, January 05, 2017 10:50 AM
To: Elizabeth S Chase <eschase@ucdavis.edu>
Subject: RE: Global Virome Project

Hello Liz,

So sorry but Marc and Valerie both have appointments during that time on the 25th. Please let me know if you need to reschedule for another day.

Best,

Hannah

Hannah Miller | Administrative Assistant

Science Philanthropy Alliance

480 S California Ave, STE 304, Palo Alto, CA 94306

hmiller@sciphil.org | +1.650.338.1203

www.sciphil.org | @sciphilorg

From: Elizabeth S Chase [mailto:eschase@ucdavis.edu]
Sent: Thursday, January 5, 2017 10:17 AM
To: Hannah Miller <hmiller@sciphil.org>
Cc: (erubin@metabiota.com) <erubin@metabiota.com>; Jonna Mazet <jkmazet@ucdavis.edu>; (dcarroll@usaid.gov) <dcarroll@usaid.gov>; Cara Chrisman <cchrisman@usaid.gov>; Elnicki Taylor (telnicki@metabiota.com) <telnicki@metabiota.com>
Subject: RE: Global Virome Project

Hello Hannah,

I just had a short meeting with the GVP executives and we were wondering if the times you had offered on January 25 might still be available. I understand it may be an inconvenience to make the change but if we could consider scheduling the GVP Group from 10am-12pm on January 25 it would be tremendously helpful.

If not we certainly understand and will keep the appointment as is on January 24.

Thank you so much,

Liz

Liz Chase

Executive Assistant to Dr. Jonna Mazet

One Health Institute

University of California, Davis

530-752-3630

eschase@ucdavis.edu

From: Hannah Miller [mailto:hmiller@sciphil.org]
Sent: Wednesday, January 04, 2017 12:11 PM

To: Elizabeth S Chase <eschase@ucdavis.edu>
Subject: RE: Global Virome Project

Great, thank you! Just sent it over ☺

From: Elizabeth S Chase [mailto:eschase@ucdavis.edu]
Sent: Wednesday, January 4, 2017 11:49 AM
To: Hannah Miller <hmiller@sciphil.org>
Subject: RE: Global Virome Project

Hi Hannah,

Yes, that would be fine. And if you would please, send a calendar invite to: (dcarroll@usaid.gov); (nwolfe@metabiota.com); Elnicki Taylor (telnicki@metabiota.com); (erubin@metabiota.com); Rebecca Benmahdi <rbenmahdi@metabiota.com>; Cara Chrisman cchrisman@usaid.gov

Simply note the time adjustment in the invitation. Thank you—Liz

From: Hannah Miller [mailto:hmiller@sciphil.org]
Sent: Wednesday, January 04, 2017 11:45 AM
To: Elizabeth S Chase <eschase@ucdavis.edu>
Subject: RE: Global Virome Project

Hello Liz,

Apologies, I was running through Marc's meetings with him this morning and he is not going to have time for a two hour meeting on the 24th. Is it possible to schedule the meeting from 1-2pm on the 24th?

Thank you and so sorry for the change!

Hannah

Hannah Miller | Administrative Assistant

Science Philanthropy Alliance

480 S California Ave, STE 304, Palo Alto, CA 94306

hmiller@sciphil.org | +1.650.338.1203

www.sciphil.org | @sciphilorg

From: Elizabeth S Chase [mailto:eschase@ucdavis.edu]
Sent: Tuesday, January 3, 2017 2:52 PM
To: Hannah Miller <hmiller@sciphil.org>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>; (dcarroll@usaid.gov) <dcarroll@usaid.gov>; (nwolfe@metabiota.com) <nwolfe@metabiota.com>; Elnicki Taylor (telnicki@metabiota.com) <telnicki@metabiota.com>; (erubin@metabiota.com) <erubin@metabiota.com>; Rebecca Benmahdi <rbenmahdi@metabiota.com>; Cara Chrisman <cchrisman@usaid.gov>
Subject: RE: Global Virome Project

Hello Hannah,

Happy New Year to you as well. It would be wonderful if we could confirm January 24 from noon to 2:00pm. Currently scheduled to attend are: Dr. Dennis Carroll, Dr. Jonna Mazet, Dr. Eddy Ruben and Dr. Nathan Wolf, all from the Global Virome Project.

It is very gracious to offer your offices as a meeting location. Would that be your Palo Alto offices on 480 S California Ave? If so, I will notify our participants.

Very Sincerely,

Liz

Liz Chase

Executive Assistant to Dr. Jonna Mazet

One Health Institute

University of California, Davis

530-752-3630

eschase@ucdavis.edu

From: Hannah Miller [mailto:hmiller@sciphil.org]
Sent: Tuesday, January 03, 2017 9:28 AM
To: Elizabeth S Chase <eschase@ucdavis.edu>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>
Subject: RE: Global Virome Project

Hello Liz,

Very nice to meet you, electronically in any case. We can certainly look at those dates. January 24 and 25th would actually be very good for both Marc and Valerie's schedules. We would be very happy to host a meeting here at our office if they'd like to come down to the South Bay, or perhaps schedule a lunch meeting. Please let me know what would be most convenient for your team. Below I have listed their availabilities for both dates:

January 24th: 8:00am-9:30am ; 12:00pm -2:00pm

January 25th: 8:00am-3:00pm

Thank you and happy new year!

Hannah

Hannah Miller | Administrative Assistant

Science Philanthropy Alliance

480 S California Ave, STE 304, Palo Alto, CA 94306

hmiller@sciphil.org | +1.650.338.1203

www.sciphil.org | @sciphilorg

From: Elizabeth S Chase [mailto:eschase@ucdavis.edu]
Sent: Friday, December 23, 2016 10:24 AM
To: Hannah Miller <hmiller@sciphil.org>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>
Subject: FW: Global Virome Project
Importance: High

Hello Hannah,

Allow me introduce myself, I am Liz Chase and I provide administrative support to Jonna Mazet. I appreciate your assistance in setting a meeting between your executives Marc Kastner and Valerie Cohn and members of the Global Virome Project.

Thank you for offering the meeting/call dates/time options for 12, 13 and 18 January. If it is at all

possible, might we look for a date/time during January 24 -26 that would accommodate a face-to-face meeting? During those three days, the top executives of the Global Virome Project will be meeting in San Francisco and it would be a perfect opportunity for a formal, face-to-face introduction with the Science Philanthropy Alliance.

If that is not possible I certainly understand, and we will look for possible alternatives, which may very well include the January 12, 13 and 18 dates you have already suggested. I look forward to working with you and send my warmest regards,

Sincerely, Liz

Liz Chase

Executive Assistant to Dr. Jonna Mazet

One Health Institute

University of California, Davis

530-752-3630

eschase@ucdavis.edu

From: [REDACTED] [mailto:[REDACTED]] **On Behalf Of** Jonna Mazet
Sent: Thursday, December 22, 2016 12:31 PM
To: Elizabeth S Chase <eschase@ucdavis.edu>
Subject: Fwd: Global Virome Project

---------- Forwarded message ----------
From: **Marc Kastner** <mkastner@sciphil.org>
Date: Thu, Dec 22, 2016 at 11:45 AM
Subject: Re: Global Virome Project
To: "Harvey V. Fineberg" <harvey.fineberg@moore.org>, Valerie Conn <vconn@sciphil.org>
Cc: "nwolfe@metabiota.com" <nwolfe@metabiota.com>, "jkmazet@ucdavis.edu" <jkmazet@ucdavis.edu>, Hannah Miller <hmiller@sciphil.org>

Dear Harvey,

Thank you for the introduction and we also wish you an enjoyable holiday.

Best,

Marc

Dear Jonna and Nathan,

We would love to hear more about your effort. I am copying our assistant, Hannah, who can set up a time for us to meet.

Sincerely,

Marc

Marc Kastner | President

Science Philanthropy Alliance

mkastner@sciphil.org | +1.650.338.1201

www.sciphil.org | @sciphilorg

From: "harvey.fineberg@moore.org" <harvey.fineberg@moore.org>
Date: Thursday, December 22, 2016 at 10:44 AM
To: Marc Kastner <mkastner@sciphil.org>, Valerie Conn <vconn@sciphil.org>
Cc: "nwolfe@metabiota.com" <nwolfe@metabiota.com>, "jkmazet@ucdavis.edu" <jkmazet@ucdavis.edu>
Subject: Global Virome Project

Dear Marc and Valerie,

I am writing to introduce Jonna Mazet and Nathan Wolfe who are engaged in an extraordinary and ambitious project to identify virtually every viral pathogen on the planet. Building on years of field experience, genomic technology, and new data analytics, the Global Virome Project is a remarkable enterprise.

I wanted bring this to your attention because of the intrinsic scientific interest and because it occurred to me that you may be aware of potential interest among members of the Science Philanthropy Alliance.

Let me take this opportunity, too, to wish you both a joyous holiday season and successful year ahead.

Warm regards,

Harvey

Harvey V. Fineberg, MD, PhD

President

Gordon and Betty Moore Foundation

From:	Elizabeth Leasure <ealeasure@ucdavis.edu>
To:	Alisa Pereira <apereira@usaid.gov>;Andrew Clements <AClements@usaid.gov>
CC:	Cassandra Louis Duthil <clouisduthil@usaid.gov>;Jonna Mazet <jkmazet@UCDAVIS.EDU>;David John Wolking <djwolking@UCDAVIS.EDU>;Katherine Leasure <kaleasure@UCDAVIS.EDU>
Sent:	1/9/2017 4:30:48 PM
Subject:	PREDICT International Travel Requests

Please find below international travel requests for your review and approval. Please let me know if you have any questions. Thanks!!

O'Rourke, O'Rourke (USA): $235 airfare each/$179 (Davis) max daily per diem

Mazet (Ghana): $9,000 **business class required due to* REDACTED /$331 (Accra) max daily per diem

Montecino (Ghana): $2,000 airfare/$331 (Accra) max daily per diem

Kelly (Ghana): $2,000 airfare/$331 (Accra) max daily per diem

Bhatta & Sharma (USA): $1,800 airfare each/$179 (Davis) max daily per diem

Multiple – OH Economic Evaluation Workshop (USA)

Travel Requests:

1. Metabiota would like to request travel approval for Tammie O'Rourke and Daniel O'Rourke to travel from Nanaimo, British Columbia, Canada to Davis, California, USA from February 8 – 11, 2017 to meet with the UCD global team.

Trip purpose: To meet with UC Davis global team to discuss USAID reporting and PREDICT Year 3 workflow.

2. UC Davis would like to request travel approval for Dr. Jonna Mazet to travel from Davis, California, USA to Accra, Ghana from February 19-24, 2017 to meet with project partners to discuss coordination and implementation of sampling, surveillance, and diagnostic activities.

Trip purpose: Dr. Mazet will be traveling to Accra with Dr. Terra Kelly in order to meet with PREDICT partners to discuss implementation of surveillance and diagnostic laboratory activities, and scoping and planning for upcoming surveillance activities and research at a new site for PREDICT (area of the 37 Military Hospital in Accra). Meetings will also be held with FAO to discuss coordination of sampling activities at shared surveillance sites.

3. UC Davis would like to request travel approval for Dr. Terra Kelly to travel from Flagstaff, Arizona, USA to Accra, Ghana from February 19-March 2, 2017 to meet with project partners to discuss coordination and implementation of sampling, surveillance, and diagnostic activities, as well as conduct additional training with team on the EIDITH database.

Trip purpose: Dr. Kelly will be traveling to Accra with Dr. Mazet in order to meet with PREDICT partners to discuss implementation of surveillance and diagnostic laboratory activities, and scoping and planning for upcoming surveillance activities and research at a new site for PREDICT (area of the 37 Military Hospital in Accra). Meetings will also be held with FAO to discuss coordination of sampling activities at shared surveillance sites, and Dr. Kelly will be conducting additional training for PREDICT implementing partners on data entry and management in the EIDITH database.

4. UC Davis would like to request travel approval for Dr. Diego Montecino to travel from Davis California, USA to Accra, Ghana from February 19-April 19, 2017 to develop and implement protocols at 37 Military Hospital research site.

Trip purpose: Dr. Montecino will be developing and implementing protocols for research to investigate the influence of straw colored fruit bat population demographics on shedding of Coronaviruses at the 37 Military Hospital site.

5. UC Davis/CMDN would like to request travel approval for Mr. Tarka Raj Bhatta and Mr. Ajay Narayan Sharma to travel from Kathmandu, Nepal to Davis, California, USA from February 19-March 5, 2017 to conduct laboratory training.

Trip purpose: Mr. Bhatta and Mr. Sharma (wet laboratory managers at Center for Molecular Dynamics Nepal (CMDN), primary implementing parter for PREDICT in Nepal) will participate in training on cloning, preparation of samples for sequencing of suspect positives, evaluation of sequences, and laboratory optimization for implementation of PREDICT viral testing activities.

6. EcoHealth Alliance would like to request approval for the **individuals listed below** to travel from **their respective departure locations (listed below)** to Washington, DC, USA from January 30 to February 2, 2017 for the One Health Economic Evaluation Workshop.

Trip purpose: This expert workshop and high-level forum on One Health economic evaluation (see 2nd bullet under Sub-activity 4.2.3 in Y3 PREDICT work plan), co-hosted by the World Bank and the PREDICT project, will convene experts to evaluate the cost-effectiveness of One Health approaches, building on the "People, Pathogens and Our Planet: The Economics of One Health" and "Drug Resistant Infections: A Threat to Our Economic Future" reports (World Bank, 2012 and 2016). Specific objectives are to: 1) generate additional economic analyses on the cost and economic options to address emerging and endemic diseases relevant to One Health, 2) identify key policy-oriented information and data gaps, and 3) recommend methods for assessing the costs and benefits of intervention options for pandemic and epidemic risk. Experts selected will help disseminate workshop outputs, including engagement of World Bank country economists in future data analysis and dissemination. Information generated will also be shared with the World Bank – World Health Organization Financing Pandemic Preparedness Task Force. Max daily per diem for Washington, DC is $251.

Travelers Name	Title/Affiliation
Jonathan Rushton	Professor of Animal Health and Food Systems Economics, University of Liverpool
Tianna Brand	Head of Programmes Department & Biological Threat Reduction, OIE
Jose Cortiñas	Officer, Assessment and methodological support Unit, European Food Safety Authority
Delia Grace	Program Manager, Food Safety & Zoonoses, ILRI
Andy Hill	BAE Systems
Guy Hutton	Development Economist, WHO
Kazuaki Miyagishima	Director, WHO Department of Food Safety and Zoonoses
Jane Richardson	Senior Officer, Evidence management, European Food Safety Authority
Dirk Pfeiffer	Chair Professor of One Health, School of Veterinary Medicine, City University of Hong Kong
Arjan Stegeman	Chair, Farm Animal Health, Utrecht University
Mieghan Bruce	Post-Doc, Institute of Infection and Global Health, University of Liverpool
Barbara Haesler	Chair, Network for Evaluation of One Health; Economics and Public Health Group, Royal Veterinary College
Jakob Zinsstag	Deputy head, Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute
Simon Ruegg	Senior Research Assistant, University of Zurich
Guillaume Fournié	Research Fellow, Veterinary Epidemiology, Economics and Public Health, Royal Veterinary College
Julio Pinto	Animal Health Officer, Food and Agriculture Organization of the UN

From: Andrew Clements <aclements@usaid.gov>
To: Elizabeth Leasure <ealeasure@ucdavis.edu>
CC: Alisa Pereira <apereira@usaid.gov>;Cassandra Louis Duthil <clouisduthil@usaid.gov>;Jonna Mazet <jkmazet@ucdavis.edu>;David John Wolking <djwolking@ucdavis.edu>;Katherine Leasure <kaleasure@ucdavis.edu>
Sent: 1/9/2017 6:15:18 PM
Subject: Re: PREDICT International Travel Requests

Travel to USA approved.

Travel to Ghana approved subject to mission concurrence.

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jan 9, 2017, at 6:31 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Please find below international travel requests for your review and approval. Please let me know if you have any questions. Thanks!!

O'Rourke, O'Rourke (USA): $235 airfare each/$179 (Davis) max daily per diem

Mazet (Ghana): $9,000 **business class required due to* REDACTED /$331 (Accra) max daily per diem

Montecino (Ghana): $2,000 airfare/$331 (Accra) max daily per diem

Kelly (Ghana): $2,000 airfare/$331 (Accra) max daily per diem

Bhatta & Sharma (USA): $1,800 airfare each/$179 (Davis) max daily per diem

Multiple – OH Economic Evaluation Workshop (USA)

Travel Requests:

1. Metabiota would like to request travel approval for Tammie O'Rourke and Daniel O'Rourke to travel from Nanaimo, British Columbia, Canada to Davis, California, USA from February 8 – 11, 2017 to meet with the UCD global team.

Trip purpose: To meet with UC Davis global team to discuss USAID reporting and PREDICT Year 3 workflow.

2. UC Davis would like to request travel approval for Dr. Jonna Mazet to travel from Davis, California, USA to Accra, Ghana from February 19-24, 2017 to meet with project partners to discuss coordination and implementation of sampling, surveillance, and diagnostic activities.

Trip purpose: Dr. Mazet will be traveling to Accra with Dr. Terra Kelly in order to meet with PREDICT partners to discuss implementation of surveillance and diagnostic laboratory activities, and scoping and planning for upcoming surveillance activities and research at a new site for PREDICT (area of the 37 Military Hospital in Accra). Meetings will also be held with FAO to discuss coordination of sampling activities at shared surveillance sites.

3. UC Davis would like to request travel approval for Dr. Terra Kelly to travel from Flagstaff, Arizona, USA to Accra, Ghana from February 19-March 2, 2017 to meet with project partners to discuss coordination and implementation of sampling, surveillance, and diagnostic activities, as well as conduct additional training with team on the EIDITH database.

Trip purpose: Dr. Kelly will be traveling to Accra with Dr. Mazet in order to meet with PREDICT partners to discuss implementation of surveillance and diagnostic laboratory activities, and scoping and planning for upcoming surveillance activities and research at a new site for PREDICT (area of the 37 Military Hospital in Accra). Meetings will also be held with FAO to discuss coordination of sampling activities at shared surveillance sites, and Dr. Kelly will be conducting additional training for PREDICT implementing partners on data entry and management in the EIDITH database.

4. UC Davis would like to request travel approval for Dr. Diego Montecino to travel from Davis California, USA to Accra, Ghana from February 19-April 19, 2017 to develop and implement protocols at 37 Military Hospital research site.

Trip purpose: Dr. Montecino will be developing and implementing protocols for research to investigate the influence of straw colored fruit bat population demographics on shedding of Coronaviruses at the 37 Military Hospital site.

5. UC Davis/CMDN would like to request travel approval for Mr. Tarka Raj Bhatta and Mr. Ajay Narayan Sharma to travel from Kathmandu, Nepal to Davis, California, USA from February 19-March 5, 2017 to conduct laboratory training.

Trip purpose: Mr. Bhatta and Mr. Sharma (wet laboratory managers at Center for Molecular Dynamics Nepal (CMDN), primary implementing parter for PREDICT in Nepal) will participate in training on cloning, preparation of samples for sequencing of suspect positives, evaluation of sequences, and laboratory optimization for implementation of PREDICT viral testing activities.

6. EcoHealth Alliance would like to request approval for the **individuals listed below** to travel from **their respective departure locations (listed below)** to Washington, DC, USA from January 30 to February 2, 2017 for the One Health Economic Evaluation Workshop.

Trip purpose: This expert workshop and high-level forum on One Health economic evaluation (see 2nd bullet under Sub-activity 4.2.3 in Y3 PREDICT work plan), co-hosted by the World Bank and the PREDICT project, will convene experts to evaluate the cost-effectiveness of One Health approaches, building on the "People, Pathogens and Our Planet: The Economics of One Health" and "Drug Resistant Infections: A Threat to Our Economic Future" reports (World Bank, 2012 and 2016). Specific objectives are to: 1) generate additional economic analyses on the cost and economic options to address emerging and endemic diseases relevant to One Health, 2) identify key policy-oriented information and data gaps, and 3) recommend methods for assessing the costs and benefits of intervention options for pandemic and epidemic risk. Experts selected will help disseminate workshop outputs, including engagement of World Bank country economists in future data analysis and dissemination. Information generated will also be shared with the World Bank – World Health Organization Financing Pandemic Preparedness Task Force. Max daily per diem for Washington, DC is $251.

Travelers Name	**Title/Affiliation**
Jonathan Rushton	Professor of Animal Health and Food Systems Economics, University of Liverpool
Tianna Brand	Head of Programmes Department & Biological Threat Reduction, OIE
Jose Cortiñas	Officer, Assessment and methodological support Unit, European Food Safety Authority
Delia Grace	Program Manager, Food Safety & Zoonoses, ILRI
Andy Hill	BAE Systems
Guy Hutton	Development Economist, WHO
Kazuaki Miyagishima	Director, WHO Department of Food Safety and Zoonoses
Jane Richardson	Senior Officer, Evidence management, European Food Safety Authority
Dirk Pfeiffer	Chair Professor of One Health, School of Veterinary Medicine, City University of Hong Kon
Arjan Stegeman	Chair, Farm Animal Health, Utrecht University
Mieghan Bruce	Post-Doc, Institute of Infection and Global Health, University of Liverpool
Barbara Haesler	Chair, Network for Evaluation of One Health; Economics and Public Health Group, Royal Veterinary College
Jakob Zinsstag	Deputy head, Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute
Simon Ruegg	Senior Research Assistant, University of Zurich
Guillaume Fournié	Research Fellow, Veterinary Epidemiology, Economics and Public Health, Royal Veterinary College
Julio Pinto	Animal Health Officer, Food and Agriculture Organization of the UN

From: Andrew Clements <aclements@usaid.gov>

CC: Tuttle, R Emerson CTR OSD OUSD ATL (US) <Robert.e.tuttle37.ctr@mail.mil>;Thompson, Chelsea L CTR OSD OUSD ATL (US) <Chelsea.l.thompson12.ctr@mail.mil>;Hannah (HHS/OGA) Burris (Hannah.Burris@hhs.gov) <Hannah.Burris@hhs.gov>;Carroll, Dennis(GH/HIDN) <DCarroll@usaid.gov>;Chak, Chantha (PHNOM PENH/OPHE) <cchak@usaid.gov>;Damrongwatanapokin, Sudarat (RDMA/OPH) <sDamrongwatanapokin@usaid.gov>;Fox, Elizabeth(GH/HIDN) <EFox@usaid.gov>;Garrison, Kama (GH/HIDN/ID) <kgarrison@usaid.gov>;Kim Thuy, Oanh (HANOI/OH) <okim@usaid.gov>;Nop, Sotheara (Phnom Penh/OPHE) <snop@usaid.gov>;Pereira, Alisa (GH/HIDN) <apereira@usaid.gov>;Sarker, Sukumar (USAID/Dhaka/PHNE) <ssarker@usaid.gov>;Taweekan, Jedsada (RDMA/PDO) <jTaweekan@usaid.gov>;Undrakh, Bulgan <bundrakh@usaid.gov>;Ross, Jonathan (HANOI/OH) <jross@usaid.gov>;Thwin, Aye Aye (RDMA/OPH) <aathwin@usaid.gov>;Kentro, Linda (Kathmandu/HFP) <LKentro@usaid.gov>;Pabst, August (GH/HIDN) <apabst@usaid.gov>;Long-Wagar, Andrea (AFR/SD) <alongwagar@usaid.gov>;Corwin, Andrew Lee <CorwinAL@state.gov>;Hada, Navin(Kathmandu/GDO) <nhada@usaid.gov>;Koek, Irene (Jakarta/Health) <ikoek@usaid.gov>;Milani, Tara (Phnom Penh/OPHE) <tmilani@usaid.gov>;Oliveros, Yolanda (Philippines/OH) <yoliveros@usaid.gov>;Linehan, Mary E (Jakarta/Health) <mlinehan@usaid.gov>;Elerian, Akmal (Cairo/OHP) <AElerian@usaid.gov>;Schar, Daniel (RDMA/OPH) <dSchar@usaid.gov>;Cobb, Mary (WBGAZA\\HHA) <mcobb@usaid.gov>;Cintron, Rachel (Jakarta/Health) <rcintron@usaid.gov>;Iademarco, Michael (CDC/OID/NCHHSTP) <MAI9@cdc.gov>;Ravji, Rushna (GH/AA/GHI) <rravji@usaid.gov>;Kolstad, Randy (Cairo/OHP) <RKolstad@usaid.gov>;Sorenson, Robert A <SorensonRA@state.gov>;Joe Annelli <Joseph.F.Annelli@aphis.usda.gov>;Juan (AGAH) (Juan.Lubroth@fao.org) Lubroth <Juan.Lubroth@fao.org>;Kalpravidh, Wantanee (FAORAP) <Wantanee.Kalpravidh@fao.org>;David Nabarro <david.nabarro@undp.org>;chadia.wannous@undp.org <chadia.wannous@undp.org>;Christopher Barrett <cbarrett@usaid.gov>;Lora.Polowczuk@hhs.gov <Lora.Polowczuk@hhs.gov>;kchafin@ncmi.detrick.army.mil <kchafin@ncmi.detrick.army.mil>;astjohn@ncmi.detrick.army.mil <astjohn@ncmi.detrick.army.mil>;Saldana, Kelly (GH/HIDN/MCH) <KSaldana@usaid.gov>;Chen, Judy (Philippines/OH) <juchen@usaid.gov>;Bagga-Taves, Sharlene (RDMA/OPH) <sbagga@usaid.gov>;Kramer, Lisa (Nairobi/EA/RHH) <lkramer@usaid.gov>;Boyer, Robbin B (GH/SPBO/OPS) <RBoyer@usaid.gov>;Scott (AGAH) Newman <Scott.Newman@fao.org>;Jonna Mazet <jkmazet@ucdavis.edu>;ssm20 <ssm20@columbia.edu>;William Karesh <Karesh@ecohealthalliance.org>;Peter Daszak <daszak@ecohealthalliance.org>;Gwenaelle.Dauphin@fao.org <Gwenaelle.Dauphin@fao.org>;beatrice.mouille@fao.org <beatrice.mouille@fao.org>;Jennifer Lasley <j.lasley@oie.int>;Brian_Mclaughlin@dai.com <Brian_Mclaughlin@dai.com>;dbj0@cdc.gov <dbj0@cdc.gov>;Petrillo, Jessica E <PetrilloJE@state.gov>;erika.elvander@hhs.gov <erika.elvander@hhs.gov>;karen.corson@med.navy.mil <karen.corson@med.navy.mil>;Clements, Andrew (GH/HIDN) <AClements@usaid.gov>;Ron Waldman <ronwaldman@email.gwu.edu>;Nancy Godfrey <ngodfrey@usaid.gov>;Elizabeth Haytmanek <ehaytmanek@usaid.gov>;Christian, Kira (CDC/CGH/DGDDER) <dot9@cdc.gov>;Swayne, David <David.Swayne@ars.usda.gov>;david.spiro@nih.gov <david.spiro@nih.gov>;CAITLIJG@ucia.gov <CAITLIJG@ucia.gov>;Lora Wentzel <lwentzel@usaid.gov>;RADHIKAC@ucia.gov <RADHIKAC@ucia.gov>;jkq8@cdc.gov <jkq8@cdc.gov>;Lisa Stevens <lstevens@usaid.gov>;Davis, Charles (Todd) (CDC/OID /NCIRD) <eou8@cdc.gov>;tmu0@cdc.gov <tmu0@cdc.gov>;Bresee, Joseph (CDC/CCID /NCIRD) <jsb6@cdc.gov>;GLEWS <glews@fao.org>;Pinto, Julio (AGAH) <Julio.Pinto@fao.org>;Dr. Damien Joly <djoly@metabiota.com>;Monarez, Susan <Susan_C_Monarez@nss.eop.gov>;Hunt, Richard <Richard_C_Hunt@nss.eop.gov>;aiuliano@cdc.gov <aiuliano@cdc.gov>;Nguyen Nguyen <ngunguyen@usaid.gov>;Eric King <eking@usaid.gov>;Corinne Ringholz <cringholz@usaid.gov>;Suwit_Somponpun@dai.com <Suwit_Somponpun@dai.com>;Milton Amayun <mamayun@usaid.gov>;Mumford, Elizabeth <mumforde@who.int>;Peter Wondergem <pwondergem@usaid.gov>;Aisatou Ngong <ngonga@state.gov>;Peter Morris <pmorris@usaid.gov>;Marietou SATIN <masatin@usaid.gov>;Higgs, Elizabeth (NIH/NIAID) [E] <ehiggs@niaid.nih.gov>;Anyana.Banerjee@hhs.gov <Anyana.Banerjee@hhs.gov>;Chu,

May <May_C_Chu@ostp.eop.gov>;John Neatherlin <jjn6@cdc.gov>;ztq9@cdc.gov <ztq9@cdc.gov>;Ben Zinner <bzinner@usaid.gov>;MATTHEHB <MATTHEHB@ucia.gov>;JESSIAM2 <JESSIAM2@ucia.gov>;Korde, Sonali <Padmini_S_Korde@nsc.eop.gov>;Amalhin Shek <ashek@usaid.gov>;Christina Lau <clau@usaid.gov>;Maureen Miller <miller@ecohealthalliance.org>;Shana Gillette <sgillette@usaid.gov>;Rachel Sayre <rsayre@usaid.gov>;ASHLEYEL <ASHLEYEL@ucia.gov>;Kendra Chittenden <kchittenden@usaid.gov>;Tarek Hussain <thussain@usaid.gov>;Lindsay Parish <lparish@usaid.gov>;Bethanne Moskov <bmoskov@usaid.gov>;Christine Kreuder Johnson <ckjohnson@ucdavis.edu>;Jerry_Martin@dai.com <Jerry_Martin@dai.com>;Cheryl Kamin <ckamin@usaid.gov>;ZHANG, Wenqing <zhangw@who.int>;stm2@cdc.gov <stm2@cdc.gov>;formentyp@who.int <formentyp@who.int>;Sobel, Jeremy (CDC/CGH /DGDDER) <qzs3@cdc.gov>;Nancy Lowenthal <nlowenthal@usaid.gov>;David Chapman <chapm026@umn.edu>;VonDobschuetz, Sophie (AGAH) <Sophie.VonDobschuetz@fao.org>;Claes, Filip (AGAH) <Filip.Claes@fao.org>;Siana Tackett <stackett@usaid.gov>;Lisa Childs <lchilds@usaid.gov>;Kyriacos Koupparis <kkoupparis@usaid.gov>;Nabil Alsoufi <nalsoufi@usaid.gov>;Wainwright, Sherrilyn H - APHIS <Sherrilyn.H.Wainwright@aphis.usda.gov>;Sonia Walia <swalia@usaid.gov>;Thomas Crehan <tcrehan@usaid.gov>;Seydou Samake <ssamake@usaid.gov>;Brown, Gib I (Geneva) <BrownGI@state.gov>;Gina Samaan <samaang@who.int>;Amy Kay <akay@usaid.gov>;ZIEGLER, Theodor <zieglerth@who.int>;BRIAND, Sylvie <briands@who.int>;Zandra Andre <zandre@usaid.gov>;Elisa Adelman <eadelman@usaid.gov>;Anna McCrerey <amccrerey@usaid.gov>;Haroun Habib <hhabib@usaid.gov>;Ashna Kibria <akibria@usaid.gov>;Angela Wang <awang@usaid.gov>;Tiffany D'Mello <tdmello@usaid.gov>;Cassandra Louis Duthil <clouisduthil@usaid.gov>;RODIER, Guenael R.M. <rodierg@who.int>;DE LA ROCQUE, Stéphane <delarocques@who.int>;cbartonbehravesh@cdc.gov <cbartonbehravesh@cdc.gov>;Lynn Adrian <ladrian@usaid.gov>;auf4@cdc.gov <auf4@cdc.gov>;malik@hku.hk <malik@hku.hk>;Karen.Sliter@aphis.usda.gov <Karen.Sliter@aphis.usda.gov>;Lalita Shankar <lshankar@usaid.gov>;Nicholas Kaufman <nkaufman@usaid.gov>;Saad El-Din Hassan <shassan@usaid.gov>;Ricardo Echalar <rechalar@usaid.gov>;Tara Simpson <tsimpson@usaid.gov>;Lim, Matthew L <LimML@state.gov>;Cara Chrisman <cchrisman@usaid.gov>;Marilyn Crane <mcrane@usaid.gov>;Tamara Chikhradze-Young <tchikhradze@usaid.gov>;Maysa Al-Khateeb <malkhateeb@usaid.gov>;Charles Lerman <clerman@usaid.gov>;Robin Martz <rmartz@usaid.gov>;MacArthur, John R. (CDC/OID /NCZVED) <zae5@cdc.gov>;Jennifer Mason <jmason@usaid.gov>;Patrick Dawson <dawson@ecohealthalliance.org>

Sent: 1/17/2017 11:03:07 AM

Subject: January 17, 2017 Emerging Pandemic Threats update

Between 23 December 2016 and January 17, 2017 (12:00 PM CET), there have been reports of 256 poultry outbreaks, 89 wild bird outbreaks, and 133 human cases due to avian influenza and MERS-CoV in 31 countries. These events took place between October 2016 and January 2017 (some countries were slow in submitting reports).

The overall numbers of poultry and wild bird outbreaks continue to be extremely high (since November 2016) due to the on-going spread of H5N6 HPAI (highly-pathogenic avian influenza) and H5N8 HPAI. In addition, there have been bird outbreaks associated with a number of other influenza viruses, including a new influenza sub-type (H5N5 HPAI) that has now been detected in wild birds in Croatia, Italy, Montenegro and the Netherlands. The sudden increase in human cases is due to H7N9 avian influenza in China during November and December. The number of human MERS-CoV cases in November and December 2016 is slightly above average compared to previous years.

Bird outbreaks/human cases by pathogen:

2 wild bird outbreaks and 1 poultry outbreak due to **"H5"** HPAI in Uganda (based on proximity to other recent bird outbreaks in Africa, the virus in Uganda is likely either H5N1 or H5N8).

14 poultry outbreaks and 1 wild bird outbreak due to **H5N1/Asia** HPAI (Egypt, India)

2 poultry outbreaks and 1 wild bird outbreak due to **H5N2** HPAI (China, USA)

3 wild bird outbreak due to **H5N5** HPAI (Croatia, Italy)

4 poultry outbreaks due to **H5N6** HPAI (China, Japan)

234 poultry outbreaks and 83 wild bird outbreaks due to **H5N8** HPAI (Bulgaria, China, Croatia, Czech Rep., Egypt, Finland, France, Germany, Greece, Hungary, India, Iran, Ireland, Israel, Italy, Netherlands, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, and UK)

1 human case due to **H7N2** AI (USA); virus transmitted from infected cats

108 human cases due to **H7N9** AI (China)

1 human case due to **H9N2** AI (China)

23 human cases due to **MERS-CoV** (Saudi Arabia)

1-571-345-4253
aclements@usaid.gov

For more information on USAID's Emerging Pandemic Threats program, see: http://www.usaid.gov/ept2

H7N9 Avian Influenza (February 2013-January 2017)

3 affected countries in 2 regions

= 1 country with local animal-to-human (and possible limited human-to-human) spread
= 2 countries** with importation of human cases from China via travel
= location (provincial level) of human cases

Reported human cases in China by province (n=913)



Beijing (10), Guangxi (4), Guizhou (2), Hebei (4), Henan (4), Hong Kong (19), Hubei (2), Jiangxi (13), Jilin (2), Liaoning (1), Macao (1), Shandong (8), Taiwan (4), Tianjin (2), Xinjiang (10).

Reported human cases by month^(n=916)



Summary of human cases:

At least 916 cases (and 358 deaths):

- 3 countries affected in 2 regions
- Age range 0-91 years (median 58)
- 69% of cases male
- **Apparent case fatality rate = 39%**
- 3% with pre-existing medical conditions
- 5% of cases in clusters of 2 or more
- 0.3% cases in health care workers
- At least 77% had contact with poultry

Source = WHO monthly reports through 1/17/17. ^ Based on date of symptom onset.

USAID FROM THE AMERICAN PEOPLE
Emerging Threats Division

UCDUSR0000058

Summary of Emergence and Spread of H5N8 HPAI[#] in Birds

Bird outbreaks (1,501):

- By year: 2014 (156); 2015 (465); 2016 (794); 2017 (86)
- By country*: **China (323)**; S. Korea (260); **Hungary (216)**; **Germany (136)**; **France (135)**; **Switzerland (87)**; **Netherlands (55)**; **Denmark (36)**; **Poland (34)**; **India (28)**; USA (22); **Israel (21)**; Japan (17); **Sweden (16)**; **Iran (14)**; **UK (14)**; **Romania (12)**; **Russia (11)**; **Finland (10)**; **Bulgaria (9)**; **Czech Rep (7)**; **Serbia (7)**; **Ukraine (7)**; **Austria (5)**; **Croatia (3)**; **Slovakia (3)**; **Slovenia (3)**; **Italy (2)**; **Egypt (2)**; Canada (1); **Greece (1)**; **Ireland (1)**; **Nigeria (1)**; **Spain (1)**; **Tunisia (1)**
- By bird type: poultry (1,112); wild birds (388); environment (1)
- By setting: farm (984); wild bird (378); village (107); slaughterhouse (20); zoo (10); environment (2); market (0)
- By bird type: at least 76% of poultry outbreaks involved ducks and/or geese
- By season: 92% outbreaks occurred between November and March
- 12.9 million birds killed or culled

No human cases reported to date^

35 affected countries in 6 regions



Bird outbreaks by month



Sources: OIE, WHO, GenBank through 1/16/17. * Includes outbreaks between October 2016 and January 2017.
^ Virus can replicate in mice (Wu et al., EID, Vol 20, No. 8, August 2014). # Highly Pathogenic (in chickens) Avian Influenza.

USAID
FROM THE AMERICAN PEOPLE
Emerging Threats Division

UCDUSR0000059

H5N6 HPAI Summary, February 2014-January 2017

Bird outbreaks (117)#:

- By country: China (49); Vietnam (36); South Korea (20); Japan (9); Laos (3)
- By year: 2014 (35); 2015 (33); 2016 (48); 2017 (1)
- By bird type: poultry (109); wild birds (8)
- By epidemiological unit: farm (51); village (37); market (19); wild bird (3); environment (3); zoo (2)
- 51% outbreaks between November and March
- 1.9 million birds killed/culled

Human cases (17^):

- All cases in 6 provinces in southeastern China
- Age range 5-65 years (median = 40.0)
- 7 male, 10 female
- Apparent case fatality rate = 35%
- 65% cases between November and March
- At least 41% had direct contact with poultry

Location of bird outbreaks and human cases



Sources: OIE and WHO reports through 1/12/17. * Number in colored circles is the total bird outbreaks or human cases per province (dots placed in approximate center of province). ^ 12 cases since Dec 2015 (including 6 in Guangdong province). # Includes outbreaks between October and January 2017.

USAID FROM THE AMERICAN PEOPLE
Emerging Threats Division

UCDUSR0000060

Summary of Emergence and Spread of H5N5 HPAI# in Birds

Bird outbreaks (5):

- By year: 2016 (4); 2017 (1)
- By country*: **Croatia (1); Italy (2); Montenegro (1); Netherlands (1)**
- By bird type: poultry (0); wild birds (5); environment (0)
- By setting: wild bird (5); farm (0); village (0); slaughterhouse (0); zoo (0); environment (0); market (0)
- By bird type: common teal (1); Eurasian wigeon (1); gadwall (1); mute swan (1); tufted duck (1)
- By season: 100% outbreaks occurred between November and March
- 6 birds killed or culled

No human cases reported to date

Note: When H5N1 and H5N8 HPAI were previously introduced into Europe, outbreaks in wild birds preceded outbreaks in poultry

4 affected countries in 1 region



Bird outbreaks by month



Sources: OIE, WHO through 1/13/17. * Includes outbreaks between October 2016 and January 2017.
Highly Pathogenic (in chickens) Avian Influenza. According to a 12/15/15 ProMED report, the H5 part of the H5N5 HPAI virus is identical to the H5 part of the H5N8 HPAI virus that has recently been circulating in Europe (including the Netherlands) suggesting that the H5N5 was recently generated by recombination of two or more influenza A viruses.

USAID
FROM THE AMERICAN PEOPLE
Emerging Threats Division

UCDUSR0000061

Detection of Specific Zoonotic Viruses that have Potential to Directly Spread within Human Populations^



- = H5N1/Asian lineage HPAI# (poultry, wild birds, humans)
- = H7N9 LPAI ## (poultry, wild birds, or humans)
- = other HPAI or LPAI (humans)
- = other HPAI including H5N1/Eur. lineage, H5N1/NA lineage (poultry, wild birds)
- = H1N1v, H1N2v, and H3N2v swine influenza (humans)
- = Ebola (humans))
- = Marburg (humans)
- = Lassa (humans)
- = Nipah (humans)
- = Middle East Respiratory Syndrome-Coronavirus (humans or animals)
- = monkeypox (primates, humans)

Sources = OIE, WHO, CDC, Ministry of Agriculture/FAO (Egypt, Indonesia), and IEDCR (Bangladesh) reports between 11/1/15 and 1/17/17. ^ While these reports reflect known infections with these viruses, there may be additional viral circulation in these and other countries that is not detected due to limitations in surveillance and/or detection. All of these viruses are from viral families with at least one member that is capable of infecting people and spreading directly from person to person without using food, water or insects as vectors. # Highly-pathogenic avian influenza. ## Low-pathogenicity avian influenza. ☐ = countries (including eastern/southeastern China, northeastern India, and most of Indonesia) using USAID avian influenza, Ebola, or other emerging pandemic threats funding between FY2015 and FY2017 for prevention, detection, and response. ★ = location where a new virus first detected.

USAID FROM THE AMERICAN PEOPLE
Global Health Security and Development Unit

UCDUSR0000062

Middle East Respiratory Syndrome– Coronavirus (MERS-CoV)

March 2012-January 2017



■ = 7 countries with animal-to- human and/or human-to-human spread

■ = 20 countries with importation of human cases from Arabian Peninsula via travel

● = 13 countries with serologically- or viral RNA-positive samples from animals

Reported human cases by country (n=1,891)



#Algeria (2), Austria (2), China (1), France (2), Germany (3), Greece (1), Italy (1), Iran (6), Malaysia (1), Netherlands (2), Philippines (2), Thailand (3), Tunisia (3) Turkey (1) UK (3), US (2); @ Bahrain (1), Egypt (1), Jordan (27), Kuwait (4), Lebanon(1), Oman (9), Qatar (17), UAE (78), Yemen (1); 1 Qatar case detected in UK.

Human cases by month of symptom onset (n=1,891)



Summary of human cases:

At least 1,891 cases (and 678 deaths):

- 27 countries affected in 4 regions
- Age range 1-109 years (median 53)
- 66% of cases male
- **Apparent case fatality rate = 36%**
- At least 40% with pre-existing medical conditions
- At least 8% had contact with camels^
- At least 37% of cases in clusters of 2 or more
- At least 13% cases in health care workers

Sources = WHO, FAO, OIE, FroMed, Flutrackers, and scientific publications through 1/16/17. ^ Includes direct and indirect contact with camels; at least 12% of cases with camel contact since September 2014 when Saudi Arabia started routinely reporting contact with animals.

USAID
FROM THE AMERICAN PEOPLE
Emerging Threats Division

UCDUSR0000063

From:	Shana Gillette <sgillette@usaid.gov>
To:	Elizabeth Leasure <ealeasure@ucdavis.edu>
CC:	PREDICTMGT <predictmgt@usaid.gov>;Jonna Mazet <jkmazet@ucdavis.edu>;David John Wolking <djwolking@ucdavis.edu>;Katherine Leasure <kaleasure@ucdavis.edu>
Sent:	2/3/2017 11:52:09 AM
Subject:	Re: PREDICT International Travel Requests

I approve.
Best,
Shana

On Thu, Feb 2, 2017 at 6:17 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Please find below international travel requests for your review and approval. Please let me know if you have any questions. Thanks!!

1. Chmura (China): $1,524 airfare/$241 (Dali), $407 (Guangzhou), $268 (Guilin), and $402 (Shanghai) max daily per diems

2. Gilardi (Rwanda, Uganda): $2,500 airfare/$294 (Kigali) and $340 (Kampala) max daily per diems

3. Kumakamba (RoC): $200 ground transportation/$290 (Brazzaville) max daily per diem

4. Gibson (Sierra Leone, Guinea): $1,520 airfare/$319 (Freetown) and $327 (Conakry) max daily per diems

Travel Requests:

1. EcoHealth Alliance would like to request travel approval for Mr. Aleksei Chmura to travel from New York, NY, USA to Dali, Guangzhou, Guilin, and Shanghai, China from February 26 – March 20, 2017 for meetings with in-country partners, field work, behavioral surveillance, and site selection work.

Trip purpose: Mr. Chmura will meet with PREDICT-2 in-Guangxi Field Coordinator, Dr. Libiao Zhang, at Guangxi Normal University in Guilin and at our Partner Laboratory based at the Guangdong Entomological Institute in Guangzhou. Together with Field Coordinator Dr. Guangjian Zhu, Mr. Chmura will coordinate and travel with full field team to sites in Yunnan Province to assist with human behavioral surveillance fieldwork, review field, lab, and data entry protocols, and prepare for 2017 PREDICT-2 field sampling. Field sites are prioritized along the wildlife trade pathways as per PREDICT-2 site selection criteria and protocols. Mr. Chmura will communicate with PREDICT-2 Metabiota partners in China as well as FAO China collaborators based in Guangzhou.

2. UC Davis would like to request travel approval for Dr. Kirsten Gilardi to travel from Davis, CA, USA to Kigali Rwanda and Kampala, Uganda from February 27 – March 12, 2017 to meet with PREDICT staff and partners.

Trip purpose: This trip will enable Dr. Gilardi to meet with PREDICT Country Coordinators from Rwanda,

Uganda and Democratic Republic of the Congo at MGVP headquarters in Musanze, Rwanda and in Kampala, Uganda. It will also allow her to conduct field site visits with staff, check on progress on Year 3 work plans in all three countries, and meet with Governments of Uganda and Rwanda partners to discuss collaboration on wildlife and human sampling for PREDICT-2.

3. Metabiota would like to request travel approval for Charles Kumakamba, DRC Lab Manager, to travel from Kinshasa, Democratic Republic of Congo to Brazzaville, Republic of Congo from March 13-17, 2017 to provide lab training for the in-country lab staff.

Trip purpose: On January 11th, 2017, the IRB for the Republic of Congo was approved. In order to begin human behavioral surveillance, and evaluate capacity for human syndromic surveillance, James Ayukekbong and Ashley Lucas will work with the behavioral team on beginning human surveillance in bush meat markets and implement a plan for concurrent animal surveillance. For the first time, samples collected during this surveillance will be tested in RoC at the National Public Health lab. Consequently, to improve work force development, James and Charles Kumakamba will perform refresher training sessions for Fabien, the lab lead in RoC and other lab staff.

4. Metabiota would like to request travel approval for Dr. Anna Gibson, Research Compliance & International Laboratory Safety Manager, to travel from Washington, DC, USA to Freetown, Sierra Leone from February 26-29, 2017, then from Freetown, Sierra Leone, to Conakry, Guinea from February 29 – March 4, 2017. In both countries, Dr. Gibson will accompany a team from UC Davis to assess laboratory plans and analyze the possibilities for laboratory strengthening activities.

Trip purpose: Sierra Leone – Dr. Gibson and the UC Davis team will assess laboratory plans and meet with Ministry and other in-country partners on Ebola Host Project engagement. Guinea – Dr. Gibson and the UC Davis team will assess laboratory capacity, laboratory reinforcement plans, and meet with in-country partners for the PREDICT laboratory site assessment.

--

Shana Gillette, PhD
Senior Risk Mitigation Adviser
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (USAID)
Office Phone: 202-712-1456
Mobile: 970-581-4853
Email: sgillette@usaid.gov

From: Elizabeth Leasure <ealeasure@ucdavis.edu>
To: PREDICTMGT <predictmgt@usaid.gov>
CC: Jonna Mazet <jkmazet@UCDAVIS.EDU>;David John Wolking <djwolking@UCDAVIS.EDU>;Katherine Leasure <kaleasure@UCDAVIS.EDU>
Sent: 3/2/2017 5:32:31 PM
Subject: Change to approved ITA: A. Chmura travel to China postponed

Hi Andrew. Due to in-country logistics, availability of partners, and delays due to Spring Festival, Aleksei Chmura's travels to China have been postponed and rescheduled to April 10 – May 15, 2017. Our apologies for the late notice; we were just made aware of the change today. Please let me know if you have any questions or require any additional information. Thanks!

1. EcoHealth Alliance would like to request travel approval for Mr. Aleksei Chmura to travel from New York, NY, USA to Dali, Guangzhou, Guilin, and Shanghai, China from February 26 – March 20, 2017 for meetings with in-country partners, field work, behavioral surveillance, and site selection work.

Trip purpose: Mr. Chmura will meet with PREDICT-2 in-Guangxi Field Coordinator, Dr. Libiao Zhang, at Guangxi Normal University in Guilin and at our Partner Laboratory based at the Guangdong Entomological Institute in Guangzhou. Together with Field Coordinator Dr. Guangjian Zhu, Mr. Chmura will coordinate and travel with full field team to sites in Yunnan Province to assist with human behavioral surveillance fieldwork, review field, lab, and data entry protocols, and prepare for 2017 PREDICT-2 field sampling. Field sites are prioritized along the wildlife trade pathways as per PREDICT-2 site selection criteria and protocols. Mr. Chmura will communicate with PREDICT-2 Metabiota partners in China as well as FAO China collaborators based in Guangzhou.

From:	Andrew Clements <aclements@usaid.gov>
To:	Elizabeth Leasure <ealeasure@ucdavis.edu>
CC:	PREDICTMGT <predictmgt@usaid.gov>;Jonna Mazet <jkmazet@ucdavis.edu>;David John Wolking <djwolking@ucdavis.edu>;Katherine Leasure <kaleasure@ucdavis.edu>;Daniel Schar (RDMA/OPH) <dSchar@usaid.gov>;Sudarat Damrongwatanapokin (RDMA/OPH) <sDamrongwatanapokin@usaid.gov>
Sent:	3/2/2017 5:58:53 PM
Subject:	Re: Change to approved ITA: A. Chmura travel to China postponed

Thanks, Liz. No problem.

Copying Dan and Sudarat for their awareness.

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Mar 2, 2017, at 7:33 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Hi Andrew. Due to in-country logistics, availability of partners, and delays due to Spring Festival, Aleksei Chmura's travels to China have been postponed and rescheduled to April 10 – May 15, 2017. Our apologies for the late notice; we were just made aware of the change today. Please let me know if you have any questions or require any additional information. Thanks!

1. EcoHealth Alliance would like to request travel approval for Mr. Aleksei Chmura to travel from New York, NY, USA to Dali, Guangzhou, Guilin, and Shanghai, China from February 26 – March 20, 2017 for meetings with in-country partners, field work, behavioral surveillance, and site selection work.

Trip purpose: Mr. Chmura will meet with PREDICT-2 in-Guangxi Field Coordinator, Dr. Libiao Zhang, at Guangxi Normal University in Guilin and at our Partner Laboratory based at the Guangdong Entomological Institute in Guangzhou. Together with Field Coordinator Dr. Guangjian Zhu, Mr. Chmura will coordinate and travel with full field team to sites in Yunnan Province to assist with human behavioral surveillance fieldwork, review field, lab, and data entry protocols, and prepare for 2017 PREDICT-2 field sampling. Field sites are prioritized along the wildlife trade pathways as per PREDICT-2 site selection criteria and protocols. Mr. Chmura will communicate with PREDICT-2 Metabiota partners in China as well as FAO China collaborators based in Guangzhou.

From: Jon Epstein <epstein@ecohealthalliance.org>
Sent: Tue, 7 Mar 2017 21:25:47 -0500
Subject: Re: CIPs request
To: "Sudarat Damrongwatanapokin D.V.M., Ph" <sdamrongwatanapokin@usaid.gov>
Cc: Jonna Mazet <jkmazet@ucdavis.edu>, Dan Schar <dschar@usaid.gov>, "Clements, Andrew(ANE/TS)" <AClements@usaid.gov>

Thanks for the clarification, Sudarat.
No problem at all with copying our partners at Metabiota on communications. I was under the impression they had been sent a separate request for CIP information.

Cheers,
Jon

On Mar 7, 2017 8:50 PM, "Sudarat Damrongwatanapokin" <sdamrongwatanapokin@usaid.gov> wrotc:

Dear Jon,
This is the advice from Dave for P2 China CIP (e-mail below) when we requested Laos_CIP. That's the reason that Metabiota was included or cced on the request for Y3 P2 China CIP.

Best regards,
Sudarat Damrongwatanapokin, D.V.M., Ph.D.
Regional Animal Health Advisor
USAID Regional Development Mission Asia
Bangkok, 10330
E-mail: sdamrongwatanapokin@usaid.gov
Tel: REDACTED, Fax: REDACTED

---------- Forwarded message ----------
From: **David McIver** <dmciver@metabiota.com>
Date: Mon, Jan 23, 2017 at 3:53 AM
Subject: Re: Draft CIPs for Laos
To: Sudarat Damrongwatanapokin <sdamrongwatanapokin@usaid.gov>
Cc: Soubanh Silithammavong <sSilithammavong@metabiota.com>, Ko Silithammavong <REDACTED>, Beth Edison <bedison@metabiota.com>, "predict@ucdavis.edu" <predict@ucdavis.edu>

Hi Sudarat,
I believe that you can send along requests to the official EcoHealth Alliance country coordinator, Zhengli Shi (zlshi@wh.iov.cn), to Hongying Li (li@ecohealthalliance.org) and Jon Epstein (epstein@ecohealthalliance.org). And yes, please copy myself and Neal Liang (nliang@metabiota.com) as well.

Thanks very much,
Dave

David McIver, PhD
PREDICT Asia Regional Coordinator | Epidemiologist
Metabiota

e: dmciver@metabiota.com
c: REDACTED

On Jan 20, 2017, at 7:19 PM, Sudarat Damrongwatanapokin <sdamrongwatanapokin@usaid.gov> wrote:

Dear David,

Thank you very much for the immediate response and apology for the short turn around time. Beginning of next week, we will send the request to partners to fill in the information for CIP. I understand that Metabiota also works in China with EcoHealth. Whom should I sent the request to? Directly to you and Jon? Thanks.

Have a great weekend.

Best regards,
Sudarat

Sent from my mobile.

On Jan 21, 2017, at 3:55 AM, David McIver <dmciver@metabiota.com> wrote:

Hi Sudarat,
Please find attached the PREDICT information for the CIP. Let us know if there is anything else we can help out with.

Thanks,
Dave

David McIver, PhD
PREDICT Asia Regional Coordinator | Epidemiologist
Metabiota

e: dmciver@metabiota.com
c: + REDACTED

On Jan 20, 2017, at 4:42 AM, Sudarat Damrongwatanapokin <sdamrongwatanapokin@usaid.gov> wrote:

Dear Soubanh,

Totally understand and sorry for the short notice. It is quite simple according to the new format for GHSA phase II countries (much less complicated than the one last year).

Thank you.

Best regards,
Sudarat

Sent from my mobile.

On Jan 20, 2017, at 7:25 PM, Soubanh Silithammavong <sSilithammavong@metabiota.com> wrote:

Dear Dr Sudarat,

I am so sorry for late reply on this due to working in the field with no internet connection. I will work with our regional coordinator Dr David McIver and get back to you by tomorrow sooner.

Best regards,
Soubanh

Get Outlook for Android

From: Sudarat Damrongwatanapokin
Sent: Friday, January 20, 6:52 PM
Subject: Fwd: Draft CIPs for Laos
To: Soubanh Silithammavong, soubanh Silithammavong

Dear Soubanh,

Please help work on PREDICT country implementation plan for Laos using the new format. It is due today (FRIDAY) COB. I did compile information from P&R and FAO in one excel sheet. Please take a look at the draft P2 activities and complete detailed information required following the CIP instruction guidelines provided below.

Since the US Ambassador Bitter from Laos will be at RDMA on Monday Jan 23, we really need your help to complete P2 activities information and send back to us as soon as possible. Please let me know if you have questions or concerns. You can reach me any time by mobile phone: + REDACTED REDACTED

Thank you very much and look forward to hearing from you the soonest.

Best regards,

Sudarat Damrongwatanapokin, D.V.M., Ph.D.

Regional Animal Health Advisor
USAID Regional Development Mission Asia
Bangkok, 10330
E-mail: sdamrongwatanapokin@usaid.gov
Tel: REDACTED, Fax: REDACTED

---------- Forwarded message ----------
From: **Sudarat Damrongwatanapokin** <sdamrongwatanapokin@usaid.gov>
Date: Wed, Jan 18, 2017 at 4:06 PM
Subject: Fwd: Draft CIPs for Asia
To: soubanh Silithammavong <ssilithammavong@metabiota.com>, Pasakorn Akarasewi <Pasakorn_Akarasewi@dai.com>, "Dr. Chinthana" <chintana.chanthavisouk@fao.org>
Cc: Kachen.Wongsthapornchai@fao.org, Wantanee Kalpravidh <wantanee.kalpravidh@fao.org>, "Black, Peter" <Peter.Black@fao.org>, Frank Pumipuntu <frank.pumipuntu@fao.org>

Dear colleagues,

It 's time to work on country implementation plan (CIP) using the new format for GHSA phase II and non-GHSA countries. It is is less complicated in comparison with those of GHSA phase I countries.

Attachment is the preliminary draft CIP for Laos. Thanks to Angela for her assistance on this. Please fill in more detailed information

CIP instructions:

We have added a “sub-activity” column where you can add more detail to the higher-level activities if necessary.The following categories should be completed at minimum: EPT partner info; activity status; Gantt chart; and comments. If an activity is delayed, explain reason in the “comment” section.To fill in the Gantt chart, type in “X” into the cell.There is a separate "travel/event tracker” tab to capture any planned/upcoming travel or other miscellaneous informationThere is a separate tab with illustrative examples

Since the US Ambassador Bitter from Laos will visit RDMA next week (Monday), we would like to have Lao CIP ready and submitted to us by Friday Jan 20 COB. Thank you very much and apologize for such a short notice.

Best regards,

Sudarat Damrongwatanapokin, D.V.M., Ph.D.

Regional Animal Health Advisor
USAID Regional Development Mission Asia
Bangkok, 10330
E-mail: sdamrongwatanapokin@usaid.gov
Tel: REDACTED, Fax: REDACTED

--

<Compile CIP P&R, FAO_Laos, Jan 20_DM.xlsx>

From: David McIver <dmciver@metabiota.com>
To: "ahuerta@state.gov" <ahuerta@state.gov>
Cc: Soubanh Silithammavong <sSilithammavong@metabiota.com>, Beth Edison <bedison@metabiota.com>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Sent: Fri, 10 Mar 2017 17:54:44 +0000
Subject: [predict] Re: Make an appointment

Hello Dr. Huerta,
I just wanted to introduce myself to you as well - thanks very much to Ko for making this connection.

I am the Metabiota Asia Regional Coordinator for the PREDICT program, and I am responsible for the three Asian PREDICT countries under the direction of Metabiota: Lao PDR, China, and Indonesia. Since I have last visited Vientiane in October, you've started your new position and I'd be very happy to meet with you to discuss our program and future plans with you. If the time and date proposed by Ko will not work for you, please let us know and we would be happy to find something more suitable. I do not yet have flights booked, but I plan on being in Vientiane from Monday morning, the 27th of March, until early Wednesday afternoon, the 29th.

Thank you very much, and I look forward to meeting you.

Dave

David McIver, PhD
PREDICT Asia Regional Coordinator | Epidemiologist
Metabiota

e: dmciver@metabiota.com
c: +REDACTED

> On Mar 9, 2017, at 9:08 PM, Soubanh Silithammavong <ssilithammavong@metabiota.com> wrote:
>
> Dear Dr Alex,
>
> I do hope you still remember me, we met at USAID Implementing Partners Meeting last November. Due to Dr David McIver, PREDICT Regional Coordinator, Metabiota Headquarter will be in Laos for couple of days I think it will be great opportunity for us to meet with you. We can update the progress of PREDICT work has been doing in Laos. So I would like to make an appointment with you on March 29,2017 at 9:30 AM at US Embassy.
>
> Best regards,
> Ko
> Soubanh Silithammavong
> PREDICT Laos Country Coordinator
> Metabiota
>
> ssilithammavong@metabiota.com
> C:+REDACTED
> Skype: REDACTED
> Souphanouvong Avenue, Sikhottabong District
> PO Box: 6644, Vientiane Lao PDR

From: "Manisone, Muongsene" <ManisoneM@state.gov>
To: "dmciver@metabiota.com" <dmciver@metabiota.com>
Cc: "ssilithammavong@metabiota.com" <ssilithammavong@metabiota.com>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Sent: Mon, 13 Mar 2017 08:55:08 +0000
Subject: [predict] RE: Make an appointment

Dear Dr. McIver:

Thank you for the message. I had been in-touch with Ko about the meeting with Alex, it is confirmed for 9am on Wednesday, March 29. Please let me know if you have any questions.

Best wishes,
Bee

Manisone Muongsene
Program Assistant
USAID/Laos Country Office
U.S. Embassy Vientiane, Lao PDR
Office: REDACTED
Mobile: REDACTED
Manisonem@state.gov

Official
UNCLASSIFIED

From: David McIver [mailto:dmciver@metabiota.com]
Sent: Saturday, March 11, 2017 12:55 AM
To: Huerta, Alexandria I
Cc: Soubanh Silithammavong; Beth Edison; predict@ucdavis.edu
Subject: Re: Make an appointment

Hello Dr. Huerta,

I just wanted to introduce myself to you as well - thanks very much to Ko for making this connection.

I am the Metabiota Asia Regional Coordinator for the PREDICT program, and I am responsible for the three Asian PREDICT countries under the direction of Metabiota: Lao PDR, China, and Indonesia. Since I have last visited Vientiane in October, you've started your new position and I'd be very happy to meet with you to discuss our program and future plans with you. If the time and date proposed by Ko will not work for you, please let us know and we would be happy to find something more suitable. I do not yet have flights booked, but I plan on being in Vientiane from Monday morning, the 27th of March, until early Wednesday afternoon, the 29th.

Thank you very much, and I look forward to meeting you.

Dave

David McIver, PhD
PREDICT Asia Regional Coordinator | Epidemiologist
Metabiota

e: dmciver@metabiota.com
c: REDACTED

On Mar 9, 2017, at 9:08 PM, Soubanh Silithammavong <ssilithammavong@metabiota.com> wrote:

Dear Dr Alex,

I do hope you still remember me, we met at USAID Implementing Partners Meeting last November. Due to Dr David McIver, PREDICT Regional Coordinator, Metabiota Headquarter will be in Laos for couple of days I think it will be great opportunity for us to meet with you. We can update the progress of PREDICT work has been doing in Laos. So I would like to make an appointment with you on March 29,2017 at 9:30 AM at US Embassy.

Best regards,
Ko
Soubanh Silithammavong
PREDICT Laos Country Coordinator
Metabiota

ssilithammavong@metabiota.com
C:+ REDACTED
Skype: REDACTED
Souphanouvong Avenue, Sikhottabong District
PO Box: 6644, Vientiane Lao PDR

Sent: Tue, 21 Mar 2017 13:57:52 -0700
Subject: Authorship Affiliation?
From: Corina Monagin <[redacted]>
To: Jonna Mazet <jkmazet@ucdavis.edu>, Matthew Blake <mblake@ucdavis.edu>

Hi Jonna and Matt,

I had two scenarios arise regarding authorship affiliation for abstracts/manuscripts that were in development before my position at UCD that I need your consult on:

1) I have had a manuscript "in progress" for about 2 years now on some older work that I did in China (*Serologic and behavioral risk survey of workers with wildlife contact in China*). It was recently rejected from EID (after 5 months of review), and I am resubmitting to One Health. This was not PREDICT-directly funded work, but we do acknowledge PREDICT and this manuscript is noted in the PREDICT publication list. Since I have left Metabiota and now have a >50% position at UC Davis, would you like me to list UCD as my current affiliation?
2) I am doing some consulting with MRI Global and am listed as an author on an abstract for the upcoming Sequencing, Finishing, Analysis in the Future Meeting (http://www.lanl.gov/conferences/sequencing-finishing-analysis-future/index.php). The abstract title is " Promoting Effective Scientific Transparency by the Exchange of Biological Materials and Electronic Data". Again – I can list UCD or not.

Thank you for helping with this one.

Regards,
Corina

From: David McIver <dmciver@metabiota.com>
To: "CorwinAL@state.gov" <CorwinAL@state.gov>
Cc: Soubanh Silithammavong <sSilithammavong@metabiota.com>, Soukkanya Athitang <sathitang@metabiota.com>, Beth Edison <bedison@metabiota.com>, Karen Saylors <ksaylors@metabiota.com>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Sent: Tue, 21 Mar 2017 21:41:15 +0000
Subject: [predict] Upcoming Visit to Vientiane

Hello Andrew,
As you have seen previously, I will soon be visiting Vientiane. I plan to leave Canada on Friday the 24th, arrive in Vientiane on Sunday the 26th, and then leave for China on Wednesday afternoon.

I would like to ask if you have any availability to meet with me on the morning of Monday the 27th? My morning is free, but I have scheduled meetings in the afternoon. I'm sorry I'm not able to meet with you on Friday when Khonchay is available, but having only received travel approval a couple of days ago, I am not able to rearrange plans to arrive in Vientiane earlier than expected.

Please let me know if you are available on the morning of the 27th, and I'd be happy to meet you at your offices. I'm looking forward to meeting you and giving you an update on all of the progress that the PREDICT program has made in Lao PDR.

Thanks,
Dave

David McIver, PhD
PREDICT Asia Regional Coordinator | Epidemiologist
Metabiota

e: dmciver@metabiota.com
c: REDACTED

From: David McIver <dmciver@metabiota.com>
To: "Corwin, Andrew L" <CorwinAL@state.gov>
Cc: Soubanh Silithammavong <sSilithammavong@metabiota.com>, Soukkanya Athitang <sathitang@metabiota.com>, Beth Edison <bedison@metabiota.com>, Karen Saylors <ksaylors@metabiota.com>, "predict@ucdavis.edu" <predict@ucdavis.edu>, "Huerta, Alexandria I" <AHuerta@state.gov>, "Kongchay, Vongsaiya" <KongchayV@state.gov>, "Martz, Robin (USAID)" <rmartz@usaid.gov>, "dschar@usaid.gov" <dschar@usaid.gov>, Sudarat Damrongwatanapokin <sdamrongwatanapokin@usaid.gov>, "Samaiphone, Thepsombandith" <SamaiphoneT@state.gov>
Sent: Thu, 23 Mar 2017 04:24:43 +0000
Subject: [predict] Re: Upcoming Visit to Vientiane

Hi Andy,
A meeting at 9:30am on Monday will work perfectly. If you can arrange for Soubanh and myself to get Embassy access, that would be fantastic.

I'm looking forward to meeting both you and Dr. Bounheaung.

Cheers,

Dave

David McIver, PhD
PREDICT Asia Regional Coordinator | Epidemiologist
Metabiota

e: dmciver@metabiota.com
c: + REDACTED

> On Mar 21, 2017, at 7:39 PM, Corwin, Andrew L <CorwinAL@state.gov> wrote:
>
> Hi David,
>
> I would welcome the opportunity to learn more about the work of PREDICT in Laos. Yes, unfortunately, Konchay, part of our USAID Lao Health Team, will be away in Bangkok during your visit. I would however like to invite Dr. Bounheaung to join us, the Embassy's resident Veterinarian (DTRA) expert who is well familiar with the predict component of the EPT 2 Initiative. Please let me know what time you are planning to arrive at the Embassy on Monday morning, 27 March: I might suggest 09:30.
>
> Pui (last person copied) will follow-up to arrange for your Embassy access.
>
> Looking forward to meeting you, and learning.
>
> Andy
>
> Andrew L Corwin
> Health Program Manager
> **USAID** /Lao People's Democratic Republic (PDR)
> Tel:
> Cell REDACTED
> Email: corwinal@state.gov

SBU
This email is UNCLASSIFIED.

From: David McIver [mailto:dmciver@metabiota.com]
Sent: Wednesday, March 22, 2017 4:41 AM
To: Corwin, Andrew L
Cc: Soubanh Silithammavong; Soukkanya Athitang; Beth Edison; Karen Saylors; predict@ucdavis.edu
Subject: Upcoming Visit to Vientiane

Hello Andrew,

As you have seen previously, I will soon be visiting Vientiane. I plan to leave Canada on Friday the 24th, arrive in Vientiane on Sunday the 26th, and then leave for China on Wednesday afternoon.

I would like to ask if you have any availability to meet with me on the morning of Monday the 27th? My morning is free, but I have scheduled meetings in the afternoon. I'm sorry I'm not able to meet with you on Friday when Khonchay is available, but having only received travel approval a couple of days ago, I am not able to rearrange plans to arrive in Vientiane earlier than expected.

Please let me know if you are available on the morning of the 27th, and I'd be happy to meet you at your offices. I'm looking forward to meeting you and giving you an update on all of the progress that the PREDICT program has made in Lao PDR.

Thanks,
Dave

David McIver, PhD
PREDICT Asia Regional Coordinator | Epidemiologist
Metabiota

e: dmciver@metabiota.com
c: REDACTED

From: "Samaiphone, Thepsombandith" <SamaiphoneT@state.gov>
To: "Corwin, Andrew L" <CorwinAL@state.gov>, David McIver <dmciver@metabiota.com>
Cc: Soubanh Silithammavong <sSilithammavong@metabiota.com>, Soukkanya Athitang <sathitang@metabiota.com>, Beth Edison <bedison@metabiota.com>, Karen Saylors <ksaylors@metabiota.com>, "predict@ucdavis.edu" <predict@ucdavis.edu>, "Huerta, Alexandria I" <AHuerta@state.gov>, "Kongchay, Vongsaiya" <KongchayV@state.gov>, "Martz, Robin (USAID)" <rmartz@usaid.gov>, "Schar, Daniel (RDMA/OPH)" <dschar@usaid.gov>, "Damrongwatanapokin, Sudarat (RDMA/OPH)" <sdamrongwatanapokin@usaid.gov>, "Manisone, Muongsene" <ManisoneM@state.gov>
Sent: Thu, 23 Mar 2017 06:56:08 +0000
Subject: [predict] RE: Upcoming Visit to Vientiane

Dear David,

Please kindly note that the access request for you and Mr. Soubanh have been made.
Passport will be needed when you come to the Embassy. The guard will keep it and return to you when you leave the building.

Please feel free to let me know if you have any questions.

Best regards,
Pui

Official
UNCLASSIFIED

From: Corwin, Andrew L
Sent: Thursday, March 23, 2017 12:43 PM
To: David McIver
Cc: Soubanh Silithammavong; Soukkanya Athitang; Beth Edison; Karen Saylors; predict@ucdavis.edu; Huerta, Alexandria I; Kongchay, Vongsaiya; Martz, Robin (USAID); Schar, Daniel (RDMA/OPH); Damrongwatanapokin, Sudarat (RDMA/OPH); Samaiphone, Thepsombandith
Subject: RE: Upcoming Visit to Vientiane

Hi Dave, Samaiphone, Thepsombandith SamaiphoneT@state.gov (copied) will arrange. She will need your passport information to process your access data.

Looking forward to meeting with you.

Andy

SBU
This email is UNCLASSIFIED.

From: David McIver [mailto:dmciver@metabiota.com]
Sent: Thursday, March 23, 2017 11:25 AM
To: Corwin, Andrew L
Cc: Soubanh Silithammavong; Soukkanya Athitang; Beth Edison; Karen Saylors; predict@ucdavis.edu; Huerta, Alexandria I; Kongchay, Vongsaiya; Martz, Robin (USAID); Schar, Daniel (RDMA/OPH); Damrongwatanapokin, Sudarat (RDMA/OPH); Samaiphone, Thepsombandith
Subject: Re: Upcoming Visit to Vientiane

Hi Andy,

A meeting at 9:30am on Monday will work perfectly. If you can arrange for Soubanh and myself to get Embassy access, that would be fantastic.

I'm looking forward to meeting both you and Dr. Bounheaung.

Cheers,

Dave

David McIver, PhD
PREDICT Asia Regional Coordinator | Epidemiologist
Metabiota

e: dmciver@metabiota.com
c: + REDACTED

On Mar 21, 2017, at 7:39 PM, Corwin, Andrew L <CorwinAL@state.gov> wrote:

Hi David,

I would welcome the opportunity to learn more about the work of PREDICT in Laos. Yes, unfortunately, Konchay, part of our USAID Lao Health Team, will be away in Bangkok during your visit. I would however like to invite Dr. Bounheaung to join us, the Embassy's resident Veterinarian (DTRA) expert who is well familiar with the predict component of the EPT 2 Initiative. Please let me know what time you are planning to arrive at the Embassy on Monday morning, 27 March: I might suggest 09:30.

Pui (last person copied) will follow-up to arrange for your Embassy access.

Looking forward to meeting you, and learning.

Andy

Andrew L Corwin
Health Program Manager
USAID /Lao People's Democratic Republic (PDR)
Tel: REDACTED
Cell: REDACTED
Email: corwinal@state.gov

SBU
This email is UNCLASSIFIED.

From: David McIver [mailto:dmciver@metabiota.com]
Sent: Wednesday, March 22, 2017 4:41 AM
To: Corwin, Andrew L
Cc: Soubanh Silithammavong; Soukkanya Athitang; Beth Edison; Karen Saylors; predict@ucdavis.edu
Subject: Upcoming Visit to Vientiane

Hello Andrew,

As you have seen previously, I will soon be visiting Vientiane. I plan to leave Canada on Friday the 24th, arrive in Vientiane on Sunday the 26th, and then leave for China on Wednesday afternoon.

I would like to ask if you have any availability to meet with me on the morning of Monday the 27th? My morning is free, but I have scheduled meetings in the afternoon. I'm sorry I'm not able to meet with you on Friday when Khonchay is available, but having only received travel approval a couple of days ago, I am not able to rearrange plans to arrive in Vientiane earlier than expected.

Please let me know if you are available on the morning of the 27th, and I'd be happy to meet you at your offices. I'm looking forward to meeting you and giving you an update on all of the progress that the PREDICT program has made in Lao PDR.

Thanks,
Dave

—
David McIver, PhD
PREDICT Asia Regional Coordinator | Epidemiologist
Metabiota

e: dmciver@metabiota.com
c: REDACTED

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Brian Bird <bhbird@ucdavis.edu>
Sent: 5/12/2017 1:19:48 PM
Subject: Re: Summary of Wednesday discussion

Yeah -- timing not great, but couldn't wait any longer I'm afraid,
J

On Thu, May 11, 2017 at 9:58 PM, Brian Bird <bhbird@ucdavis.edu> wrote:
Wow. Things are certainly moving there. I will try my best to join the zoom call this evening.

Sounds like alot of discussions are needed about SL and Guinea and the path forward?

B

On Fri, May 12, 2017 at 7:16 AM Jonna Mazet <jkmazet@ucdavis.edu> wrote:
FYI -- we will discuss tomorrow in UCD Predict all staff,
J

---------- Forwarded message ----------
From: **Jonna Mazet** <jkmazet@ucdavis.edu>
Date: Thu, May 11, 2017 at 9:14 PM
Subject: Re: Summary of Wednesday discussion
To: Eddy Rubin <erubin@metabiota.com>
Cc: Karen Saylors <ksaylors@metabiota.com>

Thanks very much, Eddy,
This summary aligns perfectly with our discussion and reflects the current plan.
Conferring with our team, USAID, and EHA (next week). To help us with the remaining planning pieces and smooth transitions.
I received word from Andrew and USAID contracts that we can assume MB subawards without restarting the DC review process, so that will be useful.
More soon,
Jonna

On Thu, May 11, 2017 at 4:48 PM, Eddy Rubin <erubin@metabiota.com> wrote:

Jonna

This is a quick summary from what we took from yesterday's conversation to make sure we're starting from the same page:

1. Metabiota will continue to manage:

a) PREDICT Information Management EIDITH activities.

b) Cameroon, DRC and Laos. Christian should travel to Cameroon and DRC for lab and staff capacity assessment.

2. For Sierra Leone and Guinea we work with the UC Davis team to make a transition to UC Davis management. We will need further guidance on how this would work contractually/administratively.

a) you'd like a list of the SL staff and responsibilities

b) we should notify field sampling staff that they will not be going back into the field anytime soon, due to budget

reductions and shift in scope.

3. Indonesia and China we will work with EcoHealthAlliance to transfer our human activities once Davis gives us the word.

a) In China, we will work to finish lab analysis, but all human syndromic surveillance has been stopped.

b) For Indo, we may have a silent transition in country, as our sub with Eijkman is necessary to the project, and questions have been submitted to USAID, so we are on standby.

4. Côte d'Ivoire and ROC these countries will continue with a limited scope until further USAID decisions are made.

a) In ROC we will continue behavioral surveillance. ITAs have been submitted for behavioral consultants to travel to DRC for training and supervision by Ashley; Karen and Prime to travel to the region in June for behavioral supervision and discussions with the Mission.

b) In CIV, the idea is to scale back to GHSA training model, but meanwhile we will continue animal sampling (LANADA) and human behavioral work (IPCI). Plan to cancel/suppress syndromic surveillance, but need to discuss the plan on how to manage lab analysis of animal samples and equipment that is in country; this discussion will occur among our team early next week and we will get you a plan/suggestions. Cancel the ITA for Ashley and Frantz.

We will provide you with more details and suggestions of possible next steps and issues with a particular focus on Sierra Leone and Guinea by mid next week, as well as a list of issues that will need some attention in the transition, per discussions with our field teams. We will continue our activities as is in all our counties for the time being.

Eddy and Karen

bhbird@ucdavis.edu

Bcc: "predict@ucdavis.edu" <predict@ucdavis.edu>
Sent: Thu, 18 May 2017 18:47:46 -0700
Subject: Re: [predict] PREDICT program launch
From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Andrew Clements <aclements@usaid.gov>
Cc: Alisa Pereira <apereira@usaid.gov>

Thanks. I could do Monday at that time. Wednesday, I have a meeting with Metabiota to work out the transition plans, but I could adjust the time if Monday doesn't work out. I'd very much like to speak to Zandra and get her input on the local team and structure to see how best to move forward and which individuals are best to keep on the team from her opinion.
We had a very long and extremely productive session with EHA here in Davis yesterday. we went through all of the transitioning countries and feel that the following is the best plan:

UCD to take over all leadership of Sierra Leone & Guinea. You know the score on those, as we'll need guidance from you on forthcoming budget to confirm scope of activities.

EHA to assume human work (which was somewhat split before) in China & Indonesia -- they are already country leads, so this should be fairly easy.
EHA is also willing and able to take over CdI and ROC. They have previous working relationship with Zandra from CDC days, as well as Bangladesh, and are ready to make a plan for remaining work within the new proposed Ebola country caps for CdI. They have a fairly new (Belgian) country liaison, who is doing a great job with other countries and is a native French speaker. For ROC, Billy has many years of experience working successfully there, which is why WCS (when he was there) originally had that country. After he went to EHA, things have been poor there, but he is ready and willing to take it back on. He is also realistic about what can be achieved and is fine with cutting or reducing scope to behavior/market if that is the best probability for success. That said, he also believes that there may be some extractive/road work that may be achievable within budget if we decide to go that way. We will not, however, have the time and resources to be successful in laboratory capacity building there. So any sampling will be contingent on exporting samples for testing, which we did to UCD in Predict-1.

Please let me know if this plan sounds on track to you,
Jonna

On Thu, May 18, 2017 at 8:17 AM, Andrew Clements <aclements@usaid.gov> wrote:

Hi Jonna,

Alisa and I talked to Zandra today and gave her a heads up on the changes coming.

Since we don't know all the details, are you available early next week to talk with her directly? She's available at 4:00 PM her time (9:00 AM your time, I think) Monday, Tuesday, or Wednesday. Do any of those work for you?

Thanks!

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On May 17, 2017, at 6:24 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Hi Andrew & Alisa,
We're working with EHA to begin to develop a transition plan for CdI tomorrow, but I'd like to then work with you on the optimal plan. Do you want to give Zandra a heads-up that we are developing a leadership

transition. The in-country staff are not fully aware of the situation, and we are trying to make a good plan and then roll it out to them sensitively. They are aware that we have put human sampling & testing on hold, as we have canceled the trainings we had planned there due to anticipation of reduced scope. Consistent with our discussion on MT, CdI is the best target for reduction in scope from pour perspective, but politically and with Zandra, there may be consequences which you can anticipate better than we can.

Please advise, we can reach out to Zandra if preferable,
Jonna

---------- Forwarded message ----------
From: **David J Wolking** <djwolking@ucdavis.edu>
Date: Tue, May 16, 2017 at 9:09 AM
Subject: Fwd: [predict] PREDICT program launch
To: Elizabeth Leasure <ealeasure@ucdavis.edu>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>

Jonna,

Just sharing so you're aware of the Mission questions here. Not sure it's the right time to respond until we talk to EHA and then MT but maybe Washington should communicate with Zandra in the meantime to check in?

Pretty awkward position for the MB team here.

David

---------- Forwarded message ---------
From: Zandra Andre <zandre@usaid.gov>
Date: Tue, May 16, 2017 at 08:43
Subject: [predict] PREDICT program launch
To: Kalpy Julien COULIBALY <jc_kalpy@yahoo.fr>
Cc: REGINA BLANDINE N'GUESSAN KOKO <nkoko@usaid.gov>, Frantz Jean Louis <fjeanlouis@metabiota.com>, Karen Saylors <ksaylors@metabiota.com>, Predict Inbox <predict@ucdavis.edu>

Hi Dr. Kalpy,
Just checking in to see where PREDICT is at in terms of the project launch. Do you have a date confirmed?

Also, how is the recruitment process moving along?

Thanks,
Dr. Zandra

Dr. Zandra Hollaway ANDRE
DVM, MPH, DACVPM
Senior One Health Team Lead
U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT
US Embassy - Abidjan, Côte d'Ivoire
T: REDACTED M: REDACTED
From the US: (301) 985-8627 x 4335

USAID.gov | ZAndre@usaid.gov | @USAIDWestAfrica

--
Sent from Gmail Mobile

Sent: Thu, 18 May 2017 18:56:57 -0700
Subject: Re: [predict] PREDICT program launch
From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Karen Saylors <ksaylors@metabiota.com>, Eddy Rubin <erubin@metabiota.com>
Cc: "predict@ucdavis.edu" <predict@ucdavis.edu>

Dear Karen & Eddy,
Just following up to let you know that Andrew also spoke to Zandra today and gave her a heads-up that the transition will be coming. I will speak to her next week, likely Monday morning. I think business-as-usual with the CdI and ROC in-country teams until we talk Wednesday, unless you have a preferred plan or timely needs. Expect EHA to reach out to you ASAP for the planning for China and Indonesia.
Hope you're well,
Jonna

On Tue, May 16, 2017 at 9:24 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

> FYI,
> J

---------- Forwarded message ----------
From: **Jonna Mazet** <jkmazet@ucdavis.edu>
Date: Tue, May 16, 2017 at 9:23 PM
Subject: Fwd: [predict] PREDICT program launch
To: AOTR/Grant Manager Andrew Clements <AClements@usaid.gov>, Alisa Pereira <apereira@usaid.gov>

Hi Andrew & Alisa,
We're working with EHA to begin to develop a transition plan for CdI tomorrow, but I'd like to then work with you on the optimal plan. Do you want to give Zandra a heads-up that we are developing a leadership transition. The in-country staff are not fully aware of the situation, and we are trying to make a good plan and then roll it out to them sensitively. They are aware that we have put human sampling & testing on hold, as we have canceled the trainings we had planned there due to anticipation of reduced scope. Consistent with our discussion on MT, CdI is the best target for reduction in scope from pour perspective, but politically and with Zandra, there may be consequences which you can anticipate better than we can.

Please advise, we can reach out to Zandra if preferable,
Jonna

---------- Forwarded message ----------
From: **David J Wolking** <djwolking@ucdavis.edu>
Date: Tue, May 16, 2017 at 9:09 AM
Subject: Fwd: [predict] PREDICT program launch
To: Elizabeth Leasure <ealeasure@ucdavis.edu>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>

Jonna,

Just sharing so you're aware of the Mission questions here. Not sure it's the right time to respond until we talk to EHA and then MT but maybe Washington should communicate with Zandra in the meantime to check in?

Pretty awkward position for the MB team here.

David

---------- Forwarded message ---------
From: Zandra Andre <zandre@usaid.gov>

Date: Tue, May 16, 2017 at 08:43
Subject: [predict] PREDICT program launch
To: Kalpy Julien COULIBALY <jc_kalpy@yahoo.fr>
Cc: REGINA BLANDINE N'GUESSAN KOKO <nkoko@usaid.gov>, Frantz Jean Louis <fjeanlouis@metabiota.com>, Karen Saylors <ksaylors@metabiota.com>, Predict Inbox <predict@ucdavis.edu>

Hi Dr. Kalpy,
Just checking in to see where PREDICT is at in terms of the project launch. Do you have a date confirmed?

Also, how is the recruitment process moving along?

Thanks,
Dr. Zandra

Dr. Zandra Hollaway ANDRE
DVM, MPH, DACVPM
Senior One Health Team Lead
U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT
US Embassy - Abidjan, Côte d'Ivoire
T: REDACTED M: REDACTED
From the US: (301) 985-8627 x 4335

USAID.gov | ZAndre@usaid.gov | @USAIDWestAfrica

--
Sent from Gmail Mobile

From: Andrew Clements <aclements@usaid.gov>
To: Jonna Mazet <jkmazet@ucdavis.edu>
CC: Alisa Pereira <apereira@usaid.gov>
Sent: 5/19/2017 8:56:23 AM
Subject: Re: [predict] PREDICT program launch

Thanks, Jonna.

I'll let Zandra know that Monday works for you. I think she is happy with the Predict team at IP, but she can verify that (or not) on the call. Can we use your conference call line if it's available?

The overall plan you described sounds good. Let's talk late next week after you've talked with Metabiota about the transition plan.

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On May 19, 2017, at 3:49 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Thanks. I could do Monday at that time. Wednesday, I have a meeting with Metabiota to work out the transition plans, but I could adjust the time if Monday doesn't work out. I'd very much like to speak to Zandra and get her input on the local team and structure to see how best to move forward and which individuals are best to keep on the team from her opinion.

We had a very long and extremely productive session with EHA here in Davis yesterday. we went through all of the transitioning countries and feel that the following is the best plan:

UCD to take over all leadership of Sierra Leone & Guinea. You know the score on those, as we'll need guidance from you on forthcoming budget to confirm scope of activities.

EHA to assume human work (which was somewhat split before) in China & Indonesia -- they are already country leads, so this should be fairly easy.
EHA is also willing and able to take over CdI and ROC. They have previous working relationship with Zandra from CDC days, as well as Bangladesh, and are ready to make a plan for remaining work within the new proposed Ebola country caps for CdI. They have a fairly new (Belgian) country liaison, who is doing a great job with other countries and is a native French speaker. For ROC, Billy has many years of experience working successfully there, which is why WCS (when he was there) originally had that country. After he went to EHA, things have been poor there, but he is ready and willing to take it back on. He is also realistic about what can be achieved and is fine with cutting or reducing scope to behavior/market if that is the best probability for success. That said, he also believes that there may be some extractive/road work that may be achievable within budget if we decide to go that way. We will not, however, have the time and resources to be successful in laboratory capacity building there. So any sampling will be contingent on exporting samples for testing, which we did to UCD in Predict-1.

Please let me know if this plan sounds on track to you,
Jonna

On Thu, May 18, 2017 at 8:17 AM, Andrew Clements <aclements@usaid.gov> wrote:
Hi Jonna,

Alisa and I talked to Zandra today and gave her a heads up on the changes coming.

Since we don't know all the details, are you available early next week to talk with her directly? She's available at 4:00 PM her time (9:00 AM your time, I think) Monday, Tuesday, or Wednesday. Do any of those work for you?

Thanks!

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On May 17, 2017, at 6:24 AM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Hi Andrew & Alisa,
We're working with EHA to begin to develop a transition plan for CdI tomorrow, but I'd like to then work with you on the optimal plan. Do you want to give Zandra a heads-up that we are developing a leadership transition. The in-country staff are not fully aware of the situation, and we are trying to make a good plan and then roll it out to them sensitively. They are aware that we have put human sampling & testing on hold, as we have canceled the trainings we had planned there due to anticipation of reduced scope. Consistent with our discussion on MT, CdI is the best target for reduction in scope from pour perspective, but politically and with Zandra, there may be consequences which you can anticipate better than we can.

Please advise, we can reach out to Zandra if preferable,
Jonna

---------- Forwarded message ----------
From: **David J Wolking** <djwolking@ucdavis.edu>
Date: Tue, May 16, 2017 at 9:09 AM
Subject: Fwd: [predict] PREDICT program launch
To: Elizabeth Leasure <ealeasure@ucdavis.edu>, "Prof. Jonna Mazet" <jkmazet@ucdavis.edu>

Jonna,

Just sharing so you're aware of the Mission questions here. Not sure it's the right time to respond until we talk to EHA and then MT but maybe Washington should communicate with Zandra in the meantime to check in?

Pretty awkward position for the MB team here.

David

---------- Forwarded message ---------

From: Zandra Andre <zandre@usaid.gov>
Date: Tue, May 16, 2017 at 08:43
Subject: [predict] PREDICT program launch
To: Kalpy Julien COULIBALY <jc_kalpy@yahoo.fr>
Cc: REGINA BLANDINE N'GUESSAN KOKO <nkoko@usaid.gov>, Frantz Jean Louis <fjeanlouis@metabiota.com>, Karen Saylors <ksaylors@metabiota.com>, Predict Inbox <predict@ucdavis.edu>

Hi Dr. Kalpy,

Just checking in to see where PREDICT is at in terms of the project launch. Do you have a date confirmed?

Also, how is the recruitment process moving along?

Thanks,
Dr. Zandra

Dr. Zandra Hollaway ANDRE
DVM, MPH, DACVPM
Senior One Health Team Lead
U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT
US Embassy - Abidjan, Côte d'Ivoire
T: + REDACTED M:+ REDACTED
From the US: (301) 985-8627 x 4335
USAID.gov | ZAndre@usaid.gov | @USAIDWestAfrica

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Tracey Goldstein <tgoldstein@ucdavis.edu>
CC: Anthony, Simon J. <sja2127@cumc.columbia.edu>
Sent: 5/26/2017 2:29:55 AM
Subject: Re: SL MS

Looking fantastic!
Attaching Heather's version here with my additions -- mostly minor. I would like to discuss the naming. I'm sure you guys have already thrashed it around ad nauseam, but I'd like to understand/weigh in on the choice. Only other substantive thing can wait for other co-author contributions -- I'd love to see a bit more emphasis on the importance of the proactive approach in either the Intro or Discussion. You covered it well within the word limit, and we may not be able to get any more emphasis there, but I'm still worried that some will give us the "So What?" without a bit more arm waving about why we should do this type of work in advance and over broad geographic ranges. Maybe we can tweak a couple of sentences in the final round when you decide on some of the other edits and suggestions from the rest of the group.
Fabulous job,
J

On Fri, May 19, 2017 at 4:10 PM, Tracey Goldstein <tgoldstein@ucdavis.edu> wrote:
Hi Jonna,

Well, here it is! There a few minor things we are need to complete (highlighted in yellow), need to remove a few refs and then number the citations, but that won't affect your review. I am also still waiting on the clean data file (should get it on Monday) to confirm all site coordinates for the map.

Once we get it back from you we will circulate to MB team and other co-authors.

Happy reading,
T

(530) 752-0412
(530) 752-3318
tgoldstein@ucdavis.edu

Discovery of a new member of the Ebola virus genus in Molossid bats in Sierra Leone.

T Goldstein[1]*, SJ Anthony[2,3,4]*, A. Gbakima[5], BH Bird[1], J Bangura[5], A Tremeau-Bravard[1], M Belaganahalli[1], H Wells[2], JK Dhanota, E. Liang[2,4], S Shapira[6,7], G Lasso Cabrera[6], C Monagin[1], F Jean Louis[5], K. Saylors, E[5]. Rubin[5], WI Lipkin[2,3], JAK Mazet[1]

* = These authors contributed equally to the study.

[1]=One Health Institute & Karen C Drayer Wildlife Health Center, School of Veterinary Medicine, University of California Davis, California (USA)
[2]=Center for Infection and Immunity, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY, 10032 (USA)
[3]=Dept of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY (USA)
[4]=EcoHealth Alliance, 460 West 34th Street, NY, New York (USA)
[5]=Metabiota, Inc. One Sutter, Suite 600, San Francisco, CA, 94104 (USA)
[6]= Department of Systems Biology, Irving Cancer Research Centre, Columbia University.1130 St. Nicholas Avenue, New York, NY 10032
[7]=Department of Microbiology & Immunology, Columbia University, 701 W. 168 St., HHSC 1208 New York, NY 10032

Word Counts

Abstract: Count = 244. Words allowed = 250
Main Text: Count = 2964 (2998 – HLW; 3015 – JM, but want to see what changes you accept or decline before cutting words). Words allowed = 3000

Abstract

Background: Despite significant interest and investment, the identification of definitive reservoir hosts of ebolaviruses has eluded us. The recent and unprecedented Ebola outbreak in West Africa highlighted the urgent need to better understand the diversity, host ecology, and transmission dynamics of filoviruses, in order to better prepare for future outbreaks.

Methods: Using a broad approach, the USAID PREDICT project sampled a wide range of potential host species in Sierra Leone (bats, rodents, and domestic animals). Consensus PCR targeting all filoviruses was used in an effort to identify the reservoir of Ebola Zaire, as well as any novel and potentially zoonotic filoviruses circulating in animals. Genetic analyses were then used to look for markers of pathogenicity and the ability to bind with human receptors.

Findings: The complete genome of a new species of ebolavirus was detected in two Molossid bat species (Bombali Ebola/2016/Mop condylurus/SLE, Bombali Ebola/2016/Chaerephon pumilus/SLE). Sequence analysis of the glycoprotein (GP) suggests the Bombali Ebolavirus has the genetic prerequisites to bind to the human Neiman Pick C1 receptor, an important first step for spillover to occur.

Interpretation: This is the first full genome of an ebolavirus to be recovered from a bat, providing strong evidence that bats are the natural reservoir of ebolaviruses. The virus was found in two insectivorous bat species living in close proximity to humans, demonstrating the potential for exposure, and appears to be competent for GP-NPC1 binding. Findings suggest that the Bombali ebolavirus could pose a zoonotic threat to humans.

Funding: United States Agency for International Development

Introduction

Despite decades of research, the reservoir of Ebola virus (EBOV) is still unknown. As a result, we know little about its transmission dynamics and remain vulnerable to new outbreaks. In 2014, EBOV emerged in the West African countries of Guinea, Sierra Leone, and Liberia. It was the largest epidemic of EBOV ever recorded; over 28,000 people became infected and 11,325 died (Lo et al). The source of the outbreak was never conclusively identified; however, the index case (a child) was reported to have had recent contact with Angolan free-tailed insectivorous bats (*Mops condylurus)* (Saéz et al., 2015). This evidence led many to speculate that *M. condylurus* or a related species could be a reservoir of EBOV and to renewed efforts to describe the diversity and ecology of these viruses.

Current evidence supports (but does not confirm) that bats are the likely reservoir of ebolaviruses. Partial sequences matching Ebola Zaire have been detected in bats in Africa (Leroy et al, 2005), but no infectious virus has been isolated or complete genomes recovered. Antibodies thought to be against ebolaviruses have also been detected in fruit and insectivorous species (Pourret et al., 2007; Hayman et al., 2012; Yuan et al. 2012); however, the diversity of filoviruses in bats is likely to be high (Towner et al. 2007; Negredo et al. 2011; Jayme et al. 2015; He et al. 2015; Yang et al 2017), and viruses within this family are prone to cross-react serologically. These antibodies could therefore reflect exposure to a related virus, rather than to Ebola Zaire. Evidence of positive selection at key glycoprotein (GP) binding residues in the Niemann-Pick C1 (NPC1) host receptor has also been reported (Ng et al. 2015), suggesting a close evolutionary relationship between bats and filoviruses. This evidence falls short of linking specific viruses (e.g. Ebola Zaire) with specific host species. In summary, while the evidence certainly points to bats as the evolutionary reservoir of ebolaviruses, conclusive proof is still lacking.

To date five different species within the genus *Ebolavirus* have been identified. These include: Zaire, Bundigbuyo, Sudan, Tai Forest, and Reston EBOV. Of these, four are known to cause severe disease in humans (Burk et al. 2016). However, it is likely that many more ebolaviruses also exist in wildlife. Identifying these viruses and experimentally testing their individual capacity for human infection would greatly enhance our understanding of the 'pre-emergent' zoonotic pool, while studying their transmission dynamics would also help with preparedness and mitigation strategies. To this end, the USAID PREDICT project initiated a survey in Sierra Leone, Guinea, and Liberia in an attempt to identify the natural reservoir of Ebola Zaire and to look for additional and potentially zoonotic filoviruses circulating in animals. Findings from our efforts in Sierra Leone are reported herein.

Methods

Animal sampling

Between March and September 2016, 1278 samples were collected by PREDICT staff from 536 animals (244 bats, 45 rodents, 242 dogs, 5 cats) from 21 locations in Sierra Leone (Figure 1). Oral and rectal swabs, as well as whole blood and urine where possible, were humanely sampled (capture and release) from each animal. Samples were collected in duplicate and placed in either Trizol or viral transport media, frozen in liquid nitrogen, and stored at -80 until analysis. All animal sampling activities were conducted with permissions from local authorities and under the Institutional Animal Care and Use Committee at the University of California, Davis (protocol number: 16048). Inactivated samples in Trizol were shipped to the One Health Institute Laboratory, University of California, Davis for analysis under the PHS permit no. 2016-06-092. Bat host species identification was confirmed by DNA barcoding of the cytochrome b (cytb) and cytochrome oxidase subunit 1 (CO1) mitochondrial genes (Townzen et al., 2008).

Viral discovery and sequencing

Total RNA was extracted using Direct-Zol RNA purification columns (Zymo Research Corp, Irvine, CA), and cDNA was prepared using Superscript III (Invitrogen, Carlsbad, CA). Samples were then screened using three different assays: 1) a nested filovirus 'family level' consensus PCR (cPCR) targeting a 680bp fragment of the filovirus L gene, 2) an ebolavirus 'genus level' cPCR targeting a 187 bp fragment of the NP gene (Towner et al., 2004); and 3) a real-time PCR specific for the Ebola Zaire species, targeting the L-gene (Jaaskelainen, et al., 2015). Primer sequences for the nested filovirus assay were: Round 1: Filo-MOD-FWD: TITTYTCHVTICAAAAICAYTGGG, FiloL.conR: ACCATCATRTTR-CTIGGRAAKGCTTT; Round 2: Filo-MOD-FWD: TITTYTCHVTICAAAAICAYTGGG, Filo-MOD-RVS: GCYTCISMIAIIGTTTGIACATT. For quantification of viral load in positive samples, a quantitative real-time PCR was designed. Primers and probe sequences were: Filo_UCD_qFor: TCTCG-ACGAAGG-TCATTAGCGA, Filo_UCD_qRev: TTGCTCTGGTACTCGCTTGGT, Filo_UCD_probe: FAM –TGC-TGGGATGCTGTCTTTGAGCCT-BHQ.

Libraries for genome sequencing were generated with both the Kapa Hyper Library kit (Kapabiosystems, Roche), as described previously (Anthony), and also with VirCapSeq-VERT (Briese et al 2015), followed by sequencing on the Illumina Miseq platform (three samples per lane, one lane for unbiased Kapa and one lane for VirCapSeq-VERT). Contigs and unique singletons were assembled as described previously (Anthony). Following genome assembly, all unassembled singletons were re-mapped to the final sequence to visualize coverage and depth across the genome. A second genome was generated by PCR walking using gene-specific primers. The termini were amplified using Rapid Amplification of cDNA ends (RACE) using anchor and virus specific primers (Li et al. 2005). Host NPC1 sequences were generated by mapping unassembled singletons onto a reference NPC1 genome.

Genetic and phylogenetic analyses

Sequences were edited using Geneious (version 9.1.7) and aligned with ClustalW. Bayesian coalescent phylogenetic analysis was implemented using BEAST. Nucleotide substitution models were chosen using jModelTest and a Yule process prior chosen to more accurately represent the speciation process. Each analysis was run for 1,000,000 generations. Maximum clade credibility trees were generated using the TreeAnnotator program in BEAST and edited using FigTree. Alignments and trees were created separately for each gene and a concatenation was used for the full genome.

The nucleotide alignment of the ebolavirus genomes was screened for recombination using the seven algorithms in the Recombination Detection Program (RDP version 4.87). Amino acid sequence similarity between ebolaviruses was compared for the same alignment across the genome by calculating the average percent identity of each sequence to the reference (match=1, mismatch=0, gaps included) in a sliding window size of 100 with a step size of 10 and plotting the values. Sequences were also analyzed using the open-access PASC tool (NCBI) which provides a histogram of BLAST-based alignment percent identities between all pairs of non-redundant (>99.5% different) filovirus genomes from GenBank in order to classify sequences taxonomically (Bao et al. 2017).

The ebolavirus nucleotide alignment was analyzed for evidence of selection using the SLAC, FEL, MEME, and FUBAR algorithms, executed in datamonkey (http://datamonkey.org/) and with the M7 and M8 codon models in codeml (PAML package). The codon models in PAML were implemented using both a gene-specific tree for each gene and a species-level tree (the concatenated alignment tree). Model fit was compared using a likelihood ratio test

($\chi^2_{df=2}$). To visualize the variation in selective pressure across the genome, the Bayes Empirical Bayes (BEB) posterior mean $\omega \pm$ standard deviation was plotted for each codon position and color-coded according to the posterior probability of $\omega > 1$.

Protein structure modeling

A sequence alignment between Zaire Ebola GP and Bombali Ebola GP was carried out with T-coffee. Interfacial residues (residues with at least one heavy atom located within 5 Å of any other heavy atom in the binding partner) were identified using the crystal structure of the Zaire GP protein bound to human NPC1 (Wang et al., 2016). Blast was used for template search and alignment, while NEST was used to model the structure of Bombali Ebola GP (Petrey et al., 2003). A non-redundant set of sequences was assembled, corresponding to proteins deposited in the Protein Data Bank (Berman et al., 2000), using a sequence identity cutoff of 1.0 with CD-HIT (Li et al., 2001). A single iteration of BLAST was run against this dataset, and the template and alignment with the lowest e-value was selected (PDB: 5FHC; e-value: $1.4\ e^{-139}$). The interaction of the human NPC1 protein with Bombali Ebola GP was assessed using a structural alignment of the GP atomic model to the crystallized human NPC1-Zaire Ebola GP protein complex (Wang et al., 2016) with SKA (Yang and Honig, 2000).

Results

Three oral swabs and two rectal swabs from four individual bats were positive using the broadly reactive filovirus 'family level' cPCR (4/244). The resulting 650 bp fragment of the ebolavirus L-gene showed 75% nucleotide and 88% amino acid identity to other known Ebola viruses. Rectal swabs for two of the four positive bats were also positive using the ebolavirus 'genus level' cPCR. The resulting 187 bp fragment of the NP gene showed 83% nucleotide identity to known ebolaviruses. All samples collected from dogs, cats, and rodents were negative by the filovirus and ebolavirus cPCRs. All samples, including from bats, were negative using the ebolavirus Zaire-specific real-time PCR.

Of the four positive bats, three were identified as *Chaerephon pumilus* based on 98% sequence identity in the Cytb gene and 99% in COI. The fourth bat was identified as *Mops condylurus* based on 98% sequence identity in the Cytb gene and 99% in COI. All remaining bats (n=240) were also barcoded (Table 1). *C. pumilus* and *M. condylurus* are both insectivorous free-tailed bats within the family *Molossidae*. The four positive bats were adult females sampled between May 21st-28th 2016, at three different sites within 50 miles of each other in the Bombali district (Figure 1). They were all sampled in and around human dwellings in small villages, where animals (poultry, goats, sheep) and crops (fruit, vegetables, oil tree, seed) were raised for local consumption and sale.

Using unbiased high throughput sequencing (UHTS), 98% of the genome was recovered from the oral swab of *M. condylurus* (Bombali Ebola/2016/Mops condylurus/SLE, Genbank Accession ##), with an average depth of 12x. Using VirCapSeq, 42% of the genome was recovered with an average depth of 5x. Gene-walking using PCR and Sanger sequencing was used to obtain a second genome from the rectal swab of *C. pumilus* (Bombali Ebola/2016/Chaerephon pumilus/SLE, Genbank Accession ##). The genome sequences obtained from each bat species shared 99.1% sequence identity; there were 154 single nucleotide polymorphisms distributed throughout the genome, 30 of which were non-synonymous.

A specific quantitative real-time PCR assay was designed to target the new Bombali ebolavirus. This assay reliably detected down to 10 genome copies with an efficiency of 91%, and did not cross react with Marburg, Lloviu, or any of the known Ebola viruses (Zaire, Sudan, Tai Forest, Bundibugyo, Reston). Viral load in the four positive samples varied from 10,000 to 4 genome copies (corresponding to Ct values of 23 to 37). Using this assay, all 244 bat samples were re-screened in case any weakly positive individuals were missed by the degenerate family and genus cPCR assays. A rectal swab from one additional *C. pumilus* was found to be weakly positive (Ct = 39).

Phylogenetic analyses demonstrated that the Bombali virus is sufficiently distinct to be considered a novel species within the ebolavirus genus, and demonstrated consistent topological arrangements in all genes except VP30 (Figure 2). Classification by NCBI's PASC tool also supported this classification of Bombali virus, and it meets all criteria for a novel species suggested by Bao et al. (Figure 3). The virus showed 53-59% nucleotide identity (64-72% amino acid) to other ebolavirus genomes, but areas of both conservation and variability were identified across the genome (Figure 4). In particular, higher variability was observed in the mucin-like domain of the glycoprotein and in the hinge region of the viral polymerase, while sequence conservation was observed in the GP binding domain (Figure

4). No evidence of recombination was observed in any of the genes. Selection analysis indicated that all genes were underdoing purifying selection, however several individual residues did show evidence of positive selection (Table 2).

The binding potential of Bombali GP to human NPC1 was also assessed. GP shared 92% of the known NPC1-interacting residues found in other Ebola viruses,with two unique mutations identified at the binding interface, P146S and P148E (Figure 5B). The structural modeling suggests these mutations do not result in steric interference and are unlikely to block binding. The corresponding NPC1 residues found within 5 Å of P146S and P148E were conserved between humans and *M. condylurus* (both have D502 and V505), further suggesting that the P146S and P148E substitutions are unlikely to prevent binding of Bombali GP to human NPC1.

The amino acid sequences of the pathogenic motifs of Bombali ebolavirus were compared with those of *Zaire Ebola* and *Reston Ebola* (Figure 4). In *Zaire ebolavirus,* the VP35 C-terminal basic amino acid motif mediates type-1 interferon response, with a critical arginine residue at position 312 (Bale 2013). This residue and the surrounding C-terminal domain from position 296 to the C-terminus had 100% identity with *Zaire ebolavirus*. However, residues 48 and 296, which are predicted to mediate VP35 C-terminal interactions with dsRNA and NP, were consistent with *Reston ebolavirus*. The two critical residues in VP24 that influence the potency of type-1 interferon antagonism via interactions with karyopherin (Reid 2006, Papppalardo et al., 2016) were also consistent with those in *Reston ebolavirus*. Within GP, the 17 aa motif that mediates immunosuppression *in vitro* (Volchkov et al. 1992; Yaddanapudi 2006) was present with 100% identity to *Zaire ebolavirus*.

Discussion

A new Ebolavirus (Bombali Ebola/2016/SLE) was identified in two bat species in Sierra Leone. This is the first complete Ebolavirus genome obtained from any bat. and supports growing evidence that bats are the natural reservoir for filoviruses. Both species (*C. pumilus* and *M. condulyrus*) are insectiviorous free-tailed bats belonging to the family *Molossidae*,. They are known to co-roost and are widely distributed across West and Sub-Saharan Africa. Additional surveillance will be required to determine if the virus is distributed throughout this range. We attribute this discovery to our broad and prospective approach, aimed at identifying filoviruses prior to spillover events with high morbidity and mortality and targeting a wide range of potential host species Taken with the widespread serologic evidence of ebolaviruses in bats across Africa and Asia, our finding underscores the likelihood that there are potentially many related viruses yet to be discovered.

It is not known whether the Bombali ebolavirus is pathogenic to humans. Some of the pathogenic motifs are more similar to Ebola Zaire, but others are more similar to *Reston Ebola*, which is not known to cause disease in humans (Pappalardo et al. 2016; Miranda 2011). Structural modeling indicated there was also no reason that the glycoprotein of Bombali ebolavirus would be unable to bind the human NPC1 receptor. Only two mutations were identified in the GP at the binding interface, both of which were predicted to be compatible with NPC1 interaction. This suggests that the Bombali ebolavirus may be able to mediate entry into human cells. While binding is not the only important factor in the emergence pathway, it does represent the first critical step in spillover and indicates that Bombali Ebola could have zoonotic potential. Additional studies focused on the role of VP24 and VP35 in modulating host immunity would help to better understand the pathogenicity of this virus.

The Bombali ebolavirus was detected in bats collected in and around human dwellings. This presumably increases the potential for human exposure to the virus and the chance for spillover. Serosurveys of people in contact with *M. condylurus* or *C. pumilus* would help to confirm whether exposure has already occurred, though given the known cross-reactivity between ebolaviruses (Macneil et al., 2011), it may be difficult to distinguish antibodies raised against Bombali from those raised against the Zaire virus during the 2014 outbreak. It might also be important to investigate whether any seropositive individuals that were previously attributed to infection with Ebola Zaire might actually represent a response to infection with Bombali Ebola or a related virus (Burke et al., 2016).

The species *M. condylurus* and *C. pumilus* have been previously suggested as hosts of ebolaviruses. Both were shown to survive experimental infection with Zaire Ebola (human Zaire-95 from Kikwit, Swaenopoel et al. 1996). *M. condylurus* was suggested as the source of the 2014 Ebola Zaire outbreak in West Africa (Saez et al., 2015) and was also shown to have antibodies against Ebola Zaire (Pourrut et al., 2007). The current literature reflects a bias towards surveys of ebolaviruses in fruit bats, and while they are clearly important hosts (Towner 2007, Leroy 2005,

Porrut 2007, Yang 2017), we support the previous suggestion by Saez et al (2015) that surveys for filoviruses in bats should include insectivorous bats with particular emphasis on species within the family *Molossidae*. Given the success of our consensus PCR approach, we further emphasize the importance of adopting broadly reactive discovery tools that are not restricted to a single virus species or strain. High throughput sequencing tools would also be appropriate but are more costly and technically demanding, especially in resource limited settings. It is important to note that this study is meant to advance our understanding of potentially zoonotic viruses circulating in wildlife. It is *not* meant to create alarm or incite the retaliatory culling of bats. While bats have been implicated as reservoirs for a number of infectious pathogens, they are also important insectivores, pollinators, and seed dispersers and thus play a vital ecosystem role. Previous studies have shown that killing or disturbing bats in their natural habitat does not necessarily reduce the risk of transmission; rather, it can increase the number of susceptible bats and enhance disease transmission through increased frequency of contact (Amman et al., EID, 2014). Any public health interventions should be considered carefully in light of this and developing evidence.

The 2014 Ebolavirus epidemic escalated, in part, due to the lack of adequate public health infrastructure and surveillance (Lo et al., 2017). Our findings highlight a need to be more prepared for future outbreaks. Identifying the genetic determinants and ecological conditions associated with emergence would greatly enhance preparedness but are contingent on a better understanding of the diversity and transmission dynamics of ebolaviruses in their natural hosts. Our study contributes to this objective by identifying a potentially zoonotic ebolavirus circulating in bats living in close proximity with humans.

Figure Legends

Figure 1. Map showing the distribution of *Mops condylurus* and *Chaerephon pumilus* (based on International Union for Conservation of Nature [IUCN] data) and the sampling locations for the study.

Figure 2. Phylogenetic trees created using amino acid sequences for each gene and for the concatenation of all genes. The values of ω were generated using the SLAC analysis in DataMonkey. Genbank accession numbers used in the phylogenetic and evolutionary analyses: ZaireEbola/1976/H.sapiens/DRC (KC242801), ZaireEbola/1995/H.sapiens/DRC (KR867676), ZaireEbola/2007/H.sapiens/DRC (KC242786), ZaireEbola/2014/H.sapiens/GIN (KT765131), ZaireEbola/2014/H.sapiens/LBR (KR075003), ZaireEbola/2015/H.sapiens/SLE (KT357856), Bundibugyo/2007/H.sapiens/UGA (KU182911), TaiForestEbola/1994/H.sapiens/CIV (KU182910), SudanEbola/2000/H.sapiens/UGA (KR063670), RestonEbola/1989/M.fascicularis/USA (NC_004161), Lloviu/2003/M.schreibersii/ESP (NC_016144), Marburg/1999/H.sapiens/DRC (JX458851), Marburg/2009/R.aegyptiacus/UGA (JX458854).

Figure 3. A histogram of all BLAST-based alignment pairwise identities between full genome filoviruses from GenBank generated by the PASC tool from NCBI. Sequences that were >99.5% identical were removed, leaving 112 non-redundant genomes. Bars are color-coded to indicate whether pairwise identities arose from two sequences classified as the same species, the same genus, or neither the same species or genus (i.e., Zaire and Marburg). The maximum pairwise identity of Bombali virus in this alignment was with Zaire ebolavirus (accession no. KU296628) at 52.98%, which is shown on the figure with a dashed red line.

Figure 4. The variation in selective pressure trends with the variation in amino acid identity across the genome. The BEB posterior mean ω ± standard deviation is shown (top) where the posterior mean ω >1 and the posterior probability of ω >1 is less than 0.5 (orange) or greater than 0.5 (red). Positions with posterior probability greater than 0.9 are marked with an asterisk. The amino acid similarity (bottom) shows the percent amino acid identity of Zaire (KC242801), Bundibugyo (KU182911), and Reston (NC_004161) ebolaviruses with the reference Bombali Ebola /2017/Mops condylurus/Sierra Leone in a sliding window size of 100 with step size 10. Sections highlighted in green (A, B, C, D) are regions of high amino acid conservation and negative selection. The amino acid sequences of these regions are shown below with amino acid changes highlighted in color. All amino acid numbering is according to Zaire ebolavirus. Blue arrows indicate probable Reston SDPs indicated by Pappalardo et al. Sections highlighted in yellow (i, ii, iii) are regions of high amino acid variation that show enriched positive selection.

Figure 5. Structural modeling
Sequence analysis and structural modeling of the interaction between the human NPC1 and the Bombali Ebola GP protein. (A) Sequence alignment of the known human-infecting Ebola GPs (Zaire, Sudan, Reston, Bundibugyo and

Tai forest) and Bombali Ebola GP (numbering corresponds to *Zaire Ebola*). Displayed regions pertain to the GP interface as dictated by the *Zaire Ebola* GP-Human NPC1 crystal structure (PDB: 5F1B). Conserved interfacial residues are colored in blue, viral-specific interfacial residues (whose physicochemical properties differ from the most common residue in a given position) are colored in yellow. Squared positions in the alignment correspond to residues whose side chain heavy atoms are within 5 Å of any heavy atom in the Human NPC1 receptor. (B) Atomic representation of the interaction between the human NPC1 (red) and the Ebola GP protein (blue). Left panel: Overview of the crystal structure between the human NPC1 (red) and the *Zaire Ebola* GP protein (blue) (PDB: 5F1B). Middle panel: Close-up view of the interface between the human NPC1 and the Zaire Ebola GP protein (PDB: 5F1B). Right panel: Close-up view of the modeled interface between the human NPC1 crystal structure (red) and the Bombali Ebola GP atomic model (blue). Displayed residues on the viral protein (residues in yellow) correspond to interfacial positions with different amino acids in the Bombali Ebola GP protein. Displayed residues on the human NPC1 (residues in white) correspond to residues with side chain heavy atoms within 5 Å of residues 146 and/or 148 in the Zaire or Bombali GP protein.

Tables

Table 1. Summary of bat species tested for Filoviruses and Bombali Ebola.

Bat Species	Bat Family	No. Tested	No. Positive by Filovirus cPCR	No. Positive by Ebolavirus genus PCR	No. Positive by qRT-PCR for Bombali Ebola
Insectivorous Bats					
Chaerephon atsinanana	Molossidae	1			
Chaerephon pumilus	Molossidae	55	3	2	4
Glauconycteris poensis	Vespertillionidae	1			
Hipposideros abae	Hipposiderdae	7			
Hipposideros jonesi	Hipposiderdae	4			
Hipposideros larvatus	Hipposiderdae	1			
Hipposideros ruber	Hipposiderdae	50			
Mops condylurus	Molossidae	52	1		1
Myotis bocagii	Vespertillionidae	3			
Neoromicia rendalli	Vespertillionidae	2			
Nycteris hispida	Nycteridae	1			
Pipistrellus nanulus	Vespertillionidae	3			
Rhinolophus fumigatus	Rhinolophidae	3			
Rhinolophus landeri	Rhinolophidae	1			
Rhinopoma microphyllum	Rhinopomatidae	1			
Scotophilus viridis	Vespertillionidae	26			
Unidentified Molossid bat	Molossidae	1			
Unidentified Nycterid bat	Nycteridae	3			
Fruit Bats					
Eidolon helvum	Pteropodidae	2			
Epomophorus gambianus	Pteropodidae	1			
Epomophorus labiatus	Pteropodidae	2			
Epomophorus minor	Pteropodidae	3			
Epomops buettikoferi	Pteropodidae	2			
Micropteropus pusillus	Pteropodidae	2			
Myonycteris angolensis	Pteropodidae	12			
Myonycteris torquata	Pteropodidae	5			
Total		**244**	**4**	**2**	**5**

Table 2. Amino acids indicated to be under positive selection for at least 2 of the 4 DataMonkey algorithms tested: SLAC, FEL, MEME, and FUBAR. Numbering is according to Zaire ebolavirus. Number in parentheses is the number of tests that indicated positive selection. Sites indicated by 3 or more methods are bolded.

Gene	Position
NP	**3(4)**, 11(2), 108(2), 502(2), 553(2), 577(2), 627(2)
VP35	63(2)
VP40	67(2)
GP	**310(4), 318(3), 321(3), 332(3)**
VP30	276(2)
VP24	None
L	202(2), 1661(2), 1731(2), 1733(2), 1737(2), 1752(2), 1774(2), 2171(2)

Acknowledgements

We thank the government of Sierra Leone for permission to conduct this work. We thank the field teams, including LAM Kenny, V Lungay, W Robert, E Amara, D Kargbo, V Merewhether-Thompson, M Kanu, E Lavallie, A Bangura, M Turay, FV Bairoh, M Sinnah, and S Yonda for performing sample collection; laboratory staff for assistance with processing the samples, including M Coomber and O Kanu (University of Makeni) and B Smith and V Ontiveros (UC Davis); B Lee for bioinformatics assistance (Columbia University); and N Randhawa for map graphics (UC Davis). This study was made possible by the generous support of the American people through the United States Agency for International Development (USAID) Emerging Pandemic Threats PREDICT project (cooperative agreement number GHN-A-OO-09-00010-00).

References

Amman BR, Carroll SA, Reed ZD, Sealy TK, Balinandi S, Swanepoel R, et al. Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog. 2012;8(10):e1002877.

Amman BR, Nyakarahuka L, McElroy AK, Dodd KA, Sealy TK, Schuh AJ, et al. Marburgvirus resurgence in Kitaka Mine bat population after extermination attempts, Uganda. Emerg Infect Dis. 2014 Oct;20(10):1761-4.

Anthony SJ, Gilardi K, Menachery VD, Goldstein T, Ssebide B, Mbabazi R, et al. Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus. mBio. 2017 Apr;8(2): e00373-17.

Bale S, Julien J, Bornholdt ZA, Krois AS, Wilson IA, Ollmann Saphire E. Ebolavirus VP35 Coats the Backbone of Double-Stranded RNA for Interferon Antagonism. J Virol. 2013 Sep; 87(18):10385–88.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28:235-42.

Briese T, Kapoor A, Mishra N, Jain K, Kumar A, Jabado OJ, Lipkin WI. Virome capture sequencing enables sensitive viral diagnosis and comprehensive virome analysis. mBio 2015;6(5):e01491-15.

Burk R, Bollinger L, Johnson JC, Wada J, Radoshitzky SR, Palacios G, et al. Neglected filoviruses, FEMS Microbiol Rev. 2016;40(4):494-519.

Jaaskelainen AJ, Moilanen K, Aaltonen K, Putkuri N, Sironen T, Kallui-Kokko H, et al. J Clin Virol. 2015;67:56-8.

Hayman DTS, Yu M, Crameri G, Wang L, Suu-Ire R, Wood JLN, et al. Ebola Virus Antibodies in Fruit Bats, Ghana, West Africa. Emerg Infect Dis. 2012 18(7):1207-09.

He B, Feng Y, Zhang H, Xu L, Yang W, Zhang Y. Filovirus RNA in Fruit Bats, China. Emerg Infect Dis. 2015 21:1675-7.

Jayme SI, Field HE, de Jong C, Olival KJ, Marsh G, Tagtag AM, et al. Molecular evidence of Ebola Reston virus infection in Philippine bats. Virol J. 2015;12:107.

Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005;438:575-6.

Li W, Jaroszewski L, Godzik A. Clustering of highly homologous sequences to reduce the size of large protein databases. Bioinformatics. 2001;17(3):282-3.

Li Z, Yu M, Zhang H, Wang HY, Wang LF. Improved rapid amplification of cDNA ends (RACE) for mapping both the 5' and 3' terminal sequences of paramyxovirus genomes. J Virol Methods. 2005;130:154-6.

Lo TQ, Marston BJ, Dahl BA, De Cock KM. Ebola: Anatomy of an Epidemic. Annu Rev Med. 2017 68:359-70.

Macneil A, Reed Z, Rollin PE. Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus. PLoS Negl Trop Dis. 2011;5(6):e1175.

Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, et al. Ebola virus entry requires the host-programmed recognition of an intracellular receptor. EMBO J. 2012;31:1947-60.

Miranda ME, Miranda NL. Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis. 2011;204 Suppl 3:S757-60.

Negredo A, Palacios G, Vázquez-Morón S, González F, Dopazo H, Molero F, et al. Discovery of an ebolavirus-like filovirus in Europe. PLoS Pathog. 2011;e1002304.

Ng M, Ndungo E, Kaczmarek ME, Herbert AS, Binger T, Kuehne AI, et al. Filovirus receptor NPC1 contributes to species-specific patterns of ebolavirus susceptibility in bats. eLife 2015;4:e11785.

Pappalardo M, Juliá M, Howard MJ, Rossman JS, Michaelis M, Wass MN. Conserved differences in protein sequence determine the human pathogenicity of Ebolaviruses. Sci Rep. 2016;6:23743.

Petrey D, Xiang Z, Tang CL, Xie L, Gimpelev M, Mitros T, et al. Using multiple structure alignments, fast model building, and energetic analysis in fold recognition and homology modeling. Proteins. 2003;53 Suppl 6:430-5.

Pourrut X, Délicat A, Rollin PE, Ksiazek TG, Gonzalez JP, Leroy EM. Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species. J Infect Dis. 2007;196 Suppl 2:S176-83.

Reid SP, Leung LW, Hartman AL, Martinez O, Shaw ML, Carbonnelle C, et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol. 2006 Jun;80(11):5156-67.

Saéz MA, Weiss S, Nowak K, Lapeyre V, Zimmermann F, Düx A, et al. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med. 2015;7(1):17-23.

Mari Saez A, Weiss S, Nowak K, Lapeyre V, Zimmerman F, Dux A, et al. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Mol Med. 2015;7, 17-23.

Swanepoel R, Leman PA, Burt FJ, Zachariades NA, Braack LE, Ksiazek TG, et al. Experimental inoculation of plants and animals with Ebola virus. Emerg Infect Dis. 1996;2(4):321-5.

Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M,et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. 2004;78(8):4330-41.

Towner JS, Pourrut X, Albarin˜o CG, Nkogue CN, Bird BH, Grard G, et al. Marburg Virus Infection Detected in a Common African Bat. PLoS One 2007;2(8): e764.

Townzen JS, Brower AV, Judd DD. Identification of mosquito blood meals using mitochondrial cytochrome oxidase subunit I and cytochrome b gene sequences. Med Vet Entomol. 2008;22:386-393.
Volchkov VE, Blinov VM, Netesov SV. The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses. FEBS Lett. 1992;305:181-4.

Wang H, Shi Y, Song J, Qi J, Lu G, Yan J, et al. Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. Cell. 2016 Jan;164(1-2):258-68

Yaddanapudi K, Palacios G, Towner JS, Chen I, Sariol CA, Nichol ST, et al. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J. 2006 Dec;20(14):2519-30.

Yang X, Zhang Y, Jiang R, Guo H, Zhang W, Li B, et al. Genetically Diverse Filoviruses in Rousettus and Eonycteris spp. Bats, China, 2009 and 2015. Emerg Infect Dis. 2017;23(3):482-6.

Yang AS, Honig B. An integrated approach to the analysis and modeling of protein sequences and structures. III. A comparative study of sequence conservation in protein structural families using multiple structural alignments. J Mol Biol. 2000;301(3):691-711.

Yuan J, Zhang Y, Li J, Zhang Y, Wang L, Shi Z. Serological evidence of ebolavirus infection in bats, China. Virol J. 2012;9:236.

From: Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>
To: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
CC: Brian Bird <bhbird@UCDAVIS.EDU>;Jonna Mazet <jkmazet@UCDAVIS.EDU>
Sent: 6/1/2017 6:41:59 AM
Subject: Re: Guinea VHF sub award and employee questions

Thanks Liz. One of this first things on my list is to assess the feasibility and timeframe of moving the staff to the subaward. It's a government lab so I'm not sure what the process will be to include individuals underneath that award, as well as individuals who are not based in Conakry where the lab is. I hope to have some information soon.

I'm also not sure if we are mandated to use a payroll company (as you are in China – your memory is correct :). I will also find that out as well.

With the current mechanism, current contracts with MB and Footprint cover the following:

- CC and Field Coordinator – end of August 2017
- PA – end of July 2017
- 11 field staff in Conakry – end of June 2017
- 11 field staff in N'Zérékoré – end of July 2017 (I extended these individuals for 2 months because this area is critical to our workplan and it gives us more time for transition).

In terms of setting up the subaward with the VHL lab, what are the next steps? I know I need to clarify the staffing issue and whether that should be included but is there anything else I can be doing in the meantime to assist?

Regards,
corina

From: Elizabeth Leasure
Date: Wednesday, May 31, 2017 at 10:48 PM
To: Corina Grigorescu Monagin
Cc: Brian Bird , Jonna Mazet
Subject: RE: Guinea VHF sub award and employee questions

Yes, ideally we would just move forward with UCD issuing a subaward to the lab in Guinea rather than having MB put a subaward in place only to have it end and be replaced by a UCD-issued subaward. Less paperwork and (hopefully) less confusing for the in-country staff.

I have no issues with Metabiota purchasing fuel cards to contribute to the cost of running the generator for sample storage while we get the subaward in place.

For the staffing, are we required to use an outside payroll company like Footprint to facilitate payroll payments in Guinea? I know Metabiota has been using a similar payroll firm in China, but I believe they are required to due to Chinese law (if my memory serves). It is much cleaner (and less expensive without the 18% fee) to just hire the in-country staff through the subaward once it is established (unless there is a very good reason to do otherwise). To avoid a break in service for in-country staff, however, I think we have no choice but to continue to pay them through the current mechanism (meaning through MB to Footprint) until the UCD subaward is in place and hiring (or individual contracting) through the subrecipient can occur.

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
530-304-1403 (cell)

From: Corina Grigorescu Monagin
Sent: Tuesday, May 30, 2017 2:27 PM

To: Elizabeth Leasure
Cc: Brian Bird; Jonna Mazet
Subject: Guinea VHF sub award and employee questions

Hi Liz,

I've started the transition of Guinea and have had a few phone calls with the Metabiota team. A couple of questions for you.

MB has not signed the sub award with the VHF lab. I'm thinking that you do not want them to proceed and that it would be initially signed with UCD? If so, I would like to authorize MB to pay for fuel cards to contribute to the cost of the generator (where our freezer and samples are stored) until we can get the sub award in place. Please advise.

In terms of the staff – all employees (contractual field staff and full time PREDICT) are paid through a payroll company "Footprint". They charge a fee of approximately 18% on all costs. I am getting a full list of staff, salary, location and contract terms and we will have to decide how to proceed. I know the ideal would be to put them all under the subcontract but I honestly don't know the possibility or length of time it will take to put in place. While I figure out our options and timeframe - Do you want to continue with Footprint or another option?

I'm sure you have tons of questions – I'm available in the afternoons (PST) when I'm back at the hotel so let me know if it's easier to talk.

Thanks
Corina

From:	Peter Daszak <daszak@ecohealthalliance.org>
To:	Andrew Clements (aclements@usaid.gov) <aclements@usaid.gov>;apereira@usaid.gov <apereira@usaid.gov>;Jonna Mazet (jkmazet@ucdavis.edu) <jkmazet@ucdavis.edu>
CC:	predict@ucdavis.edu <predict@ucdavis.edu>;William B. Karesh" <karesh@ecohealthalliance.org>;Evelyn Luciano <luciano@ecohealthalliance.org>;Alison Andre <andre@ecohealthalliance.org>;Brooke Genovese (bgenovese@ucdavis.edu) <bgenovese@ucdavis.edu>
Sent:	6/1/2017 10:10:22 PM
Subject:	Contacting the Indonesia mission and RDMA re. transition of management from MB to EHA

Hi Andrew,

Forgot to mention this today on the call, but could you please reach out (in the same way you're planning to for RoC) to Tim and the Indonesia mission, and to Dan at RDMA, to let them know about that Metabiota is transitioning out of Indonesia and China respectively, and that EHA will pick up the management of their projects in-country as part of our PREDICT acitivities. I know this isn't as significant a management change as RoC and Cd'I, but it would help a great deal if this came from USAID HQ, and then I can follow up with a phone call with both of them to let them know how we're going to manage the transition.

Please cc me and Evelyn so that we can follow up promptly, and thanks for doing this!

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

+1.212.380.4473 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

From:	Andrew Clements <aclements@usaid.gov>
To:	Peter Daszak <daszak@ecohealthalliance.org>
CC:	apereira@usaid.gov <apereira@usaid.gov>;Jonna Mazet (jkmazet@ucdavis.edu) <jkmazet@ucdavis.edu>;predict@ucdavis.edu <predict@ucdavis.edu>;William B. Karesh <karesh@ecohealthalliance.org>;Evelyn Luciano <luciano@ecohealthalliance.org>;Alison Andre <andre@ecohealthalliance.org>;Brooke Genovese (bgenovese@ucdavis.edu) <bgenovese@ucdavis.edu>
Sent:	6/2/2017 5:12:08 AM
Subject:	Re: Contacting the Indonesia mission and RDMA re. transition of management from MB to EHA

Sure, no problem. I realized last night we hadn't done that so perfect timing on the request.

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jun 2, 2017, at 12:10 AM, Peter Daszak <daszak@ecohealthalliance.org> wrote:

Hi Andrew,

Forgot to mention this today on the call, but could you please reach out (in the same way you're planning to for RoC) to Tim and the Indonesia mission, and to Dan at RDMA, to let them know about that Metabiota is transitioning out of Indonesia and China respectively, and that EHA will pick up the management of their projects in-country as part of our PREDICT acitivities. I know this isn't as significant a management change as RoC and Cd'I, but it would help a great deal if this came from USAID HQ, and then I can follow up with a phone call with both of them to let them know how we're going to manage the transition.

Please cc me and Evelyn so that we can follow up promptly, and thanks for doing this!

Cheers,

Peter

Peter Daszak
President

EcoHealth Alliance
460 West 34th Street – 17th Floor
New York, NY 10001

+1.212.380.4473 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

From: Jonna Mazet <jkmazet@ucdavis.edu>
To: Andrew Clements <aclements@usaid.gov>
CC: Alisa Pereira <apereira@usaid.gov>;Shana Gillette <sgillette@usaid.gov>;predict@ucdavis.edu <predict@ucdavis.edu>;Brooke Genovese <bgenovese@ucdavis.edu>;Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>;Brian Bird <bhbird@ucdavis.edu>;Tracey Goldstein <tgoldstein@ucdavis.edu>
Sent: 6/3/2017 7:53:00 AM
Subject: Re: DRC and ROC

Thanks (& sorry for anything I missed while in the air,), but are we good to go to schedule with Guinea Mission -- they're asking for more info.
Have a good weekend,
Jonna

On Saturday, June 3, 2017, Andrew Clements <aclements@usaid.gov> wrote:
Thanks. Safe travels.

Once I've notified the USAID staff in ROC, RDMA, and Indonesia, I will let you all know so you can follow up with the Mission staff if they have additional questions.

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jun 2, 2017, at 9:56 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Hi Andrew,
No transition in DRC at the moment. We are hopeful that all will remain stable with Metabiota there.
RoC will transition to EcoHealth Alliance, with Billy as global lead. He and Karen are discussing scope, but we will at least retain market behavior work and staff. If resources allow and science justifies, we may also sample upstream to address the new highway and possibility of change of risk in value chain with easier transportation.

EcoHealth was already lead partner in Indonesia and China, so they are managing the communication as usual and will or have informed that Metabiota is phasing out. Billy, Kevin, and Peter copied to make sure.

On my way toTanzania now,
J

On Thu, Jun 1, 2017 at 1:44 PM, Andrew Clements <aclements@usaid.gov> wrote:
Can you remind me what the transition plans are for DRC and ROC? Who would be the new implementing partners? Who would be the new country backstops? Etc.

Also, have the missions been notified of the proposed management changes for Indonesia and China? Any other countries where I need to notify missions (already covered CDI, SL, Guinea)?

Thanks!

Andrew P. Clements, Ph.D.

Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

From:	Andrew Clements <aclements@usaid.gov>
To:	Kevin Olival, PhD <olival@ecohealthalliance.org>
CC:	Dr. Jonna Mazet <jkmazet@ucdavis.edu>;Alisa Pereira <apereira@usaid.gov>;Shana Gillette <sgillette@usaid.gov>;Peter Daszak <daszak@ecohealthalliance.org>;William B. Karesh <karesh@ecohealthalliance.org>;Alison Andre <andre@ecohealthalliance.org>;predict@ucdavis.edu <predict@ucdavis.edu>
Sent:	6/4/2017 7:20:04 AM
Subject:	[predict] Re: DRC and ROC

Sure, no problem.

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jun 3, 2017, at 4:06 PM, Kevin Olival, PhD <olival@ecohealthalliance.org> wrote:

Dear Andrew,

Sorry for chiming in late here. I was in Thailand at the end of last week and met with Dan and Sudarat at RDMA. I did briefly and informally mention to both of them the transition in China and Indonesia. Andrew, it would be great if you could let them know formally.

Please let me know if you have any questions.

Thank you,
Kevin

Kevin J. Olival, PhD
Associate Vice President for Research

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4478 (direct)
1.917.856.3900 (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

On Jun 3, 2017, at 2:23 AM, Andrew Clements <aclements@usaid.gov> wrote:

Thanks. Safe travels.

Once I've notified the USAID staff in ROC, RDMA, and Indonesia, I will let you all know so you can follow up with the Mission staff if they have additional questions.

Andrew P. Clements, Ph.D.

Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jun 2, 2017, at 9:56 PM, Jonna Mazet <jkmazet@ucdavis.edu> wrote:

Hi Andrew,
No transition in DRC at the moment. We are hopeful that all will remain stable with Metabiota there.
RoC will transition to EcoHealth Alliance, with Billy as global lead. He and Karen are discussing scope, but we will at least retain market behavior work and staff. If resources allow and science justifies, we may also sample upstream to address the new highway and possibility of change of risk in value chain with easier transportation.

EcoHealth was already lead partner in Indonesia and China, so they are managing the communication as usual and will or have informed that Metabiota is phasing out. Billy, Kevin, and Peter copied to make sure.

On my way toTanzania now,
J

On Thu, Jun 1, 2017 at 1:44 PM, Andrew Clements <aclements@usaid.gov> wrote:
Can you remind me what the transition plans are for DRC and ROC? Who would be the new implementing partners? Who would be the new country backstops? Etc.

Also, have the missions been notified of the proposed management changes for Indonesia and China? Any other countries where I need to notify missions (already covered CDI, SL, Guinea)?

Thanks!

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

From:	Andrew Clements <aclements@usaid.gov>
To:	William Karesh <Karesh@ecohealthalliance.org>;Kevin Olival PhD <olival@ecohealthalliance.org>;Jonna Mazet <jkmazet@ucdavis.edu>;djwolking@ucdavis.edu <djwolking@ucdavis.edu>
CC:	Alisa Pereira <apereira@usaid.gov>;Shana Gillette <sgillette@usaid.gov>
Sent:	6/5/2017 11:54:38 AM
Subject:	Fwd: PREDICT management changes in China

RDMA Mission notified as well.

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

Begin forwarded message:

From: Andrew Clements <aclements@usaid.gov>
Date: June 5, 2017 at 1:48:52 PM GMT+2
To: "Daniel Schar (RDMA/OPH)" <dSchar@usaid.gov>, "Sudarat Damrongwatanapokin (RDMA/OPH)" <sDamrongwatanapokin@usaid.gov>
Cc: Alisa Pereira <apereira@usaid.gov>, Shana Gillette <sgillette@usaid.gov>
Subject: PREDICT management changes in China

Hi Sudarat and Dan,

I'm writing to let you know that PREDICT is undergoing some internal management changes in a few countries, including China. As a result, the role of Metabiota will be decreased and the role of EcoHealth Alliance will increase. We hope the impact will be minor and expect that any changes will not greatly alter PREDICT's interactions with the GOPRC, local partners, local PREDICT staff, and the Mission. While changes in the middle of a project are not ideal, PREDICT felt that this change was necessary to make sure it could deliver the expected results.

At this point, I do not know if PREDICT has mentioned this transition to its in-country staff and partners so please do not share this information until PREDICT has had a chance to do so.

PREDICT is available for a phone call with you to discuss the transition plan in more detail and answer any questions you have.

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

From:	William B. Karesh <karesh@ecohealthalliance.org>
To:	Andrew Clements <aclements@usaid.gov>
CC:	Kevin Olival, PhD <olival@ecohealthalliance.org>;Jonna Mazet <jkmazet@ucdavis.edu>;David Wolking <djwolking@ucdavis.edu>;Alisa Pereira <apereira@usaid.gov>;Shana Gillette <sgillette@usaid.gov>
Sent:	6/5/2017 2:42:43 PM
Subject:	Re: PREDICT management changes in China

No Changes for Laos. Metabiota still working there as planned.

BK

William B. Karesh, D.V.M
Executive Vice President for Health and Policy

EcoHealth Alliance
460 West 34th Street - 17th Floor
New York, NY 10001 USA

+1.212.380.4463 (direct)
+1.212.380.4465 (fax)
www.ecohealthalliance.org

President, OIE Working Group on Wildlife

Co-chair, IUCN Species Survival Commission - Wildlife Health Specialist Group

EPT Partners Liaison, USAID Emerging Pandemic Threats - PREDICT-2 Program

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

On Jun 5, 2017, at 8:56 AM, Andrew Clements <aclements@usaid.gov> wrote:

Question from RDMA: any changes in Laos?

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

On Jun 5, 2017, at 1:54 PM, Andrew Clements <aclements@usaid.gov> wrote:

RDMA Mission notified as well.

Andrew P. Clements, Ph.D.
Senior Scientific Adviser

Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

Begin forwarded message:

From: Andrew Clements <aclements@usaid.gov>
Date: June 5, 2017 at 1:48:52 PM GMT+2
To: "Daniel Schar (RDMA/OPH)" <dSchar@usaid.gov>, "Sudarat Damrongwatanapokin (RDMA/OPH)" <sDamrongwatanapokin@usaid.gov>
Cc: Alisa Pereira <apereira@usaid.gov>, Shana Gillette <sgillette@usaid.gov>
Subject: PREDICT management changes in China

Hi Sudarat and Dan,

I'm writing to let you know that PREDICT is undergoing some internal management changes in a few countries, including China. As a result, the role of Metabiota will be decreased and the role of EcoHealth Alliance will increase. We hope the impact will be minor and expect that any changes will not greatly alter PREDICT's interactions with the GOPRC, local partners, local PREDICT staff, and the Mission. While changes in the middle of a project are not ideal, PREDICT felt that this change was necessary to make sure it could deliver the expected results.

At this point, I do not know if PREDICT has mentioned this transition to its in-country staff and partners so please do not share this information until PREDICT has had a chance to do so.

PREDICT is available for a phone call with you to discuss the transition plan in more detail and answer any questions you have.

Andrew

Andrew P. Clements, Ph.D.
Senior Scientific Adviser
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
Email: aclements@usaid.gov

From: Elizabeth Leasure <ealeasure@ucdavis.edu>
To: Corina Grigorescu Monagin <cgmonagin@ucdavis.edu>
CC: Brian Bird <bhbird@ucdavis.edu>;Jonna Mazet <jkmazet@ucdavis.edu>
Sent: 6/5/2017 3:42:30 PM
Subject: RE: Guinea VHF sub award and employee questions

One thing you could do is confirm that their SAM.gov registration is complete. The last info I have is that it was in progress, but it will need to be complete and current in order for UCD to send out the subaward for VHF signature.

We'll also need to finalize the SOW and budget for the period May 15-Sept 30, 2017. Were the SOW and budget in the approved request that I sent you okay, or do you think a revision is required?

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
530-304-1403 (cell)

From: Corina Grigorescu Monagin
Sent: Wednesday, May 31, 2017 11:42 PM
To: Elizabeth Leasure
Cc: Brian Bird; Jonna Mazet
Subject: Re: Guinea VHF sub award and employee questions

Thanks Liz. One of this first things on my list is to assess the feasibility and timeframe of moving the staff to the subaward. It's a government lab so I'm not sure what the process will be to include individuals underneath that award, as well as individuals who are not based in Conakry where the lab is. I hope to have some information soon.

I'm also not sure if we are mandated to use a payroll company (as you are in China – your memory is correct :). I will also find that out as well.

With the current mechanism, current contracts with MB and Footprint cover the following:

- CC and Field Coordinator – end of August 2017
- PA – end of July 2017
- 11 field staff in Conakry – end of June 2017
- 11 field staff in N'Zérékoré – end of July 2017 (I extended these individuals for 2 months because this area is critical to our workplan and it gives us more time for transition).

In terms of setting up the subaward with the VHL lab, what are the next steps? I know I need to clarify the staffing issue and whether that should be included but is there anything else I can be doing in the meantime to assist?

Regards,
corina

From: Elizabeth Leasure <ealeasure@UCDAVIS.EDU>
Date: Wednesday, May 31, 2017 at 10:48 PM
To: Corina Grigorescu Monagin <cgmonagin@UCDAVIS.EDU>
Cc: Brian Bird <bhbird@ucdavis.edu>, Jonna Mazet <jkmazet@ucdavis.edu>
Subject: RE: Guinea VHF sub award and employee questions

Yes, ideally we would just move forward with UCD issuing a subaward to the lab in Guinea rather than having MB put a subaward in place only to have it end and be replaced by a UCD-issued subaward. Less paperwork and (hopefully) less confusing for the in-country staff.

I have no issues with Metabiota purchasing fuel cards to contribute to the cost of running the generator for

sample storage while we get the subaward in place.

For the staffing, are we required to use an outside payroll company like Footprint to facilitate payroll payments in Guinea? I know Metabiota has been using a similar payroll firm in China, but I believe they are required to due to Chinese law (if my memory serves). It is much cleaner (and less expensive without the 18% fee) to just hire the in-country staff through the subaward once it is established (unless there is a very good reason to do otherwise). To avoid a break in service for in-country staff, however, I think we have no choice but to continue to pay them through the current mechanism (meaning through MB to Footprint) until the UCD subaward is in place and hiring (or individual contracting) through the subrecipient can occur.

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
530-304-1403 (cell)

From: Corina Grigorescu Monagin
Sent: Tuesday, May 30, 2017 2:27 PM
To: Elizabeth Leasure
Cc: Brian Bird; Jonna Mazet
Subject: Guinea VHF sub award and employee questions

Hi Liz,

I've started the transition of Guinea and have had a few phone calls with the Metabiota team. A couple of questions for you.

MB has not signed the sub award with the VHF lab. I'm thinking that you do not want them to proceed and that it would be initially signed with UCD? If so, I would like to authorize MB to pay for fuel cards to contribute to the cost of the generator (where our freezer and samples are stored) until we can get the sub award in place. Please advise.

In terms of the staff – all employees (contractual field staff and full time PREDICT) are paid through a payroll company "Footprint". They charge a fee of approximately 18% on all costs. I am getting a full list of staff, salary, location and contract terms and we will have to decide how to proceed. I know the ideal would be to put them all under the subcontract but I honestly don't know the possibility or length of time it will take to put in place. While I figure out our options and timeframe - Do you want to continue with Footprint or another option?

I'm sure you have tons of questions – I'm available in the afternoons (PST) when I'm back at the hotel so let me know if it's easier to talk.

Thanks
Corina

From: Karen Saylors <ksaylors@metabiota.com>
To: Jonna Mazet <jkmazet@ucdavis.edu>
CC: Eddy Rubin <erubin@metabiota.com>
Sent: 6/6/2017 8:12:35 PM
Subject: brief staff transition plan

Hi Jonna.
I just want to check in on staffing during this transition and our plans for the subsequent team composition.

As you have heard, Frantz has resigned and his last day will be June 30th.
Regarding our two remaining Regional Coordinators, I hope keep both Jim and Dave, transitioning some of Dave's time to IM, as he is a strong epidemiologist and did his post-doc with HealthMap, so has a good sense of data presentation and could be helpful there. Dave is working closely with me, supporting the corrective action process, which he is now able to do with the lighter county coordination load, as he has only Laos. He is also helping transition Indo and China to EHA.

Jim is coordinating DRC and Cameroon, and he is fully focused on those two countries. He and I are doing a big syndromic surveillance training of the Cameroon team in July, and he will stay on for an additional week to focus on the corrective action for Cameroon.

Regarding Beth's role, she is working closely with me, your team, and EHA on the country transitions. Beth and I will take over the transition of West Africa from Frantz beginning in July. Beth will then take vacation from July 7-21st and after that she will go part time. We will then assign another part time PM to PREDICT, whom Beth will train, and with fewer countries PM tasks will be more manageable. Frankly, we are continuing to work on a transition plan for her after the summer, once we have a better sense of how the transition is wrapping up.

Additionally, we have been working with EHA and Brian and Corina on transitioning the 6 countries.
I've notified country partners in all countries except China, as I'm waiting for Peter's thoughts on the continuing versus closing the current hospital sites, so that I can appropriately notify the Guangdong CDC director.

As a heads up, Peter and Billy have been asking me to accompany them on an upcoming July trip to ROC and CIV, to help assure those transitions go smoothly. That would be the week of July 10-14th, and I've submitted a revised ITA today to your team, to accommodate EHA's request, pending your approval of course.

Just wanted to keep you updated on what's going on on this end!
Thanks,
Karen

From: Molly Turner <turner@ecohealthalliance.org>
To: Elizabeth Leasure <ealeasure@ucdavis.edu>
CC: Ava Sullivan <sullivan@ecohealthalliance.org>;Evelyn Luciano <luciano@ecohealthalliance.org>;Peter Daszak <daszak@ecohealthalliance.org>;predict@ucdavis.edu <predict@ucdavis.edu>
Sent: 6/8/2017 2:04:37 PM
Subject: [predict] Re: Budget templates for P2 CoAg ceiling increase (due 6-14-17)

Thanks Liz.

Can you confirm that we will also get approval to raise the approved subaward ceiling for IEDCR if we include projected increased costs in these budgets?

Thanks,
Molly

On Wed, Jun 7, 2017 at 1:42 PM, Elizabeth Leasure <ealeasure@ucdavis.edu> wrote:

Hi Molly. Please also note that costs for the M&A team and One Health Approaches (Billy and Catherine's piece of the workplan) need to go on core funds only per guidance received from USAID when budgeting last year, so please keep that in mind as your putting these budgets together. The distribution of Global costs in the templates should already reflect this (since we took this into account when finalizing the Y3 budget, and the Y3 budget was used to create the Y4 and Y5 templates you received), but I just wanted to remind you of this fact. Let me know if you have any questions.

Thanks!

Liz

Elizabeth Leasure

One Health Institute

University of California, Davis

530-754-9034 (office)

530-304-1403 (cell)

From: Elizabeth Leasure
Sent: Tuesday, June 06, 2017 10:56 AM
To: Elizabeth Leasure; Molly Turner
Cc: Ava Sullivan; Evelyn Luciano; Peter Daszak; predict@ucdavis.edu
Subject: RE: Budget templates for P2 CoAg ceiling increase (due 6-14-17)

As promised, please find attached the justification draft document for you to revise. Let me know if you have any questions.

Happy budgeting!

Liz

Elizabeth Leasure

One Health Institute

University of California, Davis

530-754-9034 (office)

530-304-1403 (cell)

From: predict-request@ucdavis.edu [mailto:predict-request@ucdavis.edu] **On Behalf Of** Elizabeth Leasure
Sent: Saturday, June 03, 2017 6:41 PM
To: Molly Turner
Cc: Ava Sullivan; Evelyn Luciano; Peter Daszak; predict@ucdavis.edu
Subject: [predict] Budget templates for P2 CoAg ceiling increase (due 6-14-17)
Importance: High

Hi Molly. As you are probably now aware, USAID has requested that we submit budgets and justifications to process an increase to the ceiling of the prime agreement, which is required in order for USAID to obligate additional funding (core and EHP) for Years 4 and 5, as we are now just $3M below the current $100M ceiling. These budgets are intended to facilitate the ceiling increase only, and do not reflect a commitment or guarantee that the funds budgeted will be received. We will still have to go through our regular budget development/approval process for Y4 later this summer, so keep that in mind as you're pulling these budgets together. This budgeting exercise (while tedious), does give us the opportunity to obtain prior approval for multiple new subawards and subcontracts at one time, as the AO has confirmed that any subawards/subcontracts included in the budgets submitted will be considered officially approved. To capitalize on this, we will need to make sure that all new subawards and subcontracts anticipated through the end of the project in 2019 are included in the detailed budgets and justifications. This means that new subrecipients and subcontractors need to be identified by name in the detailed budgets/justifications, and a scope of work for each new subaward/subcontract needs to be provided (as noted below).

In order to fulfil USAID's request and meet the submission deadline, **please submit the following items to me by COB on Wednesday, June 14th**:

1. ***Detailed budget for the balance of unspent Y3 funds*** (Excel budget template attached). Targets included on the "Summary by Country" worksheet are based on approved budgets less expenditures to date (through the April 2017 invoice). These targets DO NOT include additional funding for Y3 costs anticipated for the transitions in China, Indonesia, RoC, and Cote d'Ivoire (CDI), but please budget for these costs anyway (knowing you will exceed the stated targets). Cost share target is based on the revised Y3 cost share budget (submitted by Molly 6/2) less the Y3 cost share reported to date (Q1-Q2).

2. ***Detailed budget for Y4*** (Excel budget template attached). Targets include $1.5M for EHP (inclusive of the diagnostic budget for Columbia that has previously flowed through UCD) and $320K for GVP, as well as additional funds for in-country costs associated with activities in China, Indonesia, RoC, and CDI that are being taken over from Metabiota. If you anticipate needing to hire additional support staff to manage CDI and RoC, please include those additional costs in your budget (you can go a bit over the targets if you're factoring in such costs). If you would prefer Columbia's diagnostic budget for EHP to continue to flow through the UCD mechanism, please reduce the EHP budget target accordingly. Cost share target of $339K is based on the 5-year EHA cost share commitment ($1,136,846) less cost share reported and committed for Y1-Y3 ($458,793; assumes total Y3 commitment is met) divided evenly between Y4 and Y5 ($1,136,846 - $458,793 = $678,053/2 years = $339,026/year).

3. ***Detailed budget for Y5*** (Excel template attached). Targets include $1M for EHP (inclusive of diagnostic budget for Columbia that has previously flowed through UCD), as well as additional funds for in-country costs associated with activities in China, Indonesia, and RoC that are being taken over from Metabiota. The Ebola target does not currently include any funds for CDI, as the remainder of the non-EHP funds are included in the Y4 Ebola target; any costs you budget for CDI in Y5 will come from the Ebola target in Y4 (which is fine, just keep that in mind). If you anticipate needing to hire additional support staff to manage CDI and RoC, please include those additional costs in your budget (you can go a bit over the targets if you're factoring in such costs). If you would prefer Columbia's diagnostic budget for EHP to continue to flow through the UCD mechanism, please reduce the EHP budget target accordingly. Cost share target of $339K is based on the 5-year EHA cost share commitment (see explanation in #4 above).

4. **Budget justifications for detailed budgets #1-3 above**. Rather than have you start from scratch, we are going to pull language from the final cost application narrative for the P2 proposal and ask you to simply update it to align with the budgets noted above. The draft budget justification documents for you to revise will be sent to you in a separate email, and you will receive them no later than COB PDT Tuesday, June 6th.

5. **Scopes of work for any new subcontracts or subawards** included detailed budgets #1-3 above.

6. **A copy of your organization's current negotiated indirect cost rate agreement.**

My apologies for the very long (and probably confusing) email. I'd like to speak by phone (once you've had a chance to read through all of this) to make sure that we're on the same page and everything is clear. Perhaps sometime on Monday? I'm free any time after 10 am PDT, so please let me know what will work for you.

Thanks!!

Liz

Elizabeth Leasure

One Health Institute

University of California, Davis

530-754-9034 (office)

530-304-1403 (cell)

--
Molly Turner
Federal Grants Coordinator

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4461 (direct)
1.973.752.4627 (cell)
www.ecohealthalliance.org

EcoHealth Alliance leads cutting-edge research into the critical connections between human and wildlife health and delicate ecosystems. With this science we develop solutions that promote conservation and prevent pandemics.

From: Karen Saylors <ksaylors@metabiota.com>
To: Brian Bird <bhbird@ucdavis.edu>
Cc: Frantz Jean Louis <fjeanlouis@metabiota.com>, Eddy Rubin <erubin@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>, "Dino Goossens-Larsen" <dglarsen@metabiota.com>, Beth Edison <bedison@metabiota.com>, "Aiah Gbakima" <gbakimaaa2009@gmail.com>
Subject: Re: Sierra Leone staff contracts and details
Sent: Sat, 10 Jun 2017 15:23:21 +0000

Hi Brian.
Safe travels to Tanzania and just let us know what day later in the week you prefer.
Best,
Karen

From: Brian Bird <bhbird@ucdavis.edu>
Date: Friday, June 9, 2017 at 3:04 PM
To: Karen Saylors <ksaylors@metabiota.com>
Cc: Frantz Jean Louis <fjeanlouis@metabiota.com>, Eddy Rubin <erubin@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>, Dino Goossens-Larsen <dglarsen@metabiota.com>, Beth Edison <bedison@metabiota.com>, Aiah Gbakima <gbakimaaa2009@gmail.com>
Subject: Re: Sierra Leone staff contracts and details

Hi Karen,

It would be great to get some more details on these. I will be travelling to Tanzania Monday and Tuesday. It's possible to maybe have a call Wednesday or Thursday. I will have to check my schedule and get back to you. I imagine we can find a convenient hour. I'll reply back once I have a better sense of the schedule.

Hope you enjoy the weekend too!

-Brian

From: Karen Saylors <ksaylors@metabiota.com>
Date: Friday, June 9, 2017 at 2:58 PM
To: Brian Bird <bhbird@ucdavis.edu>
Cc: Frantz Jean Louis <fjeanlouis@metabiota.com>, Eddy Rubin <erubin@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>, Dino Goossens-Larsen <dglarsen@metabiota.com>, Beth Edison <bedison@metabiota.com>, Aiah Gbakima <gbakimaaa2009@gmail.com>
Subject: Re: Sierra Leone staff contracts and details

Hi Brian.
Sorry for the delay in getting back to you, but I'd be happy to discuss some of these transition pieces next week. Perhaps we could plan a call with you, me, Frantz, Aiah, Dino and Beth to discuss some of these details?
Beth sent a bunch of these documents onto you a few days ago, but there are a number of moving parts, so it might be easiest to jump on the phone. Monday and Tuesday morning are pretty booked up already, but please let us know what might work for you.

Best wishes and happy weekend.
Karen

From: Brian Bird <bhbird@ucdavis.edu>
Date: Monday, June 5, 2017 at 3:56 PM
To: Karen Saylors <ksaylors@metabiota.com>
Cc: Frantz Jean Louis <fjeanlouis@metabiota.com>, Eddy Rubin <erubin@metabiota.com>, Jonna Mazet <jkmazet@ucdavis.edu>, Aiah Gbakima <gbakimaaa2009@gmail.com>
Subject: Re: Sierra Leone staff contracts and details

Thanks Karen. I hope you had a great and relaxing vacation!

We didn't manage to discuss KPMG on the call today, we ran out of time. I'm hoping we can chat about KPMG the next time we talk.

Prof did mention that you could provide me with the contracts, leases, etc that we will consider to carry-on with? In particular, the staff and the UNIMAK sub award are needed to see how best to proceed.

He also mentioned on the call that the vehicles were purchased on other projects and not on PREDICT. In the SLA budget, there is a line item each year for $17,000 for a "Used Vehicle- Freetown Car". Can you clarify what that is referring too? Was this money spent?

Also, it is mentioned in the SLA budget ("PREDICT Equipment tab"), that there was ~$146k of lab supplies and equipment? We didn't have budget or plans for much of this type of equipment listed under the scope of EHP, so I'm trying to understand how/why they were listed. I remember a specific conversation about some of the equipment and they were removed from a different budget document at one point. Were these supplies purchased, and are they now in country?

Generally, it would be very helpful to reconcile the SLA budget list of items (the only budget and purchasing list I've seen) with what was actually purchased and delivered in-country. There's some pretty large differences between the various Annexes and portions of the SLA that I have (Annex A3 vs. B3 etc…). Is there someone in Metabiota who can help with that task?

Many thanks!

-b

From: Karen Saylors <ksaylors@metabiota.com>
Date: Monday, June 5, 2017 at 12:58 PM
To: Brian Bird <bhbird@ucdavis.edu>, Aiah Gbakima <gbakimaaa2009@gmail.com>
Cc: Frantz Jean Louis <fjeanlouis@metabiota.com>, Eddy Rubin <erubin@metabiota.com>
Subject: Re: Sierra Leone staff contracts and details

Hi Brian.
Just getting back from vacation, so now responding to you. Yes indeed, we have used KPMG, a payroll company in Sierra Leone, because taxes and social security are complicated in SL, but I defer to Prof to clarify how that decision was made, as it was before my time. I believe you are having a call today so Prof can definitely give you feedback on how that decision was made.

I hope all's well.
Karen

From: Brian Bird <bhbird@ucdavis.edu>
Date: Thursday, June 1, 2017 at 7:48 AM
To: Karen Saylors <ksaylors@metabiota.com>, Eddy Rubin <erubin@metabiota.com>
Cc: Aiah Gbakima <gbakimaaa2009@gmail.com>, Frantz Jean Louis <fjeanlouis@metabiota.com>
Subject: Sierra Leone staff contracts and details

HI Karen and Eddy,

Just checking in on where we are with sharing the details of the SL staff contracts/salaries/timelines and payment mechanisms.

I see in the SLA budget annex that you share that it looks like you were using a payroll company (KPMG?) to pay salaries? Is that correct? Is there an absolute requirement to use a payroll company in Sierra Leone like I've heard there is in China?

Thanks!

-Brian

Brian H. Bird DVM, MSPH, PhD
One Health Institute
1089 Veterinary Medicine Dr.
School of Veterinary Medicine
University of California, Davis
bhbird@ucdavis.edu

From: Elizabeth Leasure <ealeasure@ucdavis.edu>
To: Beth Edison <bedison@metabiota.com>
CC: Eddy Rubin <erubin@metabiota.com>;Karen Saylors <ksaylors@metabiota.com>;predict@ucdavis.edu <predict@ucdavis.edu>
Sent: 6/15/2017 4:21:18 PM
Subject: [predict] RE: Budget templates for P2 CoAg ceiling increase (due 6-14-17)

Thanks, Beth. Please send me your narratives as soon as you can.

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
530-304-1403 (cell)

From: Beth Edison [mailto:bedison@metabiota.com]
Sent: Wednesday, June 14, 2017 5:26 PM
To: Elizabeth Leasure
Cc: Eddy Rubin; Karen Saylors; predict@ucdavis.edu
Subject: Re: Budget templates for P2 CoAg ceiling increase (due 6-14-17)

Hi Liz,

Attached are our draft budgets for the remainder of Year 3 and Years 4 & 5.

I tried to include as many real costs as possible associated with our wind down in our transitioning countries. You may notice a lot of supply costs –these are items that were ordered before being advised of the transition. I have informed the new country leads which supplies are in inventory and what is en route so they can include that in their budgeting/planning.

We have had so many changes since the beginning of PREDICT 2 the budget narrative is taking longer than I had anticipated. I will have the remaining documents to you tomorrow. My apologies.

As we discussed, I'll be available to sort out the Core/Ebola funding issue or any other concerns you have.

Thank you,
Beth

Beth Edison
Program Manager, PREDICT | Metabiota
email: bedison@metabiota.com
mobile: (1)250-739-8987
skype: bethany.edison

From: Elizabeth Leasure <ealeasure@ucdavis.edu>
Date: Sunday, June 4, 2017 at 12:10 PM
To: Beth Edison <bedison@metabiota.com>
Cc: Eddy Rubin <erubin@metabiota.com>, Karen Saylors <ksaylors@metabiota.com>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Subject: Budget templates for P2 CoAg ceiling increase (due 6-14-17)

Hi Beth. As you are probably now aware, USAID has requested that we submit budgets and justifications to process an increase to the ceiling of the prime agreement, which is required in order for USAID to obligate additional funding (core and EHP) for Years 4 and 5, as we are now just $3M below the current $100M ceiling. These budgets are intended to facilitate the ceiling increase only, and do not reflect a commitment or guarantee that the funds budgeted will be received. We will still have to go through our regular budget development/approval process for Y4 later this summer, so keep that in mind as you're pulling these budgets together. This budgeting exercise (while tedious), does give us the opportunity to obtain prior approval for multiple new subawards and subcontracts at one time, as the AO has confirmed that any subawards/subcontracts included in the budgets submitted will be considered officially approved. To capitalize on this, we will need to make sure that all new subawards and subcontracts anticipated through the end of the project in 2019 are included in the detailed budgets and justifications. This means that new subrecipients and subcontractors need to be identified by name in the detailed budgets/justifications, and a scope of work for each new subaward/subcontract needs to be provided (as noted below).

In order to fulfil USAID's request and meet the submission deadline, **please submit the following items to me by COB on Wednesday, June 14th**:

1. ***Detailed budget for the balance of unspent Y3 funds*** (Excel budget template attached). Targets included on the "Summary by Country" worksheet are based on approved budgets less expenditures to date (through the April 2017 invoice). These targets DO NOT include a reduction in funding related to the transitions in China, Indonesia, RoC, Cote d'Ivoire (CDI), Guinea, and Sierra Leone, but please make sure that the budgets for these countries are reflective of the transition plans agreed to with EHA and UCD. Cost share target is zero because the Y3 commitment was met per the certifications received for Q1 and Q2.
2. ***Detailed budget for Y4*** (Excel budget template attached). Targets include $90K for GVP, as well as a reduction in funding representative of in-country costs associated with activities in China, Indonesia, RoC, CDI, Guinea, and Sierra Leone that are being taken over by other partners. Cost share target of $106K is based on the 5-year Metabiota cost share commitment ($733,118) less cost share reported for Y1-Y3 ($520,396) divided evenly between Y4 and Y5 ($733,118 - $520,396 = $212,722/2 years = $106,361/year).
3. ***Detailed budget for Y5*** (Excel template attached). Core target reflects reduction in funding representative of in-country costs associated with activities in China, Indonesia, RoC, CDI, Guinea, and Sierra Leone being taken over by other partners. The Ebola target is zero, as the remainder of the non-EHP funds are included in the Y4 Ebola target. Cost share target of $106K is based on the 5-year Metabiota cost share commitment (see explanation in #4 above).
4. **Budget justifications for detailed budgets #1-3 above**. Rather than have you start from scratch, we are going to pull language from the final cost application narrative for the P2 proposal and ask you to simply update it to align with the budgets noted above. The draft budget justification documents for you to revise will be sent to you in a separate email, and you will receive them no later than COB PDT Tuesday, June 6th.
5. **Scopes of work for any new subcontracts or subawards** included detailed budgets #1-3 above.
6. **A copy of your organization's current negotiated indirect cost rate agreement.** Please also submit copies of subrecipient NICRA's (if applicable). If any of your foreign subrecipients use an indirect cost rate greater than the standard 10% MTDC deminimis rate allowed by the Uniform Guidance (UG), please submit supporting documentation to confirm that the rate used was reviewed by your organization and deemed appropriate in accordance with the UG.

My apologies for the very long (and probably confusing) email. I'd like to speak by phone (once you've had a chance to read through all of this) to make sure that we're on the same page and everything is clear. Perhaps sometime on Monday? I'm free any time after 10 am PDT, so please let me know what will work for you.

Thanks!!
Liz

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
530-304-1403 (cell)

From: [redacted]
To: Jonna Mazet <jkmazet@ucdavis.edu>;Peter Daszak <daszak@ecohealthalliance.org>;Eddy Rubin <erubin@metabiota.com>;Nathan Wolfe <nwolfe@metabiota.com>;Dennis Carroll <dcarroll@usaid.gov>;Brooke Watson <watson@ecohealthalliance.org>;Cara Chrisman <cchrisman@usaid.gov>
Sent: 6/15/2017 7:43:50 PM
Subject: RE: 6/15 GVP Call - minutes

Hi team,

Thank you for a great call today. Here are the meeting notes: **GVP call 6/25/2017**, 10am/1pm

Agenda

1. **Update on Phase 1 Launch Countries**
   - Five phase 1 countries identified, thanks to modeling team: Cameroon, Uganda, Costa Rica, Thailand, China
   - Need for operational timeline, sample size, species at country level, in order to provide per annum cost.
   - Cross-border regions: examine if alternate sites are available with same yield
   - Global hub cost was incorporated in initial cost estimate ($757m), based on PREDICT
   - Consider verification sampling to evaluate virus discovery curve

2. **Outreach**
   - Begin pitch in New York in July or September
   - Biohub: Dennis met with Christina, and will meet again June 28. Brooke will join.
   - London pitch: week of July 10
   - Andrew Natsios (Scowcroft and Bush Foundation): Dennis is considering presentation
   - China: Peter will go to China in September, George Gao recently received funding
   - Microsoft: launched ad on preventing pandemics. Peter will reach out
   - Dan Jansen: Dennis will reach out once Costa Rica is sorted
   - Wall Street Journal: Peter will have an interview for Nature paper, can mention GVP.

3. **AOB**
   - Formal GVP launch will be at PMAC 2018
   - Dennis is compiling longer, detailed presentation deck
   - Paper for WHO Bulletin (Supplement for PMAC papers): Due 6/30

Action items

- Brooke – update operational timeline and country level cost
- All – look at outreach worksheet and send modifications to Cara
- Peter - send Cara various meeting schedules (cell symposium, vaccine congress etc.)
- Dennis – send WHO bulletin draft to Brooke
- Brooke – send revised WHO bulletin draft to Eri
- [redacted] – send revised WHO bulletin draft to Peter/Jonna
- Peter – share slide on why broad spectrum approach is critical
- (Peter – enjoy Mamawata on Congo river)

Best,

[redacted]
One health leadership fellow
University of California, Davis
One Health Institute
School of Veterinary Medicine

From: Brooke Watson [mailto:watson@ecohealthalliance.org]
Sent: Thursday, June 15, 2017 9:32 AM
To: Cara Chrisman
Cc: Jonna Mazet ; Peter Daszak ; Eddy Rubin ; Nathan Wolfe ; REDACTED ; Dennis Carroll
Subject: Re: 6/15 GVP Call - Agenda & Background Docs

Hi all,

In advance of our call today, I wanted to share a spreadsheet and a few maps that I've been working on over the past week.

As we discussed last week, I've reordered the phases, and am now summarizing values by country rather than by sampling unit. I've also taken a second look at the planning units that fall on a country border.

I'm looking forward to getting your input into how we treat these border sites. Of the 108 sampling units, If we include all borders, there are actually 60 countries that have some portion of a sampling unit within them. Some of them are clearly more positioned in one country than in another, but some are right on the border and worth discussing. I've included maps for the first five countries in the attached powerpoint file.

The phases are based on the hotspots-ranked phases that we presented in the webinar, but adapted based on what we discussed last week. Please review the phase list and advise on any changes I should make.

Looking forward to the discussion.

Best,

Brooke

On Wed, Jun 14, 2017 at 4:19 PM, Cara Chrisman <cchrisman@usaid.gov> wrote:
Hi Team,

Looking forward to speaking with many of you tomorrow. Our agenda is:

1. Update on Phase 1 Launch Countries (+ inclusion in pitch deck)
2. Outreach - updates on planned events, strategy for future events, Microsoft outreach
3. AOB

Additionally, please find attached for your review:

- Updated Pitch Deck
- Updated Outreach Plan
- Microsoft Cloud Ad

Our understanding is that Jonna and Nathan are unavailable but that the rest of us (including the Bionic Man) will be on the call. If that is incorrect or if anyone else can't attend, please let us know!

Best,
Cara



Cara J. Chrisman, PhD
Senior Infectious Diseases Technical Advisor
Emerging Threats Division
Office of Infectious Disease
Bureau for Global Health
U.S. Agency for International Development (AID)

Desk: (202) 712-1161
Cell: (202) 674-3231
E-mail: cchrisman@usaid.gov

--

Brooke Watson, MSc
Research Scientist

EcoHealth Alliance
460 West 34th Street – 17th floor
New York, NY 10001

1.212.380.4497 (direct)
1.901.493.4401 (mobile)
1.212.380.4465 (fax)
www.ecohealthalliance.org

From: Elizabeth Leasure <ealeasure@ucdavis.edu>
To: Beth Edison <bedison@metabiota.com>
CC: Eddy Rubin <erubin@metabiota.com>;Karen Saylors <ksaylors@metabiota.com>;predict@ucdavis.edu <predict@ucdavis.edu>
Sent: 6/16/2017 4:14:53 PM
Subject: [predict] RE: Budget templates for P2 CoAg ceiling increase (due 6-14-17)

Okay, thanks

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
530-304-1403 (cell)

From: Beth Edison [mailto:bedison@metabiota.com]
Sent: Friday, June 16, 2017 8:47 AM
To: Elizabeth Leasure
Cc: Eddy Rubin; Karen Saylors; predict@ucdavis.edu
Subject: Re: Budget templates for P2 CoAg ceiling increase (due 6-14-17)

Hi Liz,

No, Metabiota does not have a new NICRA in place yet however it is being actively worked on and we are on track to submit our 2017 provisional rates for DCMA approval at the end of June.

Thanks,
Beth

Beth Edison
Program Manager, PREDICT | Metabiota
email: bedison@metabiota.com
mobile: (1)250-739-8987
skype: bethany.edison

From: Elizabeth Leasure <ealeasure@ucdavis.edu>
Date: Thursday, June 15, 2017 at 9:24 AM
To: Beth Edison <bedison@metabiota.com>
Cc: Eddy Rubin <erubin@metabiota.com>, Karen Saylors <ksaylors@metabiota.com>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Subject: RE: Budget templates for P2 CoAg ceiling increase (due 6-14-17)

Does Metabiota have a new NICRA in place yet? It's been almost 3 years now, so I'm a little shocked the new NICRA hasn't been finalized yet.

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
530-304-1403 (cell)

From: Beth Edison [mailto:bedison@metabiota.com]

Sent: Wednesday, June 14, 2017 5:26 PM
To: Elizabeth Leasure
Cc: Eddy Rubin; Karen Saylors; predict@ucdavis.edu
Subject: Re: Budget templates for P2 CoAg ceiling increase (due 6-14-17)

Hi Liz,

Attached are our draft budgets for the remainder of Year 3 and Years 4 & 5.

I tried to include as many real costs as possible associated with our wind down in our transitioning countries. You may notice a lot of supply costs –these are items that were ordered before being advised of the transition. I have informed the new country leads which supplies are in inventory and what is en route so they can include that in their budgeting/planning.

We have had so many changes since the beginning of PREDICT 2 the budget narrative is taking longer than I had anticipated. I will have the remaining documents to you tomorrow. My apologies.

As we discussed, I'll be available to sort out the Core/Ebola funding issue or any other concerns you have.

Thank you,
Beth

Beth Edison
Program Manager, PREDICT | Metabiota
email: bedison@metabiota.com
mobile: (1)250-739-8987
skype: bethany.edison

From: Elizabeth Leasure <ealeasure@ucdavis.edu>
Date: Sunday, June 4, 2017 at 12:10 PM
To: Beth Edison <bedison@metabiota.com>
Cc: Eddy Rubin <erubin@metabiota.com>, Karen Saylors <ksaylors@metabiota.com>, "predict@ucdavis.edu" <predict@ucdavis.edu>
Subject: Budget templates for P2 CoAg ceiling increase (due 6-14-17)

Hi Beth. As you are probably now aware, USAID has requested that we submit budgets and justifications to process an increase to the ceiling of the prime agreement, which is required in order for USAID to obligate additional funding (core and EHP) for Years 4 and 5, as we are now just $3M below the current $100M ceiling. These budgets are intended to facilitate the ceiling increase only, and do not reflect a commitment or guarantee that the funds budgeted will be received. We will still have to go through our regular budget development/approval process for Y4 later this summer, so keep that in mind as you're pulling these budgets together. This budgeting exercise (while tedious), does give us the opportunity to obtain prior approval for multiple new subawards and subcontracts at one time, as the AO has confirmed that any subawards/subcontracts included in the budgets submitted will be considered officially approved. To capitalize on this, we will need to make sure that all new subawards and subcontracts anticipated through the end of the project in 2019 are included in the detailed budgets and justifications. This means that new subrecipients and subcontractors need to be identified by name in the detailed budgets/justifications, and a scope of work for each new subaward/subcontract needs to be provided (as noted below).

In order to fulfil USAID's request and meet the submission deadline, **please submit the following items to me by COB on Wednesday, June 14th**:

1. ***Detailed budget for the balance of unspent Y3 funds*** (Excel budget template attached). Targets

included on the "Summary by Country" worksheet are based on approved budgets less expenditures to date (through the April 2017 invoice). These targets DO NOT include a reduction in funding related to the transitions in China, Indonesia, RoC, Cote d'Ivoire (CDI), Guinea, and Sierra Leone, but please make sure that the budgets for these countries are reflective of the transition plans agreed to with EHA and UCD. Cost share target is zero because the Y3 commitment was met per the certifications received for Q1 and Q2.

2. ***Detailed budget for Y4*** (Excel budget template attached). Targets include $90K for GVP, as well as a reduction in funding representative of in-country costs associated with activities in China, Indonesia, RoC, CDI, Guinea, and Sierra Leone that are being taken over by other partners. Cost share target of $106K is based on the 5-year Metabiota cost share commitment ($733,118) less cost share reported for Y1-Y3 ($520,396) divided evenly between Y4 and Y5 ($733,118 - $520,396 = $212,722/2 years = $106,361/year).
3. ***Detailed budget for Y5*** (Excel template attached). Core target reflects reduction in funding representative of in-country costs associated with activities in China, Indonesia, RoC, CDI, Guinea, and Sierra Leone being taken over by other partners. The Ebola target is zero, as the remainder of the non-EHP funds are included in the Y4 Ebola target. Cost share target of $106K is based on the 5-year Metabiota cost share commitment (see explanation in #4 above).
4. **Budget justifications for detailed budgets #1-3 above**. Rather than have you start from scratch, we are going to pull language from the final cost application narrative for the P2 proposal and ask you to simply update it to align with the budgets noted above. The draft budget justification documents for you to revise will be sent to you in a separate email, and you will receive them no later than COB PDT Tuesday, June 6th.
5. **Scopes of work for any new subcontracts or subawards** included detailed budgets #1-3 above.
6. **A copy of your organization's current negotiated indirect cost rate agreement.** Please also submit copies of subrecipient NICRA's (if applicable). If any of your foreign subrecipients use an indirect cost rate greater than the standard 10% MTDC deminimis rate allowed by the Uniform Guidance (UG), please submit supporting documentation to confirm that the rate used was reviewed by your organization and deemed appropriate in accordance with the UG.

My apologies for the very long (and probably confusing) email. I'd like to speak by phone (once you've had a chance to read through all of this) to make sure that we're on the same page and everything is clear. Perhaps sometime on Monday? I'm free any time after 10 am PDT, so please let me know what will work for you.

Thanks!!
Liz

Elizabeth Leasure
One Health Institute
University of California, Davis
530-754-9034 (office)
530-304-1403 (cell)

From:	Andrew Clements <aclements@usaid.gov>
To:	Katherine Leasure <kaleasure@ucdavis.edu>
CC:	PREDICTMGT <predictmgt@usaid.gov>;Predict inbox <predict@ucdavis.edu>;Jonna Mazet <jkmazet@ucdavis.edu>
Sent:	6/29/2017 10:22:19 AM
Subject:	Re: PREDICT International Travel Requests

#3 approved.

I would like additional information on #8 as to how it relates to PREDICT.

All others approved subject to Mission concurrence.

On Thu, Jun 29, 2017 at 12:53 AM, Katherine Leasure <kaleasure@ucdavis.edu> wrote:

Please find below international travel requests for your review and approval. Please let me know if you have any questions. Thanks!!

1. Monagin (Guinea): $8,742 **business class required due to* REDACTED /$327 (Conakry) max daily per diem

2. Kelly (Ghana): $2,000 airfare/$331 (Accra) max daily per diem

3. O'Rourke, O'Rourke (USA): $479 each airfare/$341 (San Francisco), $179 (Davis) max daily per diems

4. Zambrana-Torrelio (Colombia): $590 airfare/$411 (Cartagena de Indias) max daily per diem

5. Anthony (Malaysia): $1400 airfare/$263 (Kuala Lumpur) max daily per diem

6. Chmura (China): $5,200 airfare/$241 (Dali), $377 (Beijing), $407 (Guangzhou), and $402 (Shanghai) max daily per diems

7. Zambrana-Torrelio (China): $2,000 airfare/$377 (Beijing) max daily per diem

8. Karesh (France): $8,000 **business class required due to* REDACTED /$568 (Paris) max daily per diem

9. Smith (Sierra Leone): $2,500 airfare/$319 (Freetown), $221 (Makeni) max daily per diems

10. Tremeau-Bravard (Senegal, Rwanda): $2,800 airfare/$264 (Dakar), $294 (Kigali) max daily per diems

11. Goldstein (Cambodia): $3,300 airfare/$236 (Phnom Penh) max daily per diem

12. Montecino (Tanzania): $2,200 airfare/$309 (Dar es Salaam), $197 (Morogoro) max daily per diems

Travel Requests –

1. UC Davis would like to request travel approval for Dr. Corina Monagin to travel from Los Angeles, California, USA to Guinea, Conakry from July 22-29, 2017 for work plan and partner meetings related to the Ebola Host Project.

Trip purpose: Dr. Corina Monagin is traveling to Conakry as PREDICT Global Lead for the PREDICT program in Guinea. Dr. Monagin is planning to assist in transitioning the implementing partner from Metabiota to UC Davis. This will include meetings with Government Ministries (Health, Agriculture, Higher Education and Scientific Research), as well as in-country partners and stakeholders. She will be working with the PREDICT team on work plan, sampling strategy, as well as quality control of samples and data.

2. UC Davis would like to request travel approval for Dr. Terra Kelly to travel from Flagstaff, Arizona, USA to Accra, Ghana from August 5-12, 2017

Trip purpose: Dr. Terra Kelly will be traveling to Accra to meet with PREDICT implementing partners to discuss implementation of surveillance and diagnostic laboratory activities and scoping and planning for upcoming surveillance activities in Year 4. Dr. Kelly will also be conducting training for PREDICT human disease surveillance partners on questionnaire administration for the risk characterization and all laboratory partners on data entry and management in the EIDITH database for laboratory results reporting.

3. Metabiota would like to request travel approval for Tammie O'Rourke and Daniel O'Rourke to travel from Nanaimo, British Columbia, Canada to San Francisco, California, USA on August 23, 2017 to meet with PREDICT Senior Management. From San Francisco, California, USA, they will travel to Davis, California, USA from August 23 – 25, 2017 to meet with UCD global team and discuss USAID reporting and data extracts.

Trip purpose: In San Francisco, they will meet with PREDICT Senior Management to discuss PREDICT Information Management concerns, progress and issues. In Davis, they will meet with the UCD global team and discuss USAID reporting and data extracts and mapping to prepare for the PREDICT data meeting September 2017.

4. EcoHealth Alliance would like to request travel approval for Mr. Carlos Zambrana-Torrelio to travel from New York, New York, USA to Cartagena de Indias, Colombia from July 23-29, 2017, to attend and present at the International Congress for Conservation Biology.

Trip purpose: As part of continued work under the CBD-WHO Joint Work Programme, Mr. Zambrana-Torrelio will present on the indicators for health that links disease emergence and biodiversity loss and the One Health approaches operationalized by PREDICT-2. In addition, he will discuss on the methods and findings from the Deep Forest project to emphasize synergies in biodiversity and disease monitoring. Presentation title: "Integrating biodiversity in conservation planning for human health and well-being." Mr. Zambrana-Torrelio also was invited to participate in a workshop session on ecosystems and human health organized by the International Union for Conservation Nature.

5. EcoHealth Alliance would like to request travel approval for Simon Anthony to travel from New York, New York, USA to Kuala Lumpur, Malaysia from July 23-30, 2017 for in-country trainings with local partners and PREDICT staff.

Trip purpose: The purpose of this trip is to meet with local sequencing companies to discuss local implementation of new technologies developed at CII (VirCapSeq) (24th July). Dr. Anthony will also conduct a three-day training workshop with PREDICT staff at the National Public Health Lab (NPHL) on PCR, cloning and sequencing, as well as sequence analysis and assay design. Dr. Anthony will also conduct a one-on-one training with Mei Ho Lee in paper writing. Outcome: Enhanced local capacity for viral discovery, sequence analysis and assay design. Planning of PREDICT papers to be led by regional staff (Mei Ho Lee).

6. EcoHealth Alliance would like to request travel approval for Mr. Aleksei Chmura to travel from New York, New York, USA to Dali, Beijing, Guangzhou, and Shanghai China from July 31 to September 5, 2017 for meetings with in-country partners, field work, behavioral surveillance, and site selection work.

Trip purpose: Mr. Aleksei Chmura will meet with PREDICT-2 Field Coordinator Dr. Libiao Zhang at Guangxi Normal University in Guilin, and at our Partner Laboratory based at the Guangdong Entomological Institute in Guangzhou in Guangdong, as well as with Dr. Changwen Ke at the Guangdong CDC in Guangzhou. Dr. Zhu and Mr. Chmura will meet with Dr. Yunzhi Zhang of the Yunnan CDC. Together with Field Coordinator Dr. Guangjian Zhu, Mr. Chmura will coordinate and travel with full field team to sites in Yunnan Province to assist with human behavioral surveillance fieldwork, review field, lab, and data entry protocols, and prepare for 2017-18 PREDICT-2 field sampling. Field sites are prioritized along the wildlife trade pathways as per PREDICT-2 site selection criteria and protocols. Mr. Chmura will communicate with PREDICT-2 Metabiota partners in China as well as new Chinese Academy of Sciences Laboratory collaborators based in Beijing.

7. EcoHealth Alliance would like to request travel approval for Mr. Carlos Zambrana-Torrelio to travel from New York, New York, USA to Beijing, China from August 19-27, 2017, to attend and present at the International Association for Ecology (INTECOL).

Trip purpose: Mr. Zambrana-Torrelio will attend the International Association for Acology to present the results produced by Modeling and Analytics Working Group of the Global Virome Project. Presentation title: "The Global Virome Project: A network of viral-diversity monitoring."

8. EcoHealth Alliance would like to request travel approval for Dr. William Karesh to travel from New York, New York, USA to Paris, France from August 21-24, 2017 to participate in the World Organization for Animal Health's (OIE) ad hoc group on killing methods for farmed reptiles for their skins and meat.

Trip purpose: Dr. Karesh will participate in the World Organisation for Animal Health's (OIE) ad hoc group on killing methods for farmed reptiles for their skins and meat. Dr. Karesh will participate in setting health and IACUC related standards for wildlife farming for OIE code purposes.

9. UC Davis would like to request travel approval for Brett Smith to travel from Sacramento, California, USA to Freetown and Makeni, Sierra Leone from July 21 to August 10, 2017 to perform laboratory training.

Trip purpose: Mr. Smith will fly to Freetown, then travel on to Makeni to perform laboratory training. The training will include staff from UNIMAK and PREDICT with invitations to MAFFS and MOH to include staff from the TEKO veterinary lab and National Public Health lab to prepare, handle and test samples using Predict protocols.

10. UC Davis would like to request travel approval for Alexandre Tremeau-Bravard to travel from Sacramento, California, USA to Dakar, Senegal from August 12-25, 2017, then to Kigali, Rwanda from August 25-30, 2017 to perform laboratory trainings.

Trip purpose: Senegal – In Dakar, Mr. Tremeau-Bravard will train lab staff from ISRA and ICAD to prepare, handle and test samples using Predict protocols. Rwanda – In Kigali, he will do a refresher lab training for staff based at NRL and RAB.

11. UC Davis would like to request travel approval for Dr. Tracey Goldstein to travel from Sacramento, California, USA to Phnom Penh, Cambodia from August 3-11, 2017 to attend meetings with government and non-governmental partners, as well provide technical guidance to the field team during planned August sampling activities.

-

Trip purpose: Dr. Goldstein will meet with government and non-governmental partners regarding coordination of PREDICT-2 activities, and will join the field team to assist with technical guidance for the concurrence sampling of human, livestock and wildlife planned for August in a bat guano farming community in Kampong Cham.

12. UC Davis would like to request travel approval for Diego Montecino to travel to Dar es Salaam and Morogoro, Tanzania from August 5-26, 2017 to support the PREDICT Tanzania team in the initiation of new in-depth methods for bat surveillance at high-risk urban interfaces.

Trip purpose: Mr. Montecino (UC Davis-based project scientist) will support the PREDICT Tanzania team to set up new methods for safely and effectively collecting non-invasive samples from a well-established urban straw-coloured fruit bat (*Eidolon helvum*) colony in Morogoro in order to test them for Coronaviruses and other priority viral threats. He will also introduce methods for counting bats present in a colony and assessing bat behavior and their interactions with people. Mr. Montecino will work hand-by-hand with the PREDICT Tanzania team to transfer the knowledge, skills, and capacity to conduct these activities following his return to the US.

Katherine Leasure

HR/Payroll/Financial Assistant

One Health Institute

University of California, Davis

530-752-7526

530-752-3318 FAX

kaleasure@ucdavis.edu

predictmgt+unsubscribe@usaid.gov
predictmgt@usaid.gov
https://groups.google.com/a/usaid.gov/d/msgid/predictmgt/014901d2f061%246a1942a0%243e4bc7e0%24%40ucdavis.edu

--

Andrew Clements, Ph.D.
Senior Scientific Advisor
Emerging Threats Division/Office of Infectious Diseases/Bureau for Global Health
U.S. Agency for International Development
Mobile phone: 1-571-345-4253
E-mail: aclements@usaid.gov

For more information on USAID's Emerging Pandemic Threats program, see: http://www.usaid.gov/ept2

From:	Katherine Leasure <kaleasure@ucdavis.edu>
To:	'Ava Sullivan' <sullivan@ecohealthalliance.org>;'Evelyn Luciano' <luciano@ecohealthalliance.org>
CC:	predict@ucdavis.edu <predict@ucdavis.edu>
Sent:	7/5/2017 5:29:34 PM
Subject:	[predict] ITAs for S. Anthony, A. Chmura, and C. Zambrana-Torrelio

Hi Ava,

FYI – the below travel has been approved. Thanks!

EcoHealth Alliance would like to request travel approval for Simon Anthony to travel from New York, New York, USA to Kuala Lumpur, Malaysia from July 23-30, 2017 for in-country trainings with local partners and PREDICT staff.
Trip purpose: The purpose of this trip is to meet with local sequencing companies to discuss local implementation of new technologies developed at CII (VirCapSeq) (24th July). Dr. Anthony will also conduct a three-day training workshop with PREDICT staff at the National Public Health Lab (NPHL) on PCR, cloning and sequencing, as well as sequence analysis and assay design. Dr. Anthony will also conduct a one-on-one training with Mei Ho Lee in paper writing. Outcome: Enhanced local capacity for viral discovery, sequence analysis and assay design. Planning of PREDICT papers to be led by regional staff (Mei Ho Lee).
EcoHealth Alliance would like to request travel approval for Mr. Aleksei Chmura to travel from New York, New York, USA to Dali, Beijing, Guangzhou, and Shanghai China from July 31 to September 5, 2017 for meetings with in-country partners, field work, behavioral surveillance, and site selection work.
Trip purpose: Mr. Aleksei Chmura will meet with PREDICT-2 Field Coordinator Dr. Libiao Zhang at Guangxi Normal University in Guilin, and at our Partner Laboratory based at the Guangdong Entomological Institute in Guangzhou in Guangdong, as well as with Dr. Changwen Ke at the Guangdong CDC in Guangzhou. Dr. Zhu and Mr. Chmura will meet with Dr. Yunzhi Zhang of the Yunnan CDC. Together with Field Coordinator Dr. Guangjian Zhu, Mr. Chmura will coordinate and travel with full field team to sites in Yunnan Province to assist with human behavioral surveillance fieldwork, review field, lab, and data entry protocols, and prepare for 2017-18 PREDICT-2 field sampling. Field sites are prioritized along the wildlife trade pathways as per PREDICT-2 site selection criteria and protocols. Mr. Chmura will communicate with PREDICT-2 Metabiota partners in China as well as new Chinese Academy of Sciences Laboratory collaborators based in Beijing.
EcoHealth Alliance would like to request travel approval for Mr. Carlos Zambrana-Torrelio to travel from New York, New York, USA to Beijing, China from August 19-27, 2017, to attend and present at the International Association for Ecology (INTECOL).
Trip purpose: Mr. Zambrana-Torrelio will attend the International Association for Acology to present the results produced by Modeling and Analytics Working Group of the Global Virome Project. Presentation title: "The Global Virome Project: A network of viral-diversity monitoring."

Katherine Leasure
HR/Payroll/Financial Assistant
One Health Institute
University of California, Davis
530-752-7526
530-752-3318 FAX
kaleasure@ucdavis.edu